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CHAPTER ONE 
GENERAL INTRODUCTION 

GENERAL INTRODUCTION 
EPIDEMIOLOGY AND ETIOLOGY OF OVARIAN CANCER 
In the western world ovarian cancer is one of the leading causes of cancer death, 
along with cancers of the lung, breast, colon, rectum, pancreas, and prostate1,2. 
It is the third most frequent gynecologic malignancy after neoplasms of the cervix 
and endometrium, and the most lethal of all gynecologic cancers. The reason 
for the high mortality of ovarian cancer lies in the difficulty of detecting the disease 
at an early stage. Consequently, more than 66% of ovarian carcinomas have already 
metastasized at the time of diagnosis3. About 80% of epithelial ovarian malignancies 
occur increasingly between the age of 40 and 70 years, although females of all 
ages may be affected4·5,6 (Table 1). 
Table 1. Relative incidence of the different primary ovarian neoplasms related to age*. 
Tumor origin Age 
up to 20 years 20-50 years > 50 years 
Coelomic epithelium 29% 71% 81% 
Germ cells 59% 14% 6% 
Specialized gonadal stroma 8% 5% 4% 
Non-specified mesenchymal cells 4% 10% 9% 
As shown in Table 1 epithelial tumors of the ovary are predominantly seen in 
women older than 50 years, while there is a relatively low rate of incidence in 
females younger than 20 years. The malignant germ cell tumors however, are 
most commonly seen in females younger than 20 years, whereas a relatively low 
rate of incidence is observed in the group of females older than 20 years. Figure 
1 shows that hospital admission in The Netherlands due to malignant ovarian 
neoplasms have its highest frequency in the female population at the age between 
50 and 75 years, while benign ovarian neoplasms are equally spread within the 
age range of 25 to 70 years (Figure 2). 
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CLASSIFICATION OF OVARIAN CANCER 
There are more than 50 types of ovarian tumors, most of which may be categorized 
into one of the three following groups7. 
a) Tumors of the surface epithelium of the ovary (75-80%)8. 
b) Sex cord-stromal tumors (4%)8. 
c) Germ cell tumors (20 %)8. 
Metastatic malignancies to the ovary (secondary ovarian cancers) account for 
a small proportion (5-10%) of all malignancies occuring in the ovary8. 
TUMORS OF THE SURFACE EPITHELIUM OF THE OVARY 
Epithelial ovarian tumors are thought to arise from the surface (coelomic) epithelium 
of the ovary, which is the mesothelium of the embryonic ovary. It is hypothesized 
that these indifferent surface epithelial cells may undergo neoplastic changes, 
during which process they retain their potential to differentiate along the various 
Miillerian pathways. This is reflected in the histological appearence of the various 
ovarian neoplasms as serous, endometrioid and mucinous tumors, resembling 
the epithelial cells that line the inner aspects of the fallopian tube, uterus and 
endocervix, respectively8. 
Benign tumors: Cystomas and cystadenomas (which can be distinguished by 
the presence of epithelial glandular elements) generally occur in women under 
the age of 40. The cysts are lined by a single layer of epithelium which, upon 
microscopic examination, may be of a serous, mucinous, or a mixed type. Tumors 
of low malignant potential (borderline tumors) generally occur in women between 
20-45 years of age. Morphologically these tumors are also usually cystic. These 
cysts are lined by a stratified epithelium, composed of columnar cells displaying 
varying degrees of atypia and sometimes accompanied with mitosis. Papillary 
fronds are frequently found9. Characteristic differential diagnostic criteria which 
separate borderline malignant cystadenomas from carcinomas, are the absence 
(in the former) of 4 layers of stratified epithelium, the absence of cribriform growth 
patterns and of course the fact that frank stromal invasion is not present. 
Malignant tumors: The most frequently occuring malignant ovarian tumors are 
those resembling tissues of Miillerian origin. These include: 
- serous carcinomas which are composed of cells resembling those lining the fallopi-
an tube. 
- mucinous carcinomas composed of cells resembling the lining of the endocervix. 
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- endometrioid carcinomas composed of columnar cells resembling the lining 
of the endometrium. 
- clear cell carcinomas composed of cells resembling the lining of the endometrial 
glands during pregnancy7. 
Different etiological factors responsible for the origin of epithelial ovarian cancer 
are united in a theory by Cramer and Welch10,11. These authors proposed that 
the first step towards malignant growth is the formation of an inclusion cyst by 
the entrapment of surface epithelium in ovarian stroma caused for instance by 
incessant ovulation or the presence of foreign bodies (asbestos/talc)12,13. The results 
of studies relating dietary factors to ovarian cancer are contradictory, while there 
is also controversy about a link that has been suggested between cancer and talc 
(Slotman and Rao14). Epidemiological data suggest a hormonal influence. As 
described by Scully9 the two major functions of the ovary, the release of mature 
ova at the time of ovulation and the secretion of steroid hormones, depend on 
stimulation by gonadotropins, follicle stimulating hormone (FSH) and luteinizing 
hormone (LH). Low gonadotropin levels are associated with a lower risk of develo-
ping ovarian cancer. As gonadotropin levels increase with age and are particularly 
high in early menopausal years, the age distribution of the incidence of ovarian 
cancer4,5 parallels this curve. Excess gonadotropin secretion in experimental models 
has been related to the development of ovarian tumors9,10,15. Gonadotropins stimulate 
steroidogenesis, and their effect could be indirect through estrogens16. Use of 
estrogens in menopause has also been associated with ovarian cancer17,18. The 
stimulation of epithelium in ovarian inclusions by gonadotropins and estrogens 
is suggested as a next step, resulting in differentiation, proliferation and sometimes 
malignant transformation. The final step in the establishment of malignant transfor-
mation of ovarian epithelium, however is unknown. This theory therefore concludes 
that inclusion cyst formation, high gonadotropin levels and high estrogen levels1718 
may increase the risk of developing ovarian cancer. 
SEX CORD - STROMAL TUMORS 
Tumors of sex-cord stroma, include those containing granulosa cells, theca cells, 
Sertoli cells or Leydig cells, either alone or in any combination19. Granulosa and 
Sertoli cells are believed to be derived from the primitive sex cords of the embryonic 
gonad. It is thought that in the postnatal ovary these undifferentiated cells of sex 
cord origin retain a bisexual potentiality, and can give rise to either granulosa 
or Sertoli cell neoplasms, which may differentiate toward female or male structures. 
Sex cord-stromal tumors account for less than 10% of all ovarian tumors. They 
may display both a benign or a malignant behavior, which on the basis of histologic 
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criteria alone, can usually not be predicted. 
Benign sex cord-stromal tumors: Benign sex cord-stromal tumors include fibroma, 
and thecoma. 
Fibromas occur at all ages, but most frequently during middle age, while less 
than 10% of the cases are encountered at the age of 30. The great majority of 
fibromas are probably derived from ovarian stromal cells. Fibromas are composed 
of spindle cells, often arranged in interlacing bundles. The cells produce collagen 
and small amounts of lipid may be present in their cytoplasm. 
Thecomas, which account for less then 1 % of all ovarian tumors9, arise from 
ovarian stromal cells. These are capable of giving rise to theca externa and theca 
interna cells along the margins of developing follicles9. Thecomas are predominantly 
composed of uniform oval or spindle shaped cells with lipid rich cytoplasm resem-
bling theca cells. They are usually estrogenic, and cause the endometrium to 
proliferate, thus inducing hyperplasia. Some tumors are largely composed of 
collagen producing fibrous components. Some thecomas contain foci of granulosa 
cells, in which case the tumor is classified as gramilosa-theca cell tumor7. 
Malignant sex cord-stromal tumors: Malignant sex cord-stromal tumors include 
granulosa cell tumor, and Sertoli-Leydig cell tumor. 
Granulosa cell tumor can occur at any age, but is unusual before puberty. This 
tumor type accounts for less than 2% of all ovarian tumors. About 25% of the 
granulosa cell tumors secrete estrogens. The tumors are composed of gonadal 
sex cord and stromal dérivâtes differentiating into granulosa and/or theca cells 
on the one hand or into Sertoli and/or Leydig cells, on the other hand9. Sertoli-
Leydig cell tumors contain structures resembling those of the seminiferous epi-
thelium of the testis. They occur in general in women between 15-40 years of 
age. The tumors contain malignant Sertoli and Leydig cells in varying proportions. 
Scully9 forworded the hypothesis that Sertoli-Leydig cell tumors arise frequently 
from a transformation of granulosa cells into cells morphologically more 
characteristic of Sertoli cells. The presence of heterologeous elements, however, 
such as cysts lined by mucin filled cells, argentaffin cells, and skeletal muscle 
cells, sometimes seen in Sertoli-Leydig cell tumors, seem to support a possible 
germ cell origin9. Ovarian teratomas, however, do not contain areas resembling 
Sertoli-Leydig cell neoplasia nor do Sertoli-Leydig cell tumors contain the structures 
most commonly encountered in ovarian teratomas i.e. neuroepithelium, skin, 
and glial tissue. 
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GERM CELL TUMORS 
Twenty percent of all (benign and malignant) ovarian tumors are of germ cell 
origin. Malignant germ cell tumors account for 3% of all malignant neoplasms 
of the ovary. Most germ cell tumors are benign and occur in pure form. However, 
they may be mixed, comprising one or more types of ovarian germ cell neoplasms19. 
Tumors derived from ovarian germ cells which show no evidence of either embryo-
nic or extra-embryonic differentiation are classified as dysgerminomas. In the 
case that they show minimal differentiation into primitive embryonic-type cells 
they are classified as embryonal cell carcinomas. When maturation is pronounced 
and the cells differentiate along embryonic pathways to produce various types 
of organoid structures, which are considered to be products of the 3 germ cell 
layers, the tumors are classified as teratomas. Differentiation along extra-embryonic 
pathways results in either choriocarcinoma, derived from trophoblasts or into 
endodermal sinus tumor", derived from yolk sac structures. 
Benign germ cell tumors: The main benign form, i.e. the dermoid cyst accounts 
for nearly 30% of all benign ovarian neoplasms8. The peak incidence occurs in 
women between 20 - 30 years of age'. These tumors are characterized by one 
or more cysts lined by epidermis-like tissue, but mesodermal, endodermal, and 
ectodermal dérivâtes are also present in most cases9. 
Linder et al.20 have shown that dermoid cysts arise after chromosome duplication 
of an oocyte that has undergone its first meiotic division. As a second possibility 
a fusion of an oocyte with a polar body has been suggested by the same author. 
Malignant germ cell tumors: Malignant germ cell tumors are in general highly 
aggressive, and may follow one of several lines of differentiation. Tumor cells 
may proliferate as undifferentiated neoplastic germ cells forming dysgerminomas 
in women, and seminomas in men. Dysgerminoma cells resemble primordial germ 
cells19 and dysgerminomas account for 1 % of all (benign and malignant) ovarian 
tumors. The endodermal sinus tumor is a highly malignant ovarian neoplasm and 
is a rare tumor, usually found in women between 10-30 years of age. Also 
embryonal cell carcinomas are rare and highly malignant tumors, usually seen 
in women under the age of thirty. The tumor is composed of embryonal cells 
of epithelial appearence9. 
METASTATIC TUMORS TO THE OVARY 
About eight percent of tumors found in the ovary have originated from tissue 
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outside the ovary. The most common primary sites for tumors metastatic to the 
ovary are breast, stomach, intestines and organs of the genital tract. Breast 
carcinoma is the most common metastatic tumor to the ovary. Colon carcinoma 
metastasis may mimic a primary ovarian tumor. The metastatic tumor cells may 
stimulate the ovarian stromal cells to differentiate into hormone producing cells7. 
MONOCLONAL ANTIBODIES (Mabs) 
A central concept in tumor immunology is that malignancies bear tumor-associated 
antigens, which are not or to a much lesser degree found in normal tissues. These 
antigens can be used as distinctive markers in diagnosis and therapy. Furthermore, 
a number of well known antigens are expressed in relation to the type of 
differentiation of a certain cell type. These antigens include immunoglobulins, 
certain cytoskeletal constituents, nuclear constituents, cell surface proteins, hormones 
and hormone receptors21. Such antigens have often been discovered by means 
of monoclonal antibodies raised against total cells or cell fractions. Certain antigens 
(Table II) have been identified that display a restricted distribution pattern in normal 
tissues and cancers. Monoclonal antibodies to such antigens may represent useful 
tools for histopathology, immunoscintigraphy and for immunotherapy. 
Ovarian tumor-associated antigens 
Markers for ovarian tumors include general molecules such as hormones and 
enzymes, as well as markers for differentiation antigens, oncofetal antigens and 
tumor-associated antigens. 
A series of different molecules, such as enzymes and hormones, detectable in 
serum and/or urine, has been investigated as general indicators of ovarian neoplasms 
and were reviewed recently by Boerman2. Since increased levels of these markers 
are associated with malignancies of various types but also with several non-
neoplastic diseases, these indicators are not being regarded as ovarian tumor 
specific. 
The category of ovarian tumor-associated antigens is presented in Table II. 
Most of these markers are however not specific for ovarian cancer. The most 
commonly used ovarian tumor-associated antigens can be summarized as follows: 
CEA was defined as a tumor-associated oncofetal antigen of the gastro-intestinal 
tract. Elevated levels of CEA occur in patients with malignancies of pancreas, 
lung, colon, rectum, etc. but also gynecological carcinomas22. In about 40% of 
ovarian carcinoma patients elevated serum levels have been found23, and therefore 
CEA quantitation has been shown to be useful to a limited extent to monitor tumor 
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Table II: Most commonly used ovarian tumor-associated antigens (for references see text) 
Carcinoembryonic antigen (CEA) 
Ovarian carcinoma-associated antigen (OC A A and OCAA-1) 
Ovarian carcinoma antigen (OCA, NB/70K) 
Tumor-associated trypsin inhibitor (TATI) 
Placental-like Alkaline Phosphatase (FLAP) 
Polymorphic Epithelial Mucin (РЕМ): HMFG, Ca, DCA, MAM-6, NCRC-11 EMA, SGA 
antigen defined by DF3 
Tumor-associated glycoprotein (TAG)-72 
Cancer antigen 125 (CA 125) 
Ovarian carcinoma-associated antigen 3 (OA 3) recognized by OV-TL 3 
Ovarian carcinoma-associated antigen recognized by OV632 
Ovarian carcinoma-associated antigen defined by MOv 18, MOv 19 
Ovarian carcinoma-associated antigen defined by OV-TL 15, OV-TL 16, OV-TL 17, OV-TL 
19, OV-TL 22, OV-TL 23, OV-TL 24, OV-TL 27, OV-TL 30, OV-TL 31 
An epithelial 200 kDa glycoprotein, recognized by BW 495/36 
Abbrevations: HMFG, human milk fat globule; DCA, ductal carcinoma antigen; EMA, epithelial mucin 
antigen; SGA, sebaceous gland antigen. 
progression or regression. 
OCAA (ovarian carcinoma-associated antigen) has been characterized as a high 
molecular weight glycoprotein and was found in serum of 70% of ovarian carcinoma 
patients, while OCAA-1, an oncodevelopmental antigen, was present in 90% 
of the malignant ovarian tumors24. 
Ovarian carcinoma antigen (OCA, NB/70K) levels have been shown to correlate 
with stage and tumor size, but not with histological type or grade25. Elevated 
NB/70 К antigen levels were found in 70% of the ovarian carcinoma patients, 
with more than 50% of patients with early stage (Stage I) showing elevated levels26. 
Placental alkaline phosphatase (FLAP), was detected by Comb et al.,27 and shown 
to present elevated serum levels in 58% of ovarian cancer patients28. 
Elevated concentrations of tumor-associated trypsin inhibitor (TATI) have been 
found in urine of patients with gynecological malignancies29. 
Ovarian carcinomas express the monoclonal antibody defined epitopes of poly-
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morphic epithelial mucin (РЕМ) in virtually all of the cases30,31'32'33. This finding 
makes these antibodies useful tools for discrimination between epithelial and non-
epithelial neoplasms, although some reactivity with non-epithelial neoplasms has 
been reported32·34·35·36. 
B72.3 has been described37,38,39 as a murine IgGl Mab, reactive with a high 
molecular weight tumor-associated glycoprotein (TAG-72), shown to be expressed 
in 77% -100% ofthe malignant epithelial cells in human primary ovarian carcino­
mas, and 71 % of metastatic epithelial ovarian cancers. The monoclonal antibody 
B72.3 showed no reactivity with normal ovarian tissues or with benign ovarian 
tumors of various histologic types. B72.3 was also succesfully used to detect ovarian 
carcinoma cells in cytologic preparations of human serous effusions and in peritoneal 
washings. As described by Simpson and Schlom39, twelve patients out of fifteen 
cases with ovarian carcinoma showed positive scans during immunoscintigraphy, 
while approximately 80% ofthe lesions demonstrated specific localization ofthe 
monoclonal antibody. As a result B72.3 has been suggested to be of potential 
utility in histo- and cytopathology, serumassay, and in vivo diagnosis40,41. 
CA 125 antigen is defined by monoclonal antibody ОС 125 and obtained after 
immunizing mice with a OVCA 433 ovarian carcinoma cell line42. CA 125 antigen 
was detected in normal adult tissues, in dérivâtes of the Miillerian duct such as 
the endocervix, endometrium, fallopian tube, and in coelomic dérivâtes such as 
peritoneum, pleura and pericardium43. Non-mucinous ovarian carcinomas partly 
express CA 12543·44·45·46·47. The clinical significance of serial CA 125 determinations 
during the management of ovarian cancer patients is beyond doubt. 
The Mab OV-TL 3 directed against ovarian carcinoma antigen OA 3 is reactive 
with more than 90% ofthe ovarian carcinomas tested, including mucinous ovarian 
carcinomas, while the OA-3 antigen has not been detected in serum of ovarian 
carcinoma patients48,49,50,51. OV-TL 3 has also been shown to be a useful Mab 
in localization of ovarian tumor xenografts52 and in imaging patients with ovarian 
cancer53. Fab· fragments of OV-TL 3 antibody have been reported to bind to 
liposomes and to be useful in targeting studies of ovarian carcinoma cells in vitro 
as well as in vivo54,55. OV-TL 3 internalisation in ovarian carcinoma cells was 
noticed upon long term ( > 3 hours) incubation studies56. 
Three hybridoma cell lines OV-TL 15, OV-TL 30 and OV-TL 31 producing 
monoclonal antibodies against ovarian carcinoma antigens, were obtained after 
immunization of mice with an undifferentiated human ovarian cystadenocarcinoma 
extract57. OV-TL 15 (IgM), OV-TL 30 (IgGl) and OV-TL 31 (IgM) reacted 
positively with 84, 84 and 74% of ovarian carcinoma samples. These Mabs were 
shown by immunoelectron microscopy to react with surface antigens of carcinoma 
cells. Based on immunoradiometric assays, high antigen levels of OA 15 and 
11 
OA 31 were found in cyst fluids from ovarian carcinoma patients. In benign ovarian 
cyst fluids however, the OA 15 antigen was hardly detectable, while OA 31 antigen 
was only present at relatively low levels57. 
Intrasplenic immunization with ovarian tumor derived cyst fluids was used to 
generate the monoclonal antibodies OV-TL 16, OV-TL 17, OV-TL 19, OV-TL 
22, OV-TL 23, OV-TL 24, OV-TL27 against human ovarian carcinomas. The 
Mabs reacted with 67 - 96% of 49 ovarian carcinoma tissues tested. Based on 
immunoelectron microscopy, all the antigens determinants defined by these Mabs 
appeared to be associated with the tumor cell membrane. OV-TL 16 (IgGl subclass) 
and OV-TL 23 (IgM class) reacted positively with 96% and 82% of a mixed 
population of ovarian carcinomas, respectively58. 
The ovarian carcinoma antigen defined by OV632 was shown to be presented 
in 80% of the non-mucinous ovarian carcinomas and was hardly detected in non-
gynecological carcinomas59, suggesting that OV632 is a useful tool in surgical 
pathology60. 
Monoclonal antibodies MOv 18 and MOv 19, directed against ovarian carcinoma 
antigens have been shown to be highly specific for ovarian carcinoma antigens, 
since nearly all non-ovarian carcinomas were negative61. 
The monoclonal antibody BW495/36 is directed against a glycoprotein of 200 
kDa in epithelial cell types, except in mesothelial cells62. 
Intermediate Filament proteins 
Intermediate filament proteins (IFPs) form a part of the intracellular cytoskeletal 
matrix present in all mammalian cells63,64. IFPs have been shown to consist of 
six different classes that are synthesized in cell type specific patterns. IFP vimentin 
normally occurs in mesenchymal cell types, while desmin is specific for muscle 
cell differentiation63. As described by Quinlan et al.,65 the IFP family as a whole 
has a very similar secondary structure, containing a central α-helical core with 
constant length (ca. 310 amino acids). Vimentin, desmin and glial filament protein 
show 60-70% sequence homology in the α-helical core region. The non-a-helical 
carboxy- and amino-terminal regions of the different proteins account for the 
differences in molecular weights of the various subunit polypeptides. Keratins 
make up a family of IFPs, which comprise 20 subtypes in the human system and 
are specific for epithelia. According to their isoelectric pH, keratins are divided 
into two groups, i.e. type I acid, and type II basic to neutral64. 
The keratins range in molecular weight between 40 and 68 kDa and have an isoelec­
tric pH between 5 and 8. Keratin 1 has the highest molecular weight and the highest 
isoelectric pH, while keratin 19 has the lowest molecular weight and a low isoelec-
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trie pH63,65. Keratin subtypes are not expressed randomly throughout epithelia, 
but occur in cell-type specific combinations63,66. As a result monoclonal antibodies 
to a specific keratin polypeptide can characterize the type of epithelium, both 
normal, premalignant, or malignant64·67. Investigations on the expression of IFPs 
in neoplasms have shown that normally malignant cells retain the specific IFPs 
present in the tissue of origin, although a number of exceptions has been reported. 
Antibodies to IFPs can discriminate between epithelial, mesenchymal, muscle, 
glial and neural tissues and between the tumors derived from these different cell 
types. In combination with other tissue-specific markers, IFP antibodies appear 
valuable markers in surgical pathology68,69. Furthermore, monoclonal antibodies 
specific for individual keratin polypeptides allow a further subclassification of 
epithelial tissues and carcinomas66,69. Immunohistochemical investigati-
ons7i,72,73,74,75,76,77jn o v a r ¡ a n neoplasms mostly used the broad-spectrum keratin 
antibodies, which did not distinguish between different lines of epithelial differentia-
tion. Therefore, when investigating keratin expression in ovarian tumors we now 
use a panel of chain-specific keratin antibodies, covering a broad-spectrum of 
keratin polypeptides. The immunocytochemical reactivity of Mabs against inter-
mediate filament proteins has been shown to be affected by the type of tissue 
fixation used. Most keratin antigens are sensitive to formalin fixation procedures 
and paraffin embedding, often resulting in a false negative reaction in immunocyto-
chemical staining assays. Another factor influencing the reactivity pattern of 
antibodies may be a selective masking of epitopes, as for example described for 
keratin 18. This phenomenon has been illustrated by Schaafsmaet al.,78 by the 
fact that four different keratin 18 antibodies showed two completely different 
expression patterns in the urinary tract epithelia. 
OUTLINE OF TÍOS THESIS 
The purpose of the study described in this thesis was to investigate the usefulness 
of monoclonal antibodies, directed against tumor-associated antigens, and 
intermediate filaments, especially keratins, in the diagnosis and subclassification 
of ovarian tumors. Such a study will also contribute to the etiology of ovarian 
cancer by investigating early changes in the transformation of normal ovarian 
cells into tumor cells. Our initial investigations were performed in vitro by 
establishing marker profiles of cultured human ovarian carcinoma cells and 
comparing them to peritoneal derived mesothelial cells. Thereafter these antibodies 
were applied to human tumor tissue material (Chapters 2 and 3) in order to establish 
the immunophenotype of the different types of neoplasms. Chapter 4 and 5 describe 
the development and characterization of specific keratin antibodies and their 
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application in the differential diagnosis between carcinomas and non-epithelial 
tumors, as well as in recognizing specific subtypes of adenocarcinomas. Chapter 
6 describes an evaluation of monoclonal antibodies to ovarian carcinoma-associated 
antigens as diagnostic tools in the gynecopathology. Chapters 7 and 8 extent the 
investigations to a larger series of normal, benign and (pre-)malignant ovarian 
tissues, tested with a large panel of antibodies. The useful ness of the individual 
reagents or their combinations in ovarian carcinoma diagnosis is discussed in 
relation to the etiology of ovarian neoplasms. 
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A human ovarian carcinoma cell line, O T N M, has been 
established from malignant ascitic fluid of a patient with a 
well-differentiated mucinous cystadenocarcmoma of the left 
ovary The cell line has been maintained m vftro for 6 months 
through 23 passages, growing in monolayers as well as in 3-
dimensional clusters, with a population doubling time of 28' i 
tir The number of chromosomes per cell varied from 67 to 
88, with a modal number of 86 Two characteristic marker 
chromosomes were recognized, consisting of partially deleted 
chromosome I With a D N A index of I 934 the tumour cell 
line was near tetraploid The epithelial character of the O T N 
14 cells was confirmed by a positive immunofluorescence re-
action with monoclonal antibodies (MAbs) against different 
keratins, and when (immuno)electron microscopy was used, 
keratin filaments and small junctional complexes were ob-
served Vimentin was also expressed in these cells, while des-
mm was not detected Cultured tumour cells reacted (weakly) 
positive with MAb OV-TL 3 as a marker for ovarian carcino-
mas, while reactivity with the anti-ovarian carcinoma MAb 
OC 125 was limited to a few cells, not permitting the detec-
tion of shed CA 125 antigen in the culture supernatant Cells 
stained heterogeneously positive for CEA marker BW 431/31, 
the presence of which was confirmed by detection of CEA 
shed into the culture medium The cell line released estradiol 
at a concentration of 130,000 pmol/L in the culture medium, 
while no progesterone or dehydroepiandrosterone sulphate 
were found Electron microscopical evidence for steroid pro-
duction was suggested m some cells showing "dense-core" 
vesicles near the Golgi areas The O T N 14 tumour cells formed 
poorly differentiated tumour nodules in nude mice, and met-
astatic cells were also found in blood capillaries Cell types 
with mucinous as well as endocrine characteristics were found 
Fstablishmenl of cell lines of human ovarian carcinoma is a 
useful means ot mvcstipating its histogenesis and carcinogen 
csis (Filmus et al 1986) hunhermore such cell lines can be 
used for the produuion ot MAbs against tumour associated 
antigens (Bast et al 1981 Poels et al 1986 Miotti et al 
1987) for evaluation of the effectiveness of anticancer drugs 
(Hill</a/ 1987 Wolf et al 1987) and for initialing target 
mg studies in Miro (fcpenetos et al 1982) as well as IH WI<> 
Although most tumour cell lines lose their highly specific 
differentiation related properties a limited number of ovarian 
carcinoma cell lines have been reported to produce hormones 
at least temporarily (Kanabust/u/ 1978 Woods er a/ 1979 
Ishiwala et al 1984 Poels et al 1988) We now describe the 
establishment and characterisation of a new human ovarian 
carcinoma cell line OTN 14 derived from a well-dilferentiated 
mucinous cystadenocarcmoma This highly malignant cell line 
released low concentrations of СЕЛ as well as estradiol and 
contained both serous and mucinous cell types 
MATERIA! ANI) MKTHODS 
Patient data 
A 47 year old female patient presented with a peritonitis 
carcinomatosa A well diftcrcntiatcd mucinous cystadenocar 
emonia was located in the left ovary, and metastatic adenocar 
cinema cells were found in the liver Extensive ascites 
production was observed in which adenocarcinoma cells were 
also diagnosed In the pre operative scrum a CFA level of 43 
/ig/l and а СЛ 125 le\el of 940 U/ml were lound 
Culture methods 
The pelleted ascitic cells were resuspended m RPMI 1640 
based culture medium (Gibco Paisley UK) Contaminating 
nicsothclial cells present in the ascitic fluid disappeared from 
the culture within S passages due to their high trypsin sensi 
tivity Details of this procedure have been described (Poels et 
al 1988) The ΟΓΝ 14 cells were routinely subcultured al a 
1 10 split ratio 
M\iopla\ina lest 
Repealed screenings for Mycoplasma by anaerobic cultiva 
lion as well as by staining with bis benzimidc (Chen 197*1) 
(Hoechst 11258 Riedel de Haen Sccl/e FRG) gave negative 
results 
Population doubling time 
Cell growth studies were carried out by culturmg cells in 
16 mm diameter 24 well plates (Costar Cambridge MA) with 
a change ot medium at 2 or 1 day intervals Cells were seeded 
at a density of IO4 cells per ml per well On subsequent days 
cells were detached with trypsin/FDTA and counted with a 
haemocytomctcr Triplicate cultures were used per 24 hr inter 
\al and the mean number of cells per ml per well »as ex­
pressed on a logarithmic scale Doubling lime was calculated 
from logarithmic growth phase cultures 
light /nurosiop\ 
Cells grown on mullispot slides (How Irvine Scotland) 
were fixed for 5 mm in cold methanol (-lO'C) and routinely 
stained with May Grunwald/Gicmsa tor PAS (positive) reac 
lion (in combination with standard diastase treatment) as well 
as with Alcian blue according to standard histological proce 
dures 
Paraffin sections from formalin fixed tissues of nude mouse 
xenografts were stained with haematoxylm and eosin PAS-
rcaclion Alcian blue and Tnchrome stain 
Ыес iron microscope 
For standard electron microscopy monolayers of tumour 
cells grown in 24-well plates (Flow), were fixed for 10 mm 
in 2% glutaraldchydc in 0 1 M phosphate buffer (рн 7 4, 420 
mOsm) at 4°C Subcutaneously growing tumour nodules were 
fixed in 2 % glutaraldehyde and 2 % paraformaldehyde in 0 1 м 
phosphate buffer рн 7 4 for 2 hr For immuno-clectron mi 
croscopy the tumour cells were pre fixed in periodate lysine-
paraformaldehyde glutaraldehyde solution (PLPG) for 10 mm 
(Gendelman et al 1983) and washed with PBS then incu­
bated first with MAbs and next with rabbil anti-mouse IgG 
peroxidase (1 100 Dako Copenhagen Denmark) The coated 
tumour cells were post fixed for 10 mm in a 2% glutaralde 
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hyde solution in 0 1 M phosphate buffer (рн 7 4) stained w ith 
0 1% diaminobenzidine-HCl and 0 01% H2O2, and further 
processed for electron microscopy according to standard pro­
cedures (Poels et al 1988) 
Indirect immunofluorescence technique 
Reactivity of MAbs on cryostat sections of tissues from 
tumour-bearing nude mice was tested (Poels et al 1986) 
Cells, grown on multispot slides (How) were pre-fixed in cold 
methanol (-20°C) for 1-2 mm, and processed in the same 
way as for IFA 
The following sets of MAbs were used Л Mouse MAbs 
against ovarian carcinoma tissues OC 12S (Bast et al , 1981), 
surface antigen OV Т1Л (Poels et al 1986) cytoplasmic 
antigen of 60% of serous ovarian carcinomas OV TLIO (data 
not shown) В Mouse MAbs against intermediate filaments 
keratin 18 RGE 51 (Ramaekers et al , 1983b), RCK 106 
(Ramaekers et al 1987), keratin 7 RCK 105 and OV TL 12/ 
30 (Ramaekers et al 1987), keratin 5 and 8 OVTLI2/5with 
a similar tissue-distribution pattern as RCK 102 (Ramaekers et 
al 1987), vimemin RV 202 (Ramaekers et al 1987, Quax 
et al , 1985), desmin RD 301 (Quax et al , 1985) С Mouse 
M Ab BW 431/31 against a CEA epitope (Bosslet et al 1985) 
and BW 495/36 against a glycoprotein of 200 kDa in epithelial 
cell types, except in mesothelial cells (Bosslet el al 1986) 
CEA and Ca 125 leveh m culture medium 
Concentrations of CEA and Ca 125 shed into the culture 
medium were determined in medium that had been changed 
every 2 days and was taken from cultures with a cell density 
between 104 and 106 cells/ml growing in 24 well plates The 
ChA content of the supernatant was measured b> an eniyme-
immune-assay (EIA) (Abbott, Quecnsborough UK) according 
to the manufacturer's instructions The Ca 125 level of the 
supernatant was measured by an immuno radio-matrix assay 
(IRMA) (Centocor, Malvern PA) according to the manufac­
turer's instructions 
Steroid production 
lo study the production of oestradiol, progesterone and 
dehydroepiandrosterone sulphate, medium samples from var­
ious sub-cultures were taken and the hormone level was mea­
sured by a radioimmune assay (Thomas et al 1977, Reynders, 
1985) Samples were taken from cell cultures 2 days after the 
medium had been renewed In all cases fresh culture medium 
was used as control m the assays 0 HCG was determined as 
described previously (Thomas et al , 1985) using an antibody 
against the free 0 HCG subunit 
Flow cytometric analyses of cellular DNA content 
Cell suspension of OTN 14 cells, at passage 7, were used 
for flow cytometric (FCM) analyses of its DNA content, 
according to the methods of Feitz et al (1985) 
Cytogenetic analyses 
After the tumour cells of passage 10 had been exposed to 
colchicine ( 1 Mg/rrd final concentration) for 90 mm they were 
prepared according to routine cytogenetic procedures (Scheres, 
1972) Fifty well-spread metaphases were photographed and 
chromosome numbers were counted Ten mitoses were studied 
in detail after G-banding of the chromosomes by trypsin-
Giemsa Four of these cells were fully karyotyped 
Xenografts m nude mice 
From various subcultures 1 5 x 106 cells were injected s с 
in the right flank of nude female BALB/c mice (TNO, Zeist, 
The Netherlands) Tumours with a mean diameter of 1 cm 
were excised and processed for light and electron microscopy 
and immunohistochemical procedures 
RFSULTS 
Light and electron microstop\ oj cell cultura 
In the established cell line the tumour cells adhered to plastic 
as well as to glass surfaces growing as monolayers some 
times forming multi layered sheets or clusters (Fig \a) The 
polygonal cells showed an epithelial growth pattern with elon­
gated processes The centrally located, round nucleus con­
tained 2^4 prominent nucleoli, perinuclear granules and 
vacuoles Although about 20 30% of the cultured cells showed 
PAS-positivc staining in the cytoplasm less than 1 % of the 
cells remained weakly posilise after diastase treatment (not 
shown) Alcian blue staining showed an equally low number 
of (slightly) positive cells indicating that the original muci­
nous character of the tumour was retained in culture only lo a 
minor extent 
By electron microscopy the cells exhibited inlracellular and 
intercellular lumina suggestive of a glandular, adenomatous 
origin The rough endoplasmic reticulum cisternac in these 
cells were fragmented, distinctly dilated and filled with a grey, 
electron-dense substance (Fig Ift) Intermediate filaments were 
abundant (Pig \i,de), and could be stained positively with 
MAbs (OV-rL12/5) against keratins (c) Although the cells 
were organized in an epithelioid arrangement in which the cell 
membranes were close to each other over long distances, 
junctional complexes of the fascia adherens type were small 
and rather scarce (e) Small fat droplets as well as glycogen 
granules were found in most cells (d) Occasionally annulate 
lamellae were detectable A mucinous origin of the tumour 
cells was not directly evident from our studies though many 
well-developed Golgi areas were present Dense-core ' vesi­
cles resembling carcinoid endocrine granules, (/) autophagic 
vacuoles and (e) mullí vesicular bodies were observed 
Morphology of OTN 14 xenografts 
About 6 weeks after s с inoculation of 2 χ IO6 tumour cells 
the xenograft had reached a diameter ot 10 mm The subcuta-
ncously located nodules, encapsulated by fibrous connective 
tissue and leukocytic cells, formed poorly differentiated (ana­
plastic) tumour foci (Fig \g) Very rarely the epithelioid cells, 
with vesicular nuclei, were organized in cord-like arrange­
ments and sometimes in adenocarcinomatous patterns Al­
though most cells were weakly PAS positive, only the centrally 
located necrotic cells showed some resistance to diastase treat­
ment The occasional Alcian blue positise staining ot small 
vacuoles also pointed to the presence of glycogen rather than 
mucin Tumour cell invasion into the surrounding connective 
tissue as well as clustering of tumour cells in the lumen of 
blood vessels was found, illustrating metastatic capacity (Fig 
1A) 
Ultrastructurally, a solid arrangement of tumour cells oc­
curred by close apposition of their smooth cell membranes and 
local intcrdigitations, leaving, in several cases, slit-like lumina 
studded with finger-shaped, microvillous protrusions (Fig li) 
Junctional complexes of the fascia adherens type were present, 
but in low numbers (Fig \i,j), sealing off the slit like lumina 
The basal lamina of the tumour cells was regularly interrupted 
(not shown) The cytoplasm of the cells was rich in interme­
diate filaments, cell organelles, glycogen, and solitary fat 
droplets 
The tumour-cell population appeared heterogeneous The 
cell types with the slit like lumina and lateral interdigitations 
had well-developed Golgi areas as well as small, uniform and 
homogeneous secretory granules (Fig \j) The electron-grey 
content was intimately apposed to the limiting membrane 
Another cell type showed a few dispersed "dense core" gran­
ules with their electron-dense content separated by clear halos 
from the limiting membranes, in addition to the Golgi areas 
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(Fig. l/t)- Apart from these cell types, a few cells were ob­
served with dilated Golgi cisternae combined with large con­
densing vacuoles (Fig. 1/) indicative of mucinous-type se­
cretion. 
Immunocylochemical studies of cell cultures 
All cultured OTN 14 cells reacted strongly with the anti-
keratin MAbs RGE 53, OV-TL 12/5, RCK 102. RCK 106, in 
the IFA techniques. An example of such a staining pattern is 
shown in Figure 2a. The reactivity with MAbs against keratin 
7 (RCK 105 and OV-TL 12/30) was strong in a limited number 
of cells only ( ± 5-15%), while most cells reacted weakly or 
not at all with these 2 MAbs (Fig. 2b). 
The epithelial character of the cell line was confirmed by a 
positive, heterogeneous reaction with the marker BW 495/36 
(Fig. 2c). As controls, the MAb to desmin (RD 301), the 
muscle specific intermediate filament protein, was used and 
shown to be negative in all cells (results not shown). OTN 14 
was no exception to the rule that cell lines can express vimen-
tin as a possible adaptation to cell culture conditions and 
showed a positive reaction with RV 202 antibody against 
vimenlin (Fig. 2d). 
While the ovarian carcinoma marker OV-TL 3 (Fig. 2e) 
continued to be expressed weakly in late passages, the antigens 
recognized by OC 125 and OV-TL 10 were gradually lost on 
most cells (Fig. 2f.g). The anti-CF.A MAb BW 431/31 showed 
very weak reactivity on most cells. However, some cell clus­
ters displayed a strong expression (Fig. 2h). 
Immunocylochemical studies on OTN 14 xenografts 
Although the use of mouse MAbs on cryostat sections of 
grafted tumours growing in nude mice gave a relatively high 
background staining, a strongly positive reaction with tumour 
cells was observed when the anti-keratin MAb RGE 53, OV-
TL 12/5 and RCK 102 were used (example shown in Fig. 2i). 
The keratin 7 antibodies (RCK 105, OV-TL 12/30) reacted 
strongly with a few cells in the nodule, while most cells 
reacted rather weakly or were completely negative (Fig. 2j). 
The anti-vimentin MAb (RV 202) was strongly positive on 
about 50% of the tumour cells, which were also positive with 
the RGE 53 antibody (Fig. 2k). The vimentin-positive cells 
often had the appearance of single or loosely arranged cells. 
A heterogencously weakly positive reaction of the BW 495/36 
epithelial marker was noticed. The reaction patterns seen with 
MAbs against CEA (BW 431/31), or against ovarian carci­
noma-associated antigens (OV-TL 3, OV-TL 10 and OC 125), 
could not be evaluated due to background fluorescence. 
Growth characteristics of the cell cultures 
Cells in the 19th passage had a doubling time of 28 '/z hr in 
logarithmic growth (Fig. 3a). Cell growth slowed down as 
confluence was reached, as a result of lack of nutrients. 
СЕЛ and Ca 125 levels in the culture medium 
At passage 19 the supcrnatanls of the growth-curve experi­
ment were tested for Ca 125 and CEA. In all samples, Ca 125 
activity remained below the level of 7.7 units/ml in the control 
culture medium. The amount of CEA produced in the same 
culture samples increased from the control level of 1.1 /ig/l to 
3.6 μg/\. while the cell density increased from IO4 to 10* cells/ 
ml (Fig. 3b). Both observations are in line with the immuno-
cytochemical data. 
Steroid production hy the cell culture 
The production of progesterone and dchydroepiandrosterone 
sulphate in the growth curve experiment did not exceed the 
control levels of 1.3 nmol/1 and 0.1 nmol/l, respectively. The 
level of ocstradiol in the culture supernatant, however, did go 
along with the increase in cell number as shown in Figure 3a, 
and rose from the control level of < 3 8 pmol/l of medium to 
140 pmol/l per I0 6 cells. However, when corrected for the 
increase in cell number during logarithmic growth, the oestra-
diol production calculated per 10" cells remained at a constant 
level of 140 pmol/l, based on a change of culture medium at 
2-day intervals. Cells of passages 10 and 23 showed similar 
results. The level of /3-HCCi in the culture supernatant re­
mained below the control level of 1 ng/l. 
DNA flow cytometry of cultured cells 
Flow cytometric analysis of propidium iodide-stained OTN 
14 cells showed that the ploidy of the tumour cells in the G ι 
phase (channel 40) was 1.934. This pscudo-tctraploid cell line 
appeared in the FCM analysis as a sharp, highly homogeneous 
peak. Cell-cycle analysis of these data showed that about 75% 
of the cells in logarithmic growth were in the G, phase, while 
17% and 8% were in the S and G2M phases, respectively. 
Cytogenetic characterization of the cell cultures 
Chromosome counts revealed an overall aneuploidy which 
resembled pseudo-telraploidy. The chromosome number per 
cell varied from 67 to 88 (X = 83.9 ± so 3.9) with a modal 
number of 86 (Fig. 4). Structural chromosome abnormalities 
were very common. All 10 cells analysed showed between 3 
and 8 marker chromosomes per cell. At least 15 different 
markers were observed. However, the origin of most of them 
remained undetermined and their appearance was sporadic. 
although 3 markers were present in each tumour cell analysed 
and were considered to be clonal. In 2 of these markers the 
short arm of chromosome 1 proved to be involved and partially 
deleted (Fig. 5), while the third marker (of which several 
copies were usually present) resembled the long arms of chro­
mosomes 4 or 5. 
None of the marker chromosomes could be recognized as a 
HcLa cell marker. 
We have described the characterization of an ovarian carci­
noma cell line, OTN 14. This line was isolated from a patient 
who presented with a well-differentiated mucinous cystadeno-
carcinoma of the ovary, which had metastasized to the liver 
and to the peritoneal cavity. The establishment of the cell line 
FIGURK 1 - Light- and electron micrographs of OTN 14 ovarian tumour cell line, (a) Monolayer of polygonal and elongated OTN 14 tumour 
cell culture. Note vacuoles and nucleoli (phase contrast). Scale bar represents 50 μιη. (b) Strongly dilated cisternae of the rough endoplasmic 
reticulum (R). Note also fat droplets and bundles of filaments. Scale bar represents 0.4 μπ\. (r) Immunoperoxidase staining of keratin filaments 
(arrows) with MAb OV-TL 12/5 in OTN 14 cells. (N - nucleus.) Scale bar represents 0.4 μτη. (rf) Detail of a tumour cell showing glycogen 
particles, filaments and fat droplets. Scale bar represents 0.4 /im. (e) Detail of a tumour cell showing a small fascia adhcrcns-likc junction and 
a multivesicular body (thick arrow). Scale bar represents 0.4 /im. (ƒ) Small "dense-core" vesicles associated with the Golgi areas. Note dense 
granules within a Golgi lamella (arrows). Scale bar represents 0.4 /im. (g) Xenograft of OTN 14 tumour cells in nude mice. The tumour nodule 
is encapsulated by fibroblasts and leukocytes. (Trichrome stain.) Scale bar represents 50 /im. (Λ) Metastasized OTN 14 tumour cells in blood 
vessels in the vicinity of a primary s.c. tumour. (Toluidine blue.) Scale bar represents 50 /im. (1) Xenografted tumour cells showing a slit-like 
lumen with microvillous formation, sealed off with (infrequently occurring) junctional complexes of the fascia adherens-type (arrows). Scale 
bar represents 0.4 μπι. (/') Xenografted tumour cell showing small secretory granules (Ihin arrows), a large microvillous and glandular lumen 
(L), darkly stained heterogeneous electron-dense lysosomes, and a single junction (thick arrow). Scale bar represents 0.4 /¿m. (k) Xenografted 
tumour cell showing uniform "dense-core" vesicles (arrows) near Golgi areas. Scale bar represents 0.4 μπι. (I) A tumour cell with dilated Golgi 
vesicles with larger electron-light, condensing vacuoles (arrows) presumably of mucinous character. Scale bar represents 0.4 μιη. 
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FIGURE 2 - Immunofluorescence micrographs of OTN 14 ovarian tumour cells, (a-h) Cultured cells incubated with MAbs against: (a) Keratin 
18: RGE 53; (i) Keratin 7: RCK 105. Note that only a few cells stained strongly, (r) BW 495/36 as epithelial and pancarcinoma marker; (</) 
Vimentin: RV 202; (e) OV-TL 3 against ovarian carcinoma; {/) OC 125 against ovarian carcinoma; (g) OV-TL 10 ovarian carcinoma; (/i) CEA: 
BW 431/31. Note that OC 125, OV-TL 10 and BW 431/31 stained only a small number of cells, (i-*) Xenografted tumour cells in nude mice. 
Tumour sections were incubated with MAbs against: (i) Keratin 18: RGE 53; If) Keratin 7: OV-TL 12/30. Note that only some of the tumour 
cells were stained strongly, (k) Vimentin: RV 202. Note that vimentin was expressed in many tumour cells. Scale bar represents 50 μπ\. 
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CHROMOSOME NUMBER 
FIGI RE 4 Distribution of chromosome counts of the OTN 14 tu­
mour cell line in the 10th subculture A modal number of S6 chro­
mosomes per cell was found. 
from ascites was facilitated by its rapid growth characteristics 
in primary culture and by limited contamination with mesothe-
lial cells. 
The epithelial nature of the tumour cell line OTN 14 was 
shown by the presence of small junctional complexes between 
cells in culture as well as in nude mice, and by the keratin 
intermediate filaments in the cells as shown by immunofluo­
rescence and immuno-electron microscopy with a panel of 
MAbs Moreover, the adenocarcinomatous nature of the cell 
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FIGURE 3 - (α) Growth curve trom the IVth subculture, combined 
with ocstradiol production curve of OTN 14 tumour cells in culture 
Each point represents the mean value of triplicate cultures The so did 
not exceed 10% The dotted bars represent ocstradiol content below 
control levels, (h) CEA production curve of OTN 14 tumour cells in 
culture medium Medium was changed every 2 days in 24 well plates 
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Representative G banded karyotype of an OTN 14 tu 
line was indicated by the presence of intercellular as well as 
intracellular slit-like lumina, and confirmed by the presence of 
keratin 7 and 18 (Ramaekers et ai. 1983с. 1987) Although 
most carcinomas usually still express the keratin filaments 
present in their cell type of origin, altered expression patterns 
have been described in neoplasms (Wu el a!.. 1982). and in 
human mesothclial cells (Connell and Rheinwald. 1983). The 
expression of keratin 7 in cell line OTN 14 in a limited 
proportion of cells, both in culture and in the xenografts, may 
be explained as a consistent neoplastic (de)differenliation step 
in this cell line. However, some adenocarcinomas of ovary 
and endometrium are negative or only partly positive with 
antibodies to keratin 7 (Fischer et al.. 1987). 
The absence of desmin filaments (characteristic of muscle 
cells) is in line with previous data, while the presence of 
vimentin in cultured OTN 14 cells can be considered as an 
adaptation to cell culture conditions, rather than being indica­
tive of mesenchymal cells (Franke el al.. 1979). An interesting 
feature was the co-expression of vimentin and keratin in 50% 
of tumour cells in the helerotransplant in nude mice. This has 
also been noted in several gynaecological adenocarcinomas 
(Puts el al.. 1987). and in metastatic carcinoma cells in body 
cavity fluid (Ramaekers el a!.. 1983a). Both phenomena, i.e.. 
reversible loss of a keratin as well as co-expression of vimen-
tin. might be related to the rapid growth and metastatic prop­
erties of this cell line. 
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Concerning the tate of ovarian carcinoma absociatcd anti 
gens as defined by MAbs OV TL 3 OC 125 and OV TL 10 
most OTN 14 cells m iura remained weakly positive for OV 
TL 3 while reactivity with OC 125 and OV TL 10 was re 
stneted to a few cells only ( < 10% ) Also shed Ca 125 antigen 
was not found in spent culture medium although the preoper 
ative Ca 125 scrum level was high (940 U/ml) Upon xeno 
grafting in nude mice the reactivity with the 3 MAbs was lost 
While OV TL 3 and OC 125 MAbs cover about 100% of the 
ovarian carcinomas in assays on cryostat sections of patients 
tumours their reactivity with cultured ovarian carcinoma cells 
was much lower Upon evaluation of other cell lines cultured 
under the same conditions as for OTN 14 the ovarian carci 
nomaceli lines EFO 21 EFO 27 (Simon el al 1983) OAW 
42 (Wilson 1984) and OV CA 433 (Bast el al 1981) did not 
react at all with OC 125 while OV TL 3 stained weakly and 
hctcrogcncously on all these cell lines (not shown) a phenom 
enon that might be related to culture conditions 
In contrast to the loss of Ca 125 expression upon culturmg 
CEA production was still maintained About 10% ot OTN 14 
cells in culture stained positively with the CFA marker BW 
431/31 resulting in a СЬА level of 5 ng/ml of medium pro 
duccd by 10^ cells after 2 days The average production per 
cell remained stable during logarithmic growth A CLA pro 
ducing ovarian carcinoma cell line has been described by 
Horowitz el al (1985) showing a comparable constant CEA 
production level per cell These authors noticed however an 
increase in the number of CEA producing cells after the 25th 
passage up to > 9 0 % The CLA production by our cell line is 
in accordance with the studies of Marchand el al (1975) and 
Woods el al (1979) showing that CEA was present only in 
mucinous ovarian tumours but not in the serous type tumours 
Subcutancously induced OTN 14 tumours in nude mice ap 
peared histologically to be poorly differentiated or even undif 
ferentiated and by light microscopy hardly any evidence of a 
mucinous origin was found The limited number of junctional 
complexes also indicates a low degree of differentiation Ultra 
structurally however several cell types were observed in the 
population Although no distinct mucinous carcinoma cells 
were seen cells with dilated Golgi cisternac and large con 
densing vacuoles reminiscent of mucinous secretion were ob 
served being suggestive of a progressive dcdiffercntiation of 
mucinous carcinoma cells (Czernobilsky el al 1983) In ad 
dition carcinoma cells were found containing either small 
secretory granules or dense core granules the latter point 
mg to an endocrine cell type The presence of the laller cell 
type was considered by S¿ymanska el al (1983) as additional 
evidence of an intestinal type epithelium as found m muci 
nous cystadcnoma.s and adenocarcinomas 
Several characteristics indicate the malignant nature of the 
OTN 14 cell line (1) The aneuploid karyotype with a nearly 
double number of chromosomes (86) per cell and a DNA 
index of 1 934 Approximately 50% of all human tumour cell 
lines have a chromosome number between 60 and 80 (Biedler 
1975) (2) Multi layering in culture a short doubling time 
(28 'A hr) in vitro and fast progressive growth upon xenograft 
ing m nude mice (reaching 10mm in 6 weeks) This is in 
accordance with a number of studies summarized by Herman 
el al (1984) demonstrating a correlation between aneuploidy 
and a more aggressive tumour course (3) Morphologically 
neoplastic features such as 2 to 4 nucleoli polymorphisms 
and an incomplete basement membrane around the tumour 
found in nude mice (4) The metastasized tumour cells in blood 
vessels in the environment of the primary tumour nodules in 
xenografts 
Our cytogenetic data most closely approach those of Hamil 
ton с I al (1983) and Smith et al (1987) who reported numcr 
ical and structural aberrations involving chromosomes I 4 or 
7 But other chromosomes (3 6) are also reported to be 
involved and as such may play a role in ovarian tumongencsis 
(Sheer el al 1987) But such changes are not restricted exclu 
sively to ovarian carcinomas None ol the chromosome mark 
crs could be rccogni/cd as a HeLa marker excluding the 
possibility of contamination with HeLa cells (Nelson Rees el 
al 1981) 
A surprising characteristic of the OTN 14 cell line is the 
constant production of oestradiol at levels of 14 pmol/l per Ю^ 
cells in 2 days The presence of dense core granules in 
several cells as argued above was highly suggestive of the 
hormone producing character of this cell line The production 
of oestradiol and related hormones in humans has been as 
enbed to granulosa and theca cells as well as to tumour cells 
derived from these cell types (Ishiwata el al 1984) although 
the epithelial ovarian tumours arc considered as non endo 
crine (Mahlck 1986) Several ovarian carcinoma cell lines 
produce hormones (Kanabus a al 1978 Woods «fu/ 1979 
Ishiwata it al 1984) We have recently described a serous 
ovarian carcinoma cell line OTN II producing high levels of 
oestradiol (Poels <f al 1988) In addition significantly in 
creased plasma levels ot androstcnedione estrone and 17(3 
estradiol and other steroid hormones were tound in patients 
with serous and mucinous ovarian carcinomas (Mahlck 1986 
Mango et al 1986) The suggestion that the surface cells of 
the ovary as a source of ovarian carcinomas arc actively 
producing steroids (Nicosia et al 1985) is in line with our 
findings of the ovarian carcinoma cell line OTN 14 releasing 
oestradiol in culture In the future this cell line will be made 
available to other imesligalors 
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We investigated the marker profile of human ascitic and 
cultured mesothehal cells, and compared it to that of ovanan 
carcinoma cells which are related in terms of their histogen­
esis, unrelated colon carcinomas being used as reference Me­
sothehal and ovarian carcinoma cells could not be distin­
guished by (intermediate) filament typing, using monoclonal 
antibodies (MAbs) to keratins, vimentins and desmins Colon 
carcinomas differed from mesothehal cells and ovarian carci­
nomas by the absence of keratin-7 filaments The epithelial 
marker BW 495/36 was completely negative on mesothehal 
cells and positive on all ovarian and colon carcinoma cells. 
While CEA was found on about 85% of all colon carcinomas, 
CEA expression on mesothehal cells and ovarian carcinoma 
cells was below 20% The ovarian carcinoma markers (OV-TL 
3, OV-TL IO, О С 125, M O V IB) were strongly positive on 
ovarian carcinomas and negative on colon carcinomas (or lim­
ited to traces of immunofluorescence on some samples) Al­
though the mesothehal cells showed weak or negative reac­
tivity with these markers, О С 125 antigen was found by 
immunoelectron microscopy on the surface of cultured me­
sothehal cells, and was shed m the culture supernatant at 
concentrations of 50, 28, and 25 CA 125 U/ml/10' positive cells 
This suggests that mesothehal cells may be responsible for the 
synthesis of CA 125 in ascitic fluid. The data indicate that 
ovarian carcinomas, mesothehal cells and colon carcinomas 
can be distinguished using a combination of anti-keratm anti­
bodies with BW 495/36 and anti-ovarian carcinoma markers. 
The human ovary is covered by a layer of cells called the 
"germinal epithelium ' This layer consists of coclomic epi 
thelial cells which also line the peritoneal surface The ovanan 
surface epithelium (Bldustcin. 1981) or ovarian mesothehum 
(Woodruff 1979) is the site of ongm of the largest group of 
ovarian tumours The formation of crypts, inclusion cysts, and 
papillary smiclures is considered to represent steps in differ­
entiation, proliferation and possible malignant transformation 
of entrapped ovarian epithelium, thought to be mediated 
through hormones (Cramer el al 1983) Although ovarian 
mesothehum as well as pelvic and extra-pelvic mesothehum 
have a common embryonic origin, local factors and/or repro 
ductive patterns may play a role in regulating growth and de­
velopment of the mcsothelium, and might explain structural 
morphological differences between ovarian mesothehum and 
adjacent peritoneal mesothehum (Nicosia and Johnson 1984) 
The distinction between malignant cells, atypical mesothe 
liai cells and mesothelial cells in ascitic fluid of patients with 
ovarian carcinoma can often present a difficult diagnostic prob 
lem (Jap et al 1981) The marker profile of 2 related cell 
types (mesothehal cells and ovarian carcinoma cells) was com­
pared to that of an unrelated tumour such as colon carcinoma, 
also frequently causing intraperitoneal ascites We have thus 
investigated the reactivity of mesothehal cells with a panel of 
MAbs to ovanan carcinoma-associated antigens, to intermedi 
ate filaments (keratin, vimentin, desmin), to the epithelial 
marker BW 495/36 and to CEA, and compared it to that of 
ovanan carcinoma and colon carcinoma cells 
MATbRlAL AND METHODS 
Patient data 
Ascitic fluid was obtained from women with ovanan carci­
noma These ascitic samples contained ovanan carcinoma cells 
and mcsothclial cells Mesothehal cells were also collected 
from patients with ascites in which no malignant cells were 
diagnosed Biopsies of ovarian carcinomas and colon carcino 
mas were snap-frozen and used for the immunofluorescence 
assay 
Culture method 
The pelleted ascitic cells were resuspended in RPMI 
1640 based culture medium (Gibco, Paisley, Scotland), and 
cultured as described tor ovarian carcinoma cell lines (Poels et 
al , 1989) The mesothehal cells could be subculturcd at a 1 2 
split ratio for a limited number of passages (7 10) Cell 
growth studies were carried out by culturing cells in plates 
containing 24-wells, 16 mm m diameter (Costar, Cambndge, 
MA) with a change of medium every 2 or 3 days Cells were 
seeded at a density ot 104 cells per ml per well On subsequent 
days cells were detached with trypsin/EDTA and counted with 
a haemocytometer (van Niekerk et al 1988) Triplicate cul 
tares were used per 24 hr interval and the mean number of cells 
per ml pier well was expressed on a logarithmic scale Doubling 
time was calculated from logarithmic growth-phase cultures 
Light and electron microscopy 
Cells grown on multispot slides (Flow, Irvine, Scotland) 
were fixed for 2 min m cold methanol ( - 20''C) and routinely 
stained with May Grunwald/Giemsa and PAS reaction (in 
combination with standard diastase treatment) and with Alcian 
blue according to standard histological procedures 
For standard electron microscopy, monolayers of tumour 
cells, grown in 24 well plates (Flow), were fixed for 10 mm in 
2% glutaraldehyde in 0 1 ч phosphate buffer (рн 7 4, 420 
mOsm) at 4°C 
For immunoelectron microscopy the tumour cells were pre­
fixed in periodate lysine paraformaldehyde-glutaraldchydc so­
lution (PLPG), for 10 mm (Gcndclman et al 1983), washed 
with PBS, then incubated with MAbs and finally with rabbit 
anti mouse IgG peroxidase (1 100, Dako, Copenhagen, Den­
mark) The coated tumour cells were post-fixed for 10 min m 
a 27c glutaraldehyde solution in 0 1 M phosphate buffer (рн 
7 4), stained with 0 1% diaminobenzidine-HC and 0 0 1 % 
H2O2, and further processed for electron microscopy (Poels et 
al 1989) 
Indirect immunofluorescence 
Reactivity of MAbs was tested by the immunofluorescence 
assay described by Poels et al (1986) Cells grown on mul­
tispot slides (How) were pre fixed in cold methanol ( 20°C) 
for 1-2 mm, and tested by the immunofluorescence assay 
No difference was seen in the expression of the different 
markers on cold methanol pre-fixed and non-prc-fixed cells 
I he following sets of MAbs were used 
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A Mouse MAbs against ovarian carcinoma OC I2S (Bast el 
ai 1981), OV TI 1 (Pocls et al 1986) OV-TL 10 tyto 
plasmic antigen of 6094 of serous ovarian carcinomas MOV 18 
(Miotti el at 1987) 
В Mouse MAbs against intermediate filaments keratin-18 
RGE 53 (Ramaekcrs el al 1983) RCK 106 (Ramackcrs el al 
1987), kcratin-7 RCK 105 and OV-TL 12/30 (Ramaekcrs el 
al 1987), broad spectrum keratins OV TL 12/5 with a sim­
ilar tissue distribution pattern to that of RCK 102 (Ramackcrs 
et al 1987), vinicntin RV 202 (Ramackcrs et al 1987, Quax 
el at ^ S U and desmm RD 301 (Quax et al . 1985) 
С Mouse MAbs BW 431/31 against a CFA epitope (Bosslet 
el al 1985) and BW 495/36 against a 200 kDa glycoprotein 
in epithelial cell types (Bosslel el al 1987) The ovanan car 
cmoma cell lines OTN 11 (Pocls el al 1989) OTN 14 (van 
Nickcrkffa/ 1988) EFO 21 EFO 27 (Simon el al 1983) 
OAW 42 (Wilson 1984) OVCa 433 (Bast el al 1981) and 
OVCAR 3 (Hamilton el al 1983) were evaluated with the 
same set of MAbs as used for the mesothclial cell strains 
CEA and CA 125 le\eli in culture medium 
Concentrations of СЬА and CA 125 shed into the culture 
medium were dctcrmmed in medium that had been changed 
every 2 days and was taken from cultures with a cell density 
varying between 10" and 10* cells/ml growing in 24 well 
plates The СЬА content of the supernatant was measured by 
an enzymc-immuno assay (EIA) (Abbott North Chicago, IL) 
and the CA 125 level was measured by an immuno radiometric 
assay (IRMA) (Centocor. Malvcm, PA) according to the man 
ufacturer s instructions 
Flaw cuometn and<uogenetit anahtes 
Flow cytometric analyses of the DNA content of the meso­
thclial cells and cytogenetic analyses were carried out as de­
scribed by van Niekcrk el al (1988) 
RfcSUl TS 
Light and electron microscope of cell cultures 
The mesothclial cell strains adhered to plastic as well as lo 
glass surfaces growing initially as monolayers They prolifcr 
ated intensely and epithelioid sheets and confluent monolayers 
initially developed within 1-2 weeks Tumour cells were rap 
idly o\crgrown by mesothclial cells and eventually degencr 
ated No contamination of the few ovarian carcinoma cells 
present in the ascitic fluid was observed after 1 week In the 
later cultures only mesothclial cells appeared to survive as 
flouRl 1 - One light and 6 elearon micrographs of mesothelial 
cell strains (a) Third passage of pure mesothelial cells (MO mono 
layer at beginning of confluence (phase contrast) Scale bar ^0 μπι 
(bj Detail of 2 mesothclial cells with lascia adherens like junctions 
(asterisk) thick bundle of peripherally located filaments (thick atrou) 
and a few long slender microvilli (5th passage) (thin arrow) Scale 
bar 0 4 μιη le) First passage a mesothelial cell with well developed 
organelles autophagic vacuoles (asterisks) lipid droplets and inier 
mediate sized hlaments Note areas with glycogen granules (arrows) 
preferentially located in the outer zone as well as within the blunt 
protrusions Scale bar 0 4 μπι (dì Detail of a mesothclial cell in the 
5th passage with numerous organelles fat droplets (asterisks) and 
dispersed intenncdialc sized filaments (arrows) Scale bar 0 4 μπι 
(e) Positive immunoperoxidase staining (airows) of peripherally lo 
catcd filaments with the OV TL 12 30 МЛЬ (cyiokeraiin 7) Scale 
bar 0 4 μιη (f) High magnification of positive immunoperoxidase 
stained filaments with the OV TL 12/S MAb (cylokeratin 5 + 7 -c 
14 t 19) Scale bar 0 4 μπι lg) Detail of positive immunoperoxi 
dase stained surtacc and microvilli of a mesothclial cell (arrows) with 
the ОС 125 MAb (against ovanan carcinoma) Cytoplasmic structures 
react negatively Scale bar 0 4 μπι 
judged by phase-contrast microscopy and after Giemsa stain­
ing An explicit distinction was to be made between these 
mesothelial cell cultures and ovarian carcinoma cell cultures 
These mesothclial cells grew as large and single flattened cells 
as well as in islets (Fig la) They did not form 3 dimensional 
clusters, even m regions of high cell density, while the smaller 
ovarian carcinoma cells grew rapidly, often overlapping in 
3-dimcnsional clusters (van Niekerk el at, 1988) Mesothelial 
cell growth stopped after confluence was reached Originally 
the ascitic, reactive mesothelial cells demonstrated strong di­
astase sensitive PAS staining while the cultured cells appeared 
to lose their glycogen 
blcctron microscopically, cultured mesothclial cells ap­
peared to be connected by moderate amounts of small fascia-
adhcrens like junctions (Fig I ft) Generally, in early subcul­
tures, most cells showed a limited number of slender microvilli 
as well as irregular and blunt protrusions decreasing in later 
passages (Fig 1ft) Peripherally localised microfilaments and 
randomly-distributed intermediate sized filaments were dis­
tinct (Fig Ifti) Well developed organelles, lipid droplets and 
electron lucent autophagic vacuoles of varying diameters were 
observed (Fig led) Abundant glycogen particles were clearly 
demonstrated in the peripheral part of the cytoplasm during the 
first subcultures but in the later ones hardly any glycogen was 
detectable (Fig к d) 
DNA flou < Mometric and cytogenetic analysis of cultured 
mesothelial cells 
Flow cytometric analysis of propidium-iodide stained meso­
thelial cell strains (MC 1 , 2 1 ) indicated that the ploidy of the 
trypsmizcd mesothelial cells (of the 5th passage) was 1 1125, 
1 114 and 1 168 respectively approximating diploid status In 
cytogenetic analyses the chromosome counts of 50 mitoses 
revealed a normal diploid (46) number of chromosomes in 
most of the cells m each culture (passage 5) 
ImmunocMochemtcal studies 
Table I shows that all mesothelial cells in ascitic samples as 
well as in culture reacted strongly with all anti-keratin MAbs in 
the immunofluorescence assay This confirms the epithelial 
character of the cells The keratins showed a filamentous net 
work in cultured mesothclial cell strains (Fig 2a-f) The im­
munoperoxidase staining was confined to parts of the penph-
crally localized, thick bundles of filaments, as shown by im-
muno-electron microscopy (Fig lef) The reactivity of anti-
kcratin MAbs with ovanan carcinoma cells in tissue sections, 
in ascites, as well as in culture, was identical to the results 
desenbed for mesothelial cells (Table I) Colon carcinomas 
were distinguished from mesothclial cells and ovanan carci­
noma cells by the absence of reactivity with anti keratin 7 
antibodies (Tabic I) 
The reactivity with the BW 495'36 MAb against a 200-kDa 
glycoprotein in epithelial cell types was negative, both in as­
citic mesothclial cells (fable I) and in the 3 cultured mesothe­
lial cell strains (Fig 2g) This epithelial marker, however was 
positively expressed on all ovanan carcinoma cells in sections, 
ascites and cell lines as well as on colon carcinomas (Table I) 
The muscle-specific intermediate filament desmm was found 
neither in mesothclial cells (Fig 2m), nor in ovarian carcinoma 
cells (Table I) Vimentin was expressed in both ascitic and 
cultured mesothclial cells (Fig 2f) as well as in ovanan carci­
noma cells (Table I) Vimentin was not found in sections of 
ovarian carcinomas 
The ovanan carcinoma markers, defined by the OV-TL 3 
and MOV 18 MAbs, were weakly expressed on the mesothelial 
cell strains (Figs 2h and 2i), and the expression was similar on 
ascitic mesothelial cells (Table II) These antibodies reacted 
strongly with ovanan carcinoma cells in tissue sections and 
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Samples obtained from 15 patients with ascites in which ovanan carcinoma cells were observed Jln one sample some sporadic cells were positive 
ascites the reactivity on ovarian carcinoma cell lines how 
ever was variable (Table II) The OC 125 and OV TI 10 
MAbs were found on less than 10% of the ascitic and cultured 
mesothehal cells staining with varying intensities (Fig 2j k) 
The OC 125 antibody label was located at the cell surface of 
the mesothehal cells as shown by immunoclcctron microscopy 
(Fig \g) OC 125 reacted positivelv with ovarian carcinoma 
cells in tissue sections and ascites (Table II) OV TL 10 was 
positive on JO out of the 50 ovarian carcinoma samples The 
reactivity of all these MAbs with ovanan carcinoma cell lines 
was variable as shown in Table II and negative on colon 
carcinomas 
The anti-СЬА BW 431/31 MAb reacted heterogeneously on 
all examined samples and did not discriminate between me 
sothehal cells ovarian carcinoma cells and colon carcinoma 
cells (Table II) 
No difterence was seen in the expression of the different 
markers when cells were fixed briefly (1-2 mm) in cold meth 
anol ( - 20°C) 
CFA and CA /25 level't m the culture medium of 
mesothelial cells 
At passage 3 the supematants of a growth curve experiment 
with a long doubling time (5-6 days) during logarithmic 
growth were tested for CA 125 and CLA on day 1 and day 17 
during growth In all day 1 samples of the 3 cell strains CA 
125 activity remained low at the level of 15 U/ml being similar 
to that seen in the control culture medium At day 17 CA 125 
activity was 25 L/ml and 28 U ml (strain MC 2 3) and in the 
third mesothelial cell strain (MC 1) the CA 125 level increased 
to 50 U/ml in 2 days while the cell density increased from 
1-2 x 10" to 1-2 x 10' cells The amount of СЬА produced 
in the same culture samples remained below the control level of 
1 2 μg/l of the control culture medium 
In a search for entena to differentiate mesothelial cells and 
related ovarian carcinomas we have investigated some cell 
characteristics of ascitic mesothelial cells as well as 3 meso 
thehal cell strains isolated from the ascites of patients with 
ovarian carcinoma The marker profile of these mesothelial 
cells was compared to that of ovarian carcinomas and of colon 
carcinomas In culture mesothelial cells appear to be epithe 
hold with a limited life-span but they could be subcultured at 
least 7-10 times When confluence was reached cell growth 
stopped Limited growth potential normal DNA index (FCM) 
analyses as well as a normal karyotype pattern arc not 
sulhcicnt to allow a distinction to be made between mesothelial 
and ovarian carcinoma cells Immunocytochcmical character­
ization using MAbs to different keratins (5/8/18/7) did not 
reveal any distinct immunoreactivity pattern for mesothelial 
lersus ovanan carcinoma cells This confirms and extends the 
data of Wu et al (19H2) using a different panel of anti keratin 
MAbs The strong expression of vimentin on cultured meso­
thehal cells (Conncll et al 1983 LaRocca and Rheinwald, 
1984) and the co expression of vimentin with keratin can be 
considered as being charactcnstic ot mesothelial cells m vivo 
(van de Molengraft et al 1986) Initiation of vimentm expres­
sion is thought to be an adaptation to cell culture conditions 
both in iura and in vno rather than being indicative ot mes­
enchymal cell origin (Franke et al 1979) I he absence of 
muscle specific desmin filaments was used as a negative con­
trol for ascertaining the epithelial character of isolated meso 
thelial or ovarian carcinoma cells Although typing with anti­
bodies to intermediate filaments did not permit a distinction to 
be made between mesothelial and ovarian carcinoma cells the 
BW 495 36 MAb appeared to discnminate between mesothe 
liai cells reacting 100% negatively and ovarian carcinoma cells 
reacting 100% positively in ascites as well as in \itro BW 
495/36 is directed against a 200 kDa glycoprotein (Bosslet et 
al 1987) not present on mesothelioma cells (Bosslet personal 
communication) This means that within a keratin positive as-
biGLRF 2 - Immunofluoreïience micrographs of mesothehal cells 
inculture ία m)Cultured mesothehal cells Cells were incubated with 
MAbs against (a) Keratin 18 RGfc 53 (b) Keratin 5 + 7 + 14 + 
19 OV FL 12/5 (с) Keratin 18 RCK 106 (d) Keratin 7 RCK 105 
(el Keratin 7 ОV TL 12/30 φ Vimentin RV 202 Note that the cells 
stam strongly with all keratin markers (g) BW 495/36 as epithelial 
and pancarcinomd marker Noie that the mesothehal cells arc com 
pletcl> negative with this marker (hl OV TL 3 against ovanan car 
cinoma (il MOV 18 against ovanan carcinoma (j) OC 125 against 
ovanan carcinoma (k) OV Tl 10 against ovanan carcinoma (IjChA 
BW 431 31 (m) RD 301 against muscle specific intermediate lila 
ments Note that OV TL 3 and MOV 18 weakly stain all mesothelial 
cells while OC 125 and OV TI 10 stain only a small number of cells 
in culture Note the CEA expression on about 20% of the cultured 
mesothelial cells Scale bar 50 μιη 
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TABLE II TUMOR MARKER PROFI! F OF MLSOllltLlAL tbLLS OVARIAN CARCINOMA CFI LS AND COLON CARCINOMA CELI S 
Ascitic2 mesothelml cells 
(n = 6) 
Mcsothelul cell strains MC 1 2 3 
Ascitic ovarian carcinoma cells 
(n = 15) 
Ovanan carcinoma3 cell lines 
OTN 14 
OTN 11 
EF0 21 
Ж ) 27 
O A W 4 2 
OVCA 441 
OVCAR 3 
Ovanan carcinoma tissue sections 
Colon carcinoma tissue sections 
(n = 10) 
OVTL3 
±1 + 
±1 + 
+/* + 
±/ + 
±/ + 
±/ + 
/• 
±/ + 
±/ + / ^ + 
1-/+ -ь 
+ /+ + 
65/65 
•> 
OV TI 10 
± ' + <1091 ι 
» 1 < 1 0 % l 
+ /+ + 
± / + < 1 0 % , 
+/ + 
+ /+ * 
-
— 
± + 
J-'+ + 
30,50 
_ 5 
OC125 
+ /+ < 1 0 % l 
± / + < 1 0 % , 
-W+ + 
±/+ <ιo% , 
± / + 
- / • * 
+ 
+ 
+ ' + J-
4λ50 
6 
Movie 
+ 
±/ + 
ND 
±/ + 
±/ + 
±/ + 
ND 
±/ + 
± 
±H 
+ !+ + 
27/30 
CtA 
BW4.il 31 
± / + < 1 0 % l 
±80% 
ND 
±90%, 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
20/60 
F + 
9/10 
+ / + + 20% 
, + + 10% 
ТЪе Пиоплсспсе nlensii) as well as the number of posilivc tclK were arbilranl> scored as - negative + weajslv pusmvc 1 pusilive + + strongly positive ND nol 
done -'Less than I0r/f of the tells rLdLltd 1 + Ihe majorit) being negauve Samples obtamid from 6 patients with ascites in whom no malignant cells were diagnosed 
1Samples obtained from IS paliLtus wilh ascites in whom ovarian tartinoma cells were observed 4~lraces were lound m 3 samples ^Traces were found in all samples 
6Traces wen. lound m I sample 
citic cell population mesothelial cells can be excluded on the 
basis of their absence of reactivity with the BW 495/36 MAb 
Concerning the colon carcinomas controls, BW 495/36 re 
acted positively with all samples In contrast to mesothelial and 
ovarian carcinoma cells, colon carcinomas and normal colon 
tissue sections (results not shown) did not express keratin 7 It 
is thus possible to distinguish reliably between mesothelial 
ovarian carcinoma and colon carcinoma cells With regard to 
the evaluation of ovarian carcinoma markers mesothelial cells 
in ascites as well as in culture reacted weakly or not at all 
with MAbs to ovanan carcinoma cells (OV TL 3 OV TL 10 
OC 125 MOV 18) All ovarian carcinoma cells in sections or 
ascites were strongly positive with one or more ot these MAbs 
However, several ovanan carcinoma cell lines largely lost their 
reactivitv with these markers alter growth in culture thus re 
stneting the value of ovanan carcinoma markers mainly to in 
vu о conditions Since colon carcinomas also reacted nega 
lively or very weakly, strong positive staining with ovarian 
carcinoma markers on tumour cells is considered as a primary 
indicator of ovanan carcinomas 
We have substantiated Ihe suggestions of Kabawat er al 
(1983) Bast and Knapp (1984) and Bergmann el al (1987) 
that CA 125 might be synthesized by pentoneal cells by show 
ing that a low but significant level of CA 125 antigen was shed 
in the culture supematants of mesothelial cells In addition, we 
showed by immunoelectron microscopy that CA 125 antigen 
was located on the surface of several mesothelial cells For 
differential cytodiagnosis in ascites, CA 125 positive mesothc 
liai cells can be distinguished by their negative reactivity with 
the BW 495/36 marker 
Reports on the presence of CEA on mesothelial cells, me 
sotheliomas and ovanan carcinomas are conflicting Few me 
sotheliomas exhibiting CEA-positive staining have been dc 
scribed (Silcocks et al 1986, Walts el al 1983) Absence of 
CEA epitopes on mesotheliomas as well as reactive mesothelial 
cells have also been reported by Marshall et al (1984) Гага -
c\Uetal (1985) and Heydemian pr a/ (1985) Although ВW 
431/31 MAb does not react with CEA-cross-reactive antigens, 
we found that it strongly stained a minority (20%) of cultured 
mesothelial cells The in vitro incidence of CEA-positive me­
sothelial cells might reflect differentiating and proliferative 
state of cells by analogy with the expression of CEA in tran­
sitional epithelial cells (Shevchuck et al 1981) The CEA 
marker could not distinguish between mesothelial, ovanan car 
cinoma and colon carcinoma cells In contrast to the ovarian 
carcinoma cell line OTN 14 mesothelial cells in culture did not 
shed CEA antigen in the supernatant This directly supports the 
suggestion of Faravclli et al (1985) that CEA although 
present in adenocarcinomas, is not always released in measur­
able amounts in effusions 
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CHAPTER FOUR 
USE OF MONOCLONAL ANTIBODIES TO KERATIN 7 IN THE 
DIFFERENTIAL DIAGNOSIS OF ADENOCARCINOMAS. 
F. C. S. Ramaekers, С. C. van Niekerk, L. G. Poels, E. Schaafsma, 
A. Huijsmans, H. Robben, G. Schaart and G. P. Vooijs. 
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Use of Monoclonal Antibodies to Keratin 7 in 
the Differential Diagnosis of Adenocarcinomas 
Frans Ramaekers,* Cathanna van Niekerk.t 
Lambert Poels.t Ewout Schaafsma,* Anita 
Huijsmans,* Hannie Robben,* Gert Schaart,* 
and Peter VOOIJS* 
Ιιυηιΐΐκ lh/)cin>innl о/ l'{ilb<ìlaf>) * I mf Í мі/l Itityiikll 
\І//НЧ!І/І \l/niLXt}i ittici ІІн í)i/>arlim til <t/ ( ili /iioiogi 
iltitl ІІыЫо%\ t ί ни LI ui) dj \rf/>lifH η \t/nH l>i n 
llx Suhl ι lunch 
Monoclonal antibodies ( MAbs) to specific keratin 
subtypes uere prepared and characterized by im 
munoblotlmg and immunohtstochemtcal assays 
on human cell cultures and normal and malignant 
human tissues (ham specific MAbs to keratin 7 
(RCK 105 OV 11 12/І0) and keratin 18(R(,L· î j . 
K( к 106 (KIS 2) as well as broadly cross react 
tng keratin MAbs (RCK 102 OV TL 12/4) could be 
shown to react with different types of human epi 
theltal tissues and were therefore tested for their 
usefulness m the differential diagnosis of carcino 
mas The two broad spectrum antibodies stained 
ι trtttally all of the more than i 50 carcinomas 
tested especially when combined, and dtstin 
gutshed them from most nonepithelial tumors The 
keratin 18 MAbs distinguished adenocarcinomas 
(which are keratin 18 positive) from most squa 
mous cell carcinomas (which are generally keratin 
18 negative) The MAbs to keratin 7 could be 
shown to recognize specific subtypes ofadenocarci 
noma and could, for example, distinguish between 
ovarian carcinomas (keratin 7positive) and caret 
nomas of the gastrointestinal tract (keratin 7 neg 
ative) or between transitional cell carcinomas 
(keratin ''positive) and prostate cancer (keratin 
7 negative) In general, malignancies showed the 
expected keratin reactivity pattern as concluded 
from the keratin pattern of its cell of origin or its 
type of differentiation The use of an extended series 
of malignancies did however, also illustrate that 
exceptions to this rule exist For example, certain 
antibodies to keratin 18 stained tumor areas in 
squamous cell carcinomas of the lung Also a cer 
tain percentage of tumors, which generally showed 
no keratin 7 expression, were positive with RCK 
105 or OV TI 12/iO On the other hand a certain 
percentage of tumors which were generally post 
tire for keratin "* did not shou a staining reaction 
withthese YlAbs hurthermore subtle differences he 
tween reactivity patterns of different MAbs recog 
ntztng the same keratin protein were obsemed, 
both in the normal and malignant human tissues 
indicating that specific keratin epitopes may be 
masked m certain tissues and that unmasking of 
such epitopes can occur with malignant progres 
Sion This phenomenon may he of some use in a 
further subtyptng of carcinomas especially those 
of the gastrointestinal tract Despite these excep 
tmnal staining patterns, the keratin MAbs de 
scribed above have proved to be useful tools in the 
characterization of epithelial tumors in routine 
htstopathology and < ytopathology, in which they 
add to a more refined diagnosis of (ademt )c arc ino 
mas (Am J Pathol 1990 П(>М1-655) 
Keratins have been recognized to be epithelium specific· 
intermediale filament proteins and to comprise a family of 
at least 19 different polypeptides ' ? not including the hair 
keratins3 Also malignancies derived from such epithelial 
tissues have been shown to express specific keratins ' ' 
Combinations of the 19 different keratin proteins are dis 
tnbuted in a more or less tissue specific fashion as initially 
delected by two dimensional gel electrophoretic proce 
dures 1 The use of chain specific monoclonal antibodies 
(MAbs) to individual keratins has conlirmed these bio 
chemical studies and allows the immunohistochemical 
distinction between different epilhelia and carcinomas 
For example certain MAbs to keratin 18 separate most 
squamous cell carcinomas from adenocarcinomass 
while the degree of differentiation in a squamous epithelial 
tumor can be estimated by the use of keratin 10 or keratin 
13 MAbs8 
In a recent study9 we have described the preparation 
of a MAb specific for keratin 7 (RCK 105) and have shown 
Accepted (or publication November 1 1989 
To obtaïi antibodies OV TL 12/5 and OVTL 12/30 please contact 
Dr L Pods 
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Table 1 Ki(iLfii¡t\ I'dtUnnuf Monoclonal Kt иііш \ntib<uln\ tu ΜαΙιφη/ίΐΐ f f)¡tl)i hal Ilntnan //ss//ts 
Broad Keratin 7 Keratin 18 
Diagnosis 
RCK 
10? 
OVTL 
12/5 
RCK 
105 
OVTL 
12/30 
RGE 
53 
RCK 
106 
CK 
18? 
Squnmous ( oll сагппогтіаь 
Squamous coll ca vulva 
Squamous с ell ca vulva 
Keratinizing squamous cell ca penis 
Lymph node metastasis poorly diH squamous 
célica perns 
Moderately diff squamous cell ca cervix 
Keratinizing squamous coll ca tongue 
Keratinizing squamous cell cd pdrolis 
Well diH squarnoub coll cd oosophdyus 
Lymph nodo moldsLisis poorly diH squamous 
coll ( a 
I ymph nodo met squamous cell ca 
Lung tumors 
Squamous cell carcinoma 
Adenocarcinoma 
Small cell anaplastic ca 
Carcinoid 
AdenocarcmoTias o( the Gl Irdcl 
Modoralrly diH mucinous adonoc a slomach 
Moderately difl aciorux a slomach 
ModtHdlely'poorly dill aiJenoca slomach 
Poorly dill adenoca slomich 
Poorly dift adenoca stomach 
Poorly dift anaplastic ca stomach 
Anaplastic ca stomach 
Metastasis of a slomach adenocarcinoma in 
the ovaries 
Signet ring coll ca stomach 
Mucinous adonoi a slomach 
Adenoca slomai h 
Anapldslrc adenoca stomach 
Malignarli degenerated adenovillous polypous 
stomach 
Adenocarcinoma jejunum 
Well/moderately diH mucinous adenoca 
colon 
Welldiff adenoca colon 
Moderately diff adenoca colon 
Moderalely diH adenoca colon 
Moderately diH parlly papillary adenoca 
colon 
Molastabis ol Ihis tumor in the ovary 
Moderately diH multifocal adenoca colon 
Metastasis ot this tumor in the ovary 
Metastasis ot a moderately dift adenoca of 
the colon 2x 
Poorly diff adenoca colon 
Poorly dift adenoca colon 
Metastasis ot a mucinous colon adenoca in 
the ovary 2x 
Inleslrnal carcinoids 2x 
Carcinomas ol Ihe pancreas 
Carcinoma in pancreas (aulopsy material ot 
palient with lung metastases) 
Mucinous adenocarcinoma 
Adenocarcinoma 
Papillary adenocarcinoma 
Liver tumors 
Hepatoblastoma 
Hepatocellular carcinoma 
Hepalocellutar carcinoma 
Hepalocellular carcinoma 
Breast carcinoma 
104 
104 
6X 
10X 
I 
^ 
+ 
+ 
+ 
1 
' 
-
+ 
+ 
»§ 
I 
1 
+ 
+t 
-
-t 
t 
t 
I 
+/-
-· 
t 
+t 
+ 5 
t 
ι & 
-
+ t 
I t 
t 
-
t 
+§ 
+ & - t 
+ 
^§ 
+ 
+ t 
+ ι 
ι t 
1 
f 
3X 
2X 
5X 
2X 
2ΊΧ 
80X 
+ § 
П 
1 
•f 
t 
+ 
+ 
+ 
+ 
+/-
+§ 
+t 
+t 
+ 
+§ 
+§ 
+t 
+ 
i t 
+§ 
+ t 
+t 
t § 
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Table 1 {(.onniiHcti) 
Diagnosis 
Female genilal Iracl carcinomas 
Anaplastic carcinoma of the cervix 
Adenosquamous carcinoma of Ihe cervix 
Metastasis of a fallopian tube adenoca 
cervix 
Serous cysladenocarcmoma 
Mucinous cysladenocarcmoma 
Endometrioid carcinoma 
Metastasis endometrioid ca on the 
mesocolon 
Nonclassified ovarian carcinomas 
Choriocarcinoma 
Liver metastasis of a chonoca 
Brenner tumor 
Male genital tract tumors 
Anaplastic seminoma 
Embryonal cell carcinoma 
Prostate carcinoma 
Urinary tract carcinomas 
Renal cell carcinoma (Grawilz tumor) 
Renal cell carcinoma 
Renal cell carcinoma 
Renal cell carcinoma 
Renal coll carcinoma 
Wilm s lumor 
Wilm s tumor 
Transitional cell carcinomas 
Miscellaneous 
Mesothelioma 
Carcinoid 
Adrenal pheochromocytoma 
in the 
2 1 X 
6X 
ΘΧ 
4 x 
5X 
11X 
6 X 
2 X 
6 X 
2 X 
эх 
I X 
59X 
4 X 
?1X 
2 X 
2 X 
RCK 
102 
+ 
+ 
+ 
+ 
+ 
+ 
1 
t 
+ 
+ 
+ 
-
+ 
+ 
1 
i 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
(Τ 
t 
-
Broad 
O V T L 
12/5 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 1 
f 
-
+ 
+ 
-
Keratin 7 
RCK OV TL 
105 12/30 
+ t 
+ t l·· 
+ + 
+ 1 + 
+ 
+ T + 
+ + 
+ + 
+ + 
+ 
+ + 
-
-" 
-· -* 
-
-· 
f 
-
-
-
+ § 
+ 
t-§ 
-
RGE 
53 
+ 
+ 
+ 
+ 
+ 1 
+ 
f 
+ t 
+ 
-
+ t 
+ 
*-
+ § 
-t 
+ § 
+ 
+ # 
+ T 
t 
-
Keratin 1Θ 
RCK 
106 
+ 
Η 
+1 
H I 
+ 
+ 
+ 
+ 
+ 
1 
f i 
-
CK 
1 8 2 
+ 1 
+ 
ι 
t 
+ 
-
+ 
+ / - Weakly positive 
' Some sporadic cells positive (m one or some specimens) 
t Partly positive 
} Some positive edses or cases with positive areas 
§ Sometimes also tumors with negative areas or sporadically complelely negative tumors were lound 
1
 For RCK 102 40 cases were examined 
Τ Only few cases were examined with these antibodies 
# Variable stairung pattern with 32 cases completely positive and 26 cases partly positive One negatwe case showed squamoid differenlialion 
that among normal human eptthelta such a reagent can 
distinguish different types of columnar and glandular epi-
thelia Other authors have already pointed to the useful 
ness of keratin 7 MAbs in tumor diagnosis , 0 ' ! 
In the underlying study the applicability of this MAb in 
the differential diagnosis of carcinomas was (urther ежат 
med Because we were, however, aware of Ihe fact lhat 
epitope masking may be a common feature when work 
mg with monoclonal (keratin) antibodies, we prepared a 
second MAb to keratin 7 (OVTL 12/30) and used it in 
parallel with RCK 105 This antibody was obtained after 
immunization of mice with a human ovarian tumor cell 
line13 and had been tested only on cultured cells , 4 , 5 
In this paper the antibody is characterized further by 
tmmunoblotling and applied to normal human epithelial 
tissues and to carcinomas Next to these keralm 7 MAbs 
broadly cross reacting monoclonal keralm antibodies 
(RCK 102 and OV TL 12/5), as well as antibodies lo kera­
tin 18 (RGE 53, RCK 106, CK 18 2) were used in this 
study 
Materials and Methods 
Tissues and Cell Cultures 
Fresh normal and neoplastic human tissues (Tables 1 and 
2) were obtained immediately after surgery or during au­
topsy, frozen m liquid nitrogen, and stored either in liquid 
nitrogen or at -80 С 
Frozen sections (4 to 7 μηη thick) were cut on a cryo­
stat, air dried, and in most cases also fixed in methanol 
(-20 C) for 5 minutes and dipped in acetone All tissue 
specimens were diagnosed using hematoxylin and eosm 
(H&E) stained paraffin sections Ovarian carcinoma cell 
lines OTN11, OTN14, EFO-21, EFO 27, OAV\M2. OVCA 
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Table 2 Л/фІісаНіт of Keratin MAh\ ni Differential Iunior Diagnosis 
£» 
» 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
io 
11 
12 
13 
14 
Sex 
F 
F 
F 
F 
F 
M 
F 
F 
M 
M 
F 
F 
F 
F 
Age 
53 
41 
65 
66 
65 
74 
27 
64 
47 
70 
60 
56 
56 
Localizalion 
Pelvic cavity 
Ovary 
Abdomen 
Inguinal lymph node 
Liver 
Prostale 
Omentum 
Ovary and kidney 
Cervical lymph node 
Axillary lymph node 
Lung 
Small bowel 
Omentum 
Peritoneum 
Histologic 
appearance 
Moderately 
differentiated 
adenocarcinoma 
Moderately 
differentiated 
adenocarcinoma 
Poorly diflerenlialed 
adenocarcinoma 
Poorly differentiated 
adenocarcinoma 
Poorly differen'ialed 
adenocarcinoma 
Poorly diiferenlialed 
carcinoma 
Undifferentiated 
large cell 
carcinoma 
Large cell 
carcinoma 
Poorly diiferenlialed 
adenocarcinoma 
Undifferentiated 
large cell 
carcinoma 
Adenocarcinoma 
Poorly differentiated 
adenocarcinoma 
Poorly differentiated 
carcinoma 
Undifferentiated 
carcinoma 
DD for localization/ 
classification primary 
malignancy 
Coion or ovary 
Colon or ovary 
Colon or ovary 
Gl tract, ovary or others 
Gl tract (nver bile 
ducts, stomach or 
colon) 
Urmary bladder or 
prosiate 
Ovary or others 
Kidney or ovary 
Lung, prostate, or 
others 
Lung urinary bladder, 
or others 
Lung, Gl Iracl or 
others 
Ovary or Gl tract 
Ovary or Gl tract 
Ovary or others 
RCK 
102 
nd 
nd 
+ 
nd 
nd 
nd 
+ 
+ 
+ 
nd 
nd 
nd 
no 
+ 
HCK 
105 
-
+ 
+ 
+ 
+ 
I 
, 
+ 
RCK 
106 
nd 
nd 
Ί
-
+ 
+ 
+ 
+ 
+ 
+ 
nd 
nd 
+ 
+ 
Final diagnosis 
Colon carcinoma 
Colon carcinoma 
metastasis 
Ovarian carcinoma 
Ovarian carcinoma 
Care noma of the 
extrahepalic bile 
ducts 
Transitional cell 
carcinoma 
Ovarian carcinoma 
Renal cell carcinoma 
metastasis 
Lung carcinoma 
DD lung carcinoma or 
transitional cell 
carcinoma 
Bronchioalveolar 
carcinoma 
Endometrioid carcinoma 
Endometrioid carcinoma 
Mixed Mulleran tumor 
Remarks 
Elevated Ca 125 serum level but no 
immunohistologic OC 125 
reactivity 
Colon carcinoma resecled θ months 
be'ore detection of second 
tumor 
Immunohistologic reactivity with 
ovarian ca markers OC 125 and 
OVTL3 
Obstructive jaundice 
Bladder tumor removed 7 years 
before detection of extension 
into prostate 
Renal cell carcinoma in left kidney 
Lung biopsy posilive lor cancer, 
prostate biopsy negative lor 
cancer PSA negative 
Cytology positive for urinary bladder 
carcinoma Surgery revealed 
transitional cell carcinoma pT2 
G3 
Diagnosis supported by clinical 
data 
Immunohistochemical reactivity with 
ovarian tumor marker OV Tl 3 
Immunonislochemical reactivity with 
ovarian tumor markers OV TL 3 
and OC 125 
No immunohistochemical reaclivily 
with ovarian tumor markers 
OV TL 3 or OC 125 
nd nol dülcmned 
DD ditlcrcnlial diagnosis 
433 and OVCAR 3 were grown as described ' ' l 5 while 
cell lines T24 RT4 HeLa TRI46 (provided by Dr Ε В 
Lane ICRF London) KB WiDr LLCMK2 and A431 
were grown in Eagle s Minimum Essential Medium 
(EMEM) containing 10% newborn bovine serum 
lmmuno(histo)chemical Assays 
The indirect immunofluorescence technique on (rozen 
sections (either air dried and/or fixed in methanol with or 
without an additional acelone fixation step) was per 
formed essentially as described before I C " Also the im 
munoperoxidase technique used on Irozen sections in 
this study has been publishedβ 
Cell cultures were washed with phosphate buffered 
saline (PBS) fixed in methanol/acetone as described 
above and rehydrated with PBS before the first antibody 
was added 
One and two dimensional SDS Polyacrylamide gel 
electrophoresis and immunoblottmg of Triton X 100-ex 
traded cytoskelelon preparations of cell cultures and 
solid tumor tissue wore done as described by Ramaekers 
et al9 and Broers el al " 
Antibodies 
The following mouse monoclonal antibody preparations 
were used in this study 
1) Antibodies OV TL 12/5 and OV TL 12/30 were ob 
tamed from a fusion of Sp2/0 Aq14 myeloma cells 
with spleen cells from mice immunized with OTN 
11 ovarian carcinoma cells , э These cells were 
grown in RPM11640 containing 15% lelal calf se 
rum (FCS),3 Cell suspensions were cryopreserved 
in medium containing 10% FCS and 10% dimethyl 
sulfoxide and stored in liquid nitrogen 
Eight week old male Balb/c mice were immunized 
by seven subsequent inlraperiloneal injections at 
2 to 3 week intervals with 2 lo 3X10° cultured OTN 
11 tumor cells '3 'b Three days after the last in|ec 
lion the spleen was aseptically removed and fusion 
was performed by incubating 8x10' lymphocytes 
with 4X10' mouse SP2/0 Agi4 myeloma cells in 
the presence of 0 5 ml of a 50% (volume/volume) 
polyethylene glycol 4000 solution for 1 minute at 37 
С arcording to Ihe lechnique of Kohier and 
Milstem'8 and modified by Kennet el a l , 9 Growth 
conditions cloning and testing procedures were 
essentially as described before for OV TL 3 , 6 
2) Antibody RCK 10? amouseMAb has been found 
to be specific for keralms 5 and 8 (lor keratin no 
mencldture see Moll et al ') A parlial charactenza 
lion of this antibody recognizing many epithelial lis 
sues and tumor types has been described be 
fore9 
3) Antibodies RGE 53 RCK 106 and CK 18 2 have 
been shown to recognize specifically epitopes on 
keratin 1 8 6 9 It should be noted that in certain tis 
sues keralin 18 epitopes delected by Ihe individual 
antibodies may be masked ^ 
4) Antibody RCK 105 has been shown to react spe 
cifically with keratin 7 and as a result to react with 
transitional epithelium and a subpopulation ol co 
lumnar and glandular epithelia ""^ 
Next to these additional monoclonal keralin antibod 
íes were used in the immunoblottmg studies to determine 
the exact nature of the antibodies described above They 
included antibodies M20 (anti keratin 8) 61310 (anti kera 
tin 4) AF3 (recognizing Ihe basic keralms 1 to θ)2' LP2K 
(anti keralin 19 a gilt from Dr Ε В Lane I ondon) and 
E3 (anti Keratin 17 see Guelslcin et a l" a gift from Dr 
S M Troyanovsky Moscow) and RKSE 60 (anil keratin 
10) see Broers et al 'and Guelstein el al *" Furthermore 
the antibody RV202 specific for vimcntm 9 " was applied 
in the immunoblottmq assays 
Results 
Monoclonal Antibody Characterization by 
Immunoblottmg 
Keratin antibodies RCK 106 RGE 53 and CK 18 2 have 
been characterized extensively as described before ь ' x 
For this study antibodies OV TL 12/30 RCK 105 OV Tl 
1?/5 and RCK 102 were further characterized by one 
and two dimensional imrrunoblotting procedures 
The characterization of RCK 105 has been described9 
and was performed mainly by immunoblotling of cyloskel 
etal preparations of cell lines 
Figure la shows a comparative one dimensional im 
munoblottmg study ol this antibody with antibody АЕЗ21 
indicating that in those cell lines containing among olh 
ers keratin 7 only this protein band is recognized by RCK 
105 (Figure 1 a compare lanes 3 and 4 and lanes 5 and 
6) Those cell lines known not to contain keratin 7 also do 
not show reactivity with RCK 105 in the blots (Figure 1a 
compare lanes 7 and 8 and lanes 9 and 10) A human 
foreskin preparation containing several of the high molec 
ular weight keratins (Figure 1a lane 1) is also negative lor 
RCK 105 (Figure 1a lane 2) The keratin 7 nature of the 
RCK 105 antigen was further confirmed by two dimen 
sional immunoblottmg (Figure 1 b and c) To extend the 
immunochemical characterization ol RCK 105 to human 
malignant tissues we used cytoskolclal preparations of 
45 
Ій 
9 E·* 
τ 
1 2 3 4 β β ^ * 8 9 10 1 2 Э 4 Β β 
rñ j 
9 
1 2 3 4 
h 
• 
1 2 3 4 
,i 
1 2 3 4 
.-18 — «Mg Щ 
1 2 3 4 1 2 3 4 
I 
m 
0 
Ig«, 
^ « - «. 
1 2 3 4 
Ρ r 
1 
. 4 8 
7 — -
* α 
1» «pi» 
^шт^ 
В _ ^ ^ 8 M 
3 4 S 3 4 S 
Figure 1 Imnninohlotttng assays and indirect immunofluorescence micrographs (f. n) of antibodies RCK І05 (α-e). OV TL І2/Ю 
(J tn>. OV-TL I2/5(n uiandRCK 102(i-z) a: Cytoskeletal preparations from ьеі eral tissues and cell lines stained и ith antibody 
RCK IOS (lanes 2. 4. 6, H. 10) or uttb antibody ATj (lanes 1. Ì. 5, 7, 9} The cytoskeletal extracts uerefrom tbefollouing tissues or 
cell cult mes lanes I and 2 human foreskin keratins, lanes Í and 4. HeLa cells lanes 5 and 6. KB cells lanes 7 and 8 WiDr cells 
lanes 9 and ¡0. IICMK 2 cells Note that the antibody /If Ì recognizes several keratins (amongst uhich 7 and 8 indicated as such) 
and their breakdou η products The protein band recognized by RCK ¡05 comigrates и Uh the keratin 7 band and is not risible in 
those preparations thai bare no detectable amounts of keratin 7 in the AS3 incubated blots (lanes 7-10) b: Tuo dimensional 
innuuntihlotting oj R( К 105 an KH cells С Tu о dimensional immunoblotling of RCK 10$ on AÍM cells Ó One dimensional inimu 
nohlotting oj AYA IOS он с \ toskelí tal preparations from a lung adenocarcinoma (lane 1) and sei eral transitional cell carcinomas 
oj the bladder (lanes 2 6) Note reactinty uith the cytokeratin 7 hand and to a much lesser extent uith breakdou η products e: 
Immunoblotting ofR(K ¡05 on a tu о dimensional blot of an adenocarc inoma of the lung rei ealedonly one immunoreactue protein 
spot migrating m the position of keratin 7 The blot и as reincubated и ith RCK 106 and LP2K staining keratins 8 and 19 respectively. 
и hich и ere used as markers f: l m munojluorescence micrograph of OV TL ¡2/jO on a cultured human mesotbelial cell g,h: Cytoskel 
elal preparations pom Hel a (lane ¡ ). R¡4 (lane 2) and A4 il (lane i) tells as и ell as a keratin preparation from human foreskin 
(lane 4), showing that OV Tl ¡2/І0 reacts only uith (preparations containing) keratin 7 As a control antibody RCK ¡02 и as used 
to renn ubate the blot shoii η in (g) resulting m blot (h) and indicating that the protein band recognized by OVTL ¡2/30 is situated 
betueen keratins 5 and 8 on these one dimensional blots l-k: ¡mmunoblots containing с ytoskeletal preparations from HeLa cells 
(lane ¡). bonne lens (lane 2). A4M tells (lane i) and RT4 cells (lane 4). initially incubated и ith OV TL t2/30sbou ingonh keratin 
7 and hreakdoun products (Figure ti), and thereafter subsequently reincubated и uh RCK ¡06 (Figure ¡j) indicating the position 
ofkvratin ¡8. and R\ 202 (Figure Ik) to indicate the position of nmentin (ι) I. m: Tuo dimensional immunoblots of a cytoskeletal 
preparation oj RT4 celts incubated и ith OVTl ¡2/^0 (Figure H ) and thereafter и ith RCK 102 ( Figure 1m) П: Immunofluorescente 
micrograph of OV TL 12/5 on cultured human mesotbelial cells O' One dimensional immunoblotting assay of OVTL ¡2/5 on cy-
toskeletal extracts of RT-i cells (lane 1 ) a squamous cell carcinoma of the lung (lane 2) esophageal epithelium (lane _i) and a 
transitional cart moma of the urinary bladder ( lane 4) p - r Tuo dimensional immunoblotting stud) on a cy toskeletal preparation 
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solid bladder transilional cell carcinomas and lunq carci 
nomas Figures Id and e show two examples o) one and 
Iwo dimensional immunoblols ol these preparations indi 
eating that also in tumor tissues only keralm 7 is recog 
mzedbyRCKIOS 
Antibody OV TL 12/30 also was lound to specifically 
react with keratin 7 This antibody has been shown in a 
previous study1'1 to stain intermediate filament structures 
in cultured ovarian carcinoma cells and mesolhelial cells 
(Figure 1 f ) Figure Ig shows immunoblottmg studies with 
OV TL 12/30 on gel eleclrophoretically separated cy 
toskeletal preparations ol human cell lines including 
HeLa RT4 andA431 as well as on a keratin preparation 
of human foreskin Also a vimentm containing bovine lens 
cytoskelctal preparation was run on a similar gel (Figures 
l i lok) 
From these experiments it is clear that OV TL 12/30 
reacts with a 54 kd protein band in the cell lines but not 
with the foreskin keratins or with vimentm Remcubation 
of immunoblots with antibody RCK 102 (specific for kera 
tins 5 and 8 Figure 1 h and dala presented below) iridi 
caled that the keratin polypeptide delected by OV TL 12/ 
30 has a molecular weight that is slightly higher than kera 
tin θ but less than that of keratin 5 When comparing Fig 
ures li to к it is obvious that the OV TL 12/30 antigen has 
a molecular weight slightly less than that of vimentm Two 
dimensional immunoblots further substantiated the kera 
tin 7 character of this protein (Figures 11 and m) 
Antibody OV TL 12/5 also stained a filamentous net 
work in the cultured ovarian carcinoma cells described in 
Materials and Methods and mesothelial cells in the indi 
reet immunofluorescence assay (Figure In) In immu 
noblottmg studies this antibody could be shown to react 
with cytoskeletal proteins ol epithelial but not ol nonepi 
thelial cells and tissues lor example tissue of the eye lens 
Several protein bands recognized by OV TL 12/5 migrate 
in the positions between keratins 5 and 19 in keratin con 
taming preparations Irom RT4 esophagus as well as lung 
and bladder cancer (Figure 1o) Two dimensional immu 
noblottmg studios on RT4 cytoskeletal preparations 
showed that OVTL 12/5 reacts with keratins 7 and 19 
(Figures 1p to r) Immunoblottmg studies on TRI46 су 
toskeletal preparations (known to contain keratins 5 6 8 
14 17 and 18 see Qumlan el al') revealed lhal m these 
cells OV TL 12/5 reacted with keratins 5 and 14 (Figures 
1s to u) This was confirmed by remcubation of the immu 
noblots with antibodies specifically recognizing several 
other basic and acidic keratins (see legends to Figures 
1 q r t and u) In conclusion OV TL 12/5 recognizes epi 
topes in keratins 5 7 14 and 19 
Antibody RCK 102 has been briefly described be 
fore9 ^ In many cultured epithelial cells this latter antibody 
reacts with keratin filaments Immunoblotlmg results on 
such cell lines show that RCK 102 reacts with keratin 8 
(Figure 1v and w) Using skin keratin preparations and 
cytoskeletal extracts of tumors containing among others 
keratin 5 indicated that RCK 102 also recognizes this lat 
ter keratin protein (Figures 1v to x) 
No other keratins were recognized by the antibody 
Also two dimensional immunoblollmg of cell lines (Figure 
1 y) normal tissues (for example human foreskin Figure 
1z) and tumors (bladder transitional cell carcinomas and 
lung carcinomas see Broers et al") revealed that RCK 102 
recognizes only keratins 5 and 8 
Monoclonal Keratin Antibody Reactivity 
Patterns in Normal Human Tissues 
The results of immunohistochemical staining experiments 
(using either the indirect immunofluorescence or immuno 
peroxidase technique) on normal human epithelial tissues 
using most of the antibodies described above are sum 
manzed m Ramaekers et al9 and in Schaafsma et al ^ In 
general nonepithelial tissues such as connective tissue 
blood vessels and blood cells lymphoid tissue spleen 
nerve tissue and muscle tissue (both smooth and stri 
ated) were negative with the keralm antisera However 
occasionally we have observed keratin staining m pat 
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ches of smooth muscle cells especially in myometrium 
Also occasionally stromal cells in the prostate showed 
keratin reactivity 
Broadly Cross reacting Antibodies RCK 102 
andOV TL 12/5 
Antibody RCK 102 stained virtually all epithelial cell 
types with the exception of the suprabasal keratinizing 
cells in the epidermis and the semmilerous tubules in the 
testis This latter cell lype has been described not to con 
tain keratins at all¿i Ttic keratinizing epidermal cells were 
however positively stained with antibody OV TL 12/5 
This monoclonal antibody shows reactivity with most of 
the epithelial cells tesled although no staining reaction 
was observed in cardiac glands acini and islet cells of the 
pancreas hepatocytes or in the proximal lubules of the 
kidney I hese différences in Ihe reaction patterns of RCK 
102 and OV TL 12/5 can be explained by the observation 
described above that OV TL 12/5 does not react with ker 
aim 8 
As a result a combination of both anlibodies allows 
the detection of virtually all keratin containing epilhelia 
Keratin 7 Antibodies RCK 105 and OV TL 12/30 
The antibodies specifically recognizing keralm 7 (RCK 
105 and OV TL 12/30) showed reactivity patterns in the 
normal tissues essentially as described beforeΒ 9 Λ > In 
briet both antibodies reacted in the columnar and glandu 
lar epithelium of the lung cervix breast bile ducts col 
lectmq ducts in prostate mesolhelium and surface epithe 
hum of the ovary the epithelium lining the fallopian tubes 
rete epithelium in the testis and epididymis epithelium In 
the kidney glomeruli and proximal tubules were negative 
An increasing number ol cells became positive for the 
keratin 7 antibodies when going trom the distal ducts to 
the cdlecling tubules Also transitional epithelium in the 
bladder was found to be strongly positive although in a 
heterogeneous fashion ^ 
In general no reaction was found with RCK 105 in (ke 
ralmizing) squamous epilhelia myoepithelium hepato 
cyles or the epilhelia lining the gaslrointeshnal tract and 
prostatic acinar epithelium OV TL 12/30 reacted in a sim 
liar way with the exception that the surface epithelium of 
the stomach and duodenum as well as myoepithelial 
cells were positive with this antibody Because cardiac 
and gastric glands were not stained by OV TL 12/30 this 
antibody may be used to distinguish between surface epi 
thelium which is positive and glands in the stomach and 
duodenum which are negative On the other hand this 
antibody discriminates between surlace epithelium of the 
colorectal part and the small intestine which is negative 
and stomach epithelium which is positive With respect 
to the myoepithelial cells it should however be staled 
that positivity or negativity in these flattened cells is often 
difficult to interpret 
Another striking difference in the staining patterns ol 
RCK 105 and OV TL 12/30 was observed in the prostate 
in which OV TL 12/30 stained part of the luminal and basal 
cells of the acini while RCK 105 reacted occasionally with 
some luminal cells With respect to the nonreactivity of 
the keratin 7 antibodies in hepatocytes of normal liver it 
should be staled that in patients with acule and chronic 
cholestasis we have observed keratin 7 expression in he 
patocytes ?л 
Keratin 18 Antibodies RGE 53, ЯСК 706, 
and CK 18-2 
All three keratin 18 antibodies reacted with glandular 
and ductal epilhelia including those of the gastrointestinal 
tract prostate and kidney and with hepatocytes and 
mesolhelium as described before09 No reaclion was 
seen in squamous epithelia most myoepithelial cells and 
most basal cells in the cervix prostate and lung 
In the transitional epithelium ol the bladder only the 
superlicial umbrella cells reacted positively with RGE 53 
while antibodies RCK 106 and CK 18 2 in addition also 
stained the basal and intermediate cell layer ot the bladder 
epithelium ^ 
Monoclonal Keratin Antibody Reactivity 
Patterns in Malignant Human Tissues 
The results of the immunohislochemical studies on hu 
man malignant epithelial tissues are summarized in Table 
1 and illustrated in Figures 2 to 4 In general malignancies 
of nonepithelial origin such as (non Hodgkin) lympho 
mas (ibrous histiocytomas leiomyosarcomas rhabdo 
myosarcomas and other son tissue tumors including Ew 
mgs sarcoma and epithelioid cell sarcoma as well as 
melanoma were negative with all keratin antibodies ap 
plied Occasionally keratin positive cells were observed 
in such nonepithelial malignancies (see for example 
Guelstem et aP) and in the tumor stroma (Figure 21) 
Broadly Cross-reacting Keratin Antibodies 
(left panels in Figures 2 to 4) 
Antibody RCK 102 gave a positive reaction in virtually 
all the 365 primary and metaslalic epithelial neoplasms 
tesled including squamous cell carcinomas of different 
degrees ot diffcrenliation transitional cell carunomas ad 
enocarcmomas hepatocellular carcinoma (small cell) an 
aplastic carcinomas mesotheliomas and carcinoids An 
tibody OV TL 12/5 tested in a smaller series of carcmo 
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Figure 2 Mttwgra/ìh·, of immunoperoxÍdase[й~С, g-i) ami immunoßuorescetice (d-f, j-l) assays showing ihe reactfpit} pattertts oj 
RCK IIL'iaiimlg). Ol / / /_'/5(d, ani/1), ИСК /06(Ь, e, h. к). ИСК /05 (Cl, I), amlO\ TL /_'/jO(f) m a */namoiis celUarcinnma о/ 
Ihc ι ιι/ΐί-ι (a-c). a n adcnocarL inuma of the vomathió-i). an adeiiuLartinoma o/ the со/он (g-i). and an intestinal iartint>id{\-\) 
(magnlßcaUom'X ISO-.WO) 
mas showed a similar staining pattern However, in some 
tumors this antibody was only partly positive, or stained 
less cells than RCK 102 probably due to the fact that it 
does not recognize keratin 8 Negative reactions with 
both reagents were obtained in anaplastic seminoma. 
known not to contain keratins and in two cases of adrenal 
pheochromocytoma Antibody OV TL 12/5 was, further-
more found to be negative in two cases of renal cell carci 
noma in two cases of breast carcinoma and in one case 
of a small cell anaplastic carcinoma of the lung in which 
RCK 102 was positive 
Keratin 7 Antibodies 
(right panels in Figures 2 to 4) 
In general, antibody RCK 105 was positive in carcino-
mas that are derived from the normal epithelial tissues 
also positive for this antibody Similarly, carcinomas de 
rived from epithelia that were negative for RCK 105 did 
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Figure 4 Micrographs oj immunofluorescence assays showing the reactivity patterns oj OV '11 /J/5(a). RCK IOJ{d, h), HOI 5i{e, ι) 
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not, in general, react with this reagent For example, 
primary and metastatic squamous cell carcinomas in 
diverse tissues were normally negative for RCK 105 
However, exceptions to this rule were encountered in 
squamous cell carcinomas ol the lung in which 2 of 10 
cases were completely reactive, and 3 of 10 cases 
showed focal areas of RCK 105 positivity The other 
keratin 7 antibody OV-TL 12/30 showed a positive reac 
tion in even more of the pulmonary squamous cell carci 
nomas, with 3 of 10 cases completely positive and focal 
reactions in 4 other cases This unexpected staining re 
action is probably a result of the well known heteroge 
neous composition of these tumors, as extensively de 
scribed before β Strikingly, also in a lymph node metas­
tasis of a squamous cell carcinoma, antibodies RCK 
105 and OVTL 12/30 showed different staining pat 
terns in that OV-TL 12/30 gave a positive reaction in 
some of the tumor cells 
Adenocarcinomas of the lung were completely posi­
tive for the keratin 7 antibodies, with some small areas 
negative for RCK 105 The adenocarcinomas of the gas 
trointestmal tract were in general negative for RCK 105 
with the exception of some tumors in which sporadic posi­
tive cells were found 
Again, similar to what has been observed in the squa 
mous cell carcinomas, OVTL 12/30 stained more of 
these gastrointestinal adenocarcinomas than RCK 105 
For example, three stomach carcinomas were partly or 
completely positive for OV-TL 12/30 Furthermore, two 
carcinoids of the small intestine showed a positive reac 
tion in some of the tumor cells with OV-TL 12/30 
Carcinomas of the pancreas were positive for both 
RCK 105 and OV TL 12/30, with one case partly positive 
for RCK 105 
In the malignant tumors of the liver three different stain­
ing patterns were observed with the keratin 7 antibodies 
5 1 
Five of eight hepatocellular carcinomas were negative 
with RCK 105 and showed some sporadic positive cells 
with OV TL 12/30 Two out of these eight cases were pos 
itive with both antibodies and in one case only OV TL 1 ?/ 
30 was positive while RCK 105 showed staining in some 
cells In a case of hepatoblastoma RCK 105 was again 
negative while OV TL 1 ?/30 was partly positive (see also 
van Eyken el al25) 
Breast carcinomas of all types were generally positive 
with the keralin 7 MAbs In 9 of 80 cases however the 
invasive tumor areas were negative lor RCK 105 The 24 
cases in which the reaction patterns of OV TL 12/30 were 
compared lo those of RCK 105 showed one extra case 
that was negative (or OV TL 12/30 while this tumor was 
partly positive lor RCK 105 The epithelial tumors of the 
female genital tract also were positive for both MAbs al 
beil only partly in some cases 
All tumors ol the male genital tract examined by us 
particularly prostate carcinoma were negative for RCK 
105 or showed only sporadic positive cells However OV 
TL 12/30 again showed reactivity in more cells than RCK 
105 With respect to the tumors ol the urinary tract we 
have observed that the greater part of renal cell carcmo 
mas is negative for the keratin 7 antibodies with 2 of 27 
cases positive and a sporadic positive reaction in 6 cases 
with RCK 105 and in 6 additional cases with OV TL 12/ 
30 All (our cases ol Wilm s lumors as well as two cases 
of adrenal carcinoma were negative when examined lor 
keratin 7 expression 
However transitional cell carcinomas of the urinary 
Iract were generally positive (or keratin 7 with the excep 
tion of 6 ol 59 cases that were partly or completely nega 
live tor RCK 105 (see also Schaatsma et аіл) 
Ol the neuroendocrine lumors examined two carci 
noids of unknown origins were lound lo be negative while 
also lung carcinoids were mdinly unreaclive tor RCK 105 
However 3 ol 10 of Ihese latter lumors showed a focal or 
complete posilivity with Ihis MAb (see also Broers el als) 
Part of the small cell anaplastic carcinomas ol the lung 
examined in this study were to a relatively large exlenl 
positive lor RCK 10b (2 of 6 cases) and OV TL 12/30 (3 
of 6 cases) 
Finally ol the nine mesotheliomas examined in frozen 
sections with RCK 105 seven cases wore completely or 
partly positive one case was negative and one case 
showed a few scattered positive cells When lested in 
smears ol fine needle aspirates obtained from patients 
with pleural fluid containing mesothelioma 9 of 12 cases 
were positive and 2 cases were negative for RCK 102 
while in one case the tumor colls were partly positive 
Keratin 18 Antibodies (middle panels in Figures 2 
to 4) 
As reported before6 Ihe antibodies to cylokeratm 18 
(RGE 53 and RCK 106 were lested in most cases while 
CK 18 2 was applied only occasionally) generally do 
not stain squamous cell carcinomas An exception lo this 
rule however is (ound in cases of pulmonary squamous 
cell carcinoma especially in which the moderately and 
poorly differentiated lumors become partly positive lor 
RGL 53 and even more so for RCK 106 (see also Broers") 
Adenocarcinomas of all tissues and their metastases 
as well as hepalocellular carcinomas and hepaloblasto 
mas mesotheliomas carcinoids and small cell anaplas 
tic carcinomas are positive lor the CK 18 antibodies albeit 
only partly in a few cases 
A signilicantly different staining pattern o( the three CK 
18 antibodies was observed in transitional cell carcmo 
mas of the urinary tract There RGE 53 showed an exten 
sive staining pattern however with varying intensities 
and preference for the superficial cell layers in grades 1 
and 2 tumors as reported earlier Χ ί ' RCK 106 and CK 
18 2 normally stained all the tumor cells in these cases x 
Anti-keratin 7 as an Aid in Routine 
Histopathology 
To demonstrate the usefulness ol cylokeratm 7 antibod 
íes in the differential diagnosis of tumor cases in which it 
was difficult or impossible to reach a satisfactory conclu 
sion on the basis ol routine histology on the one hand 
and to show the limitation of Ihese reagents in routine pa 
thology on the other hand we illustrate 14 separate diag 
nostic problem cases (Table 2) which are not included in 
Table 1 In 12 ol Ihese cases Ihe keralin 7 expression 
pattern allowed a conclusive diagnosis or restricted Ihe 
number ol possible diagnoses In several instances these 
immunohislochemical results were supported by clinical 
data However in two cases (Table 2 cases 13 and 14) 
one a poorly differentiated carcinoma and one an un 
differentiated carcinoma the cylokeratm 7 staining pat 
tern did not correlate with the final diagnosis In these 
cases the combined histopathologic diagnoses of several 
experienced pathologists as well as immunocytochemi 
cal results with specific tumor markers supported the di 
agnosis of endometrial carcinoma and mixed Mulleran tu 
mor respectively 
Discussion 
Keratin immunocytochemistry has proved to be a valu 
able additional technique in the routine diagnosis of can 
cers that pose problems on morphologic examination 
Broad spectrum (polyclonal rabbit or mouse monoclonal) 
keralin antisera can be used to separate epithelial Irom 
nonepithelial malignancies28 Recenlly Ihe development 
of chain specific keratin MAbs has allowed the immuno 
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cytochemical distinction between different types of nor 
mal epithelia and as a result also between different types 
ol epithelial malignancies For example MAbs to keratin 
18 can dislmguish between adenocarcinomas (which are 
generally keratin 18 positive) and mosl squamous cell car­
cinomas (which are generally keratin 18 negative, lor ex 
ceplions see Broers et al") 
Recently the use ol different keratin 7 MAbs by several 
authors β 10-1? п 2' x ** 3' has revealed that the expres 
Sion of this keralm lype is restncled to a subgroup within 
the glandular lypes of normal human epilhelia As a con 
sequence MAbs to keralm 7 can apparently distinguish 
belween different types ol adenocarcinomas For exam 
pie colorectal carcinomas and hepatocellular carcinomas 
were found to be negative for keratin 7, while pancreatic 
carcinomas and bile duct carcinomas were posilive ю и 
However, van Eyken et al,'10 after studying an extended 
series of hepatocellular carcinomas, found that these tu 
mors can express keratin 7, albeil in a variable number of 
cells On Ihe other hand, some carcinomas of the ovary, 
as well as some ductal breast carcinomas, which were 
expected to be positive, showed no or only heteroge­
neous keratin 7 expression'0 a, see also van Niekerk et 
al'4 for a helerogeneous reaction pattern in the ovarian 
carcinoma cell line OTN 14 
These inconsistencies have urged us to meticulously 
test a comprehensive series of epithelial malignancies for 
the presence of keratin 7 To avoid as much as possible 
false-negative outcomes as a result ol epitope masking 
we have used Iwo MAbs lo keralm 7, which were ob 
tamed Irom different fusions and most probably recognize 
different epitopes Next lo these keralm 7 MAbs we have 
used two other groups of keratin MAbs, ie, Iwo broad 
spectrum MAbs and three keratin 18 MAbs Generally, 
the two broadly cross reacting antibodies OVTL 12/5 
and RCK 102, can when combined, separale most carci 
nomas, which are positive, from nonepithelial malignan­
cies, which are generally negative Some exceptions of 
keratin positive nonepithelia) tumors include, for example, 
leiomyomas and leiomyosarcomas,·0 chondrosarcomas 
and chondroblastomas Also malignant nonepithelial 
components in teratocarcmomas were found to be posi 
live for RCK 102, as well as for RGE 53 (Oosterhuis et al, 
to be published) To distinguish between different sub 
groups ol carcinomas in problem cases in which routine 
histologic techniques do not allow a precise diagnosis, 
antibodies to keratins 18 and 7 have proved to be very 
useful The keratin 18 antibodies can, in general, recog 
mze adenocarcinomas, hepatocellular carcinomas and 
hepatoblastoma, mesotheliomas, transitional cell carcmo 
mas, and neuroendocrine tumors, but normally do not re­
act with squamous cell carcinomas Squamous cell carci­
nomas of Ihe lung may be an exception lo this rule be­
cause an increasing number of keratin 18-positive cells 
are found in these malignancies with a decreasing degree 
of differentiationβ Similarly, squamous cell carcinomas of 
the oral cavity and laryngeal area may show keratin 18 
positivity, in particular at their front of invasion into sur 
rounding stromal tissue (Schaafsma el al, to be pub­
lished) Similarly, keratin 7 has been found in poorly 
differentiated squamous cell carcinomas of the lung 8 
Both keratin 7 MAbs were lesled lor Iheir reactivity on 
frozen seclions of normal human tissues and showed 
some discrepancies in their staining patterns Antibody 
OVTL 12/30 showed a reaction m part of the tongue 
squamous epithelium, some myoepilhelial cells, prostate 
acini and surface epithelium of stomach and duodenum 
tissues, which were negative for RCK 105 Similarly, dis­
crepancies were found in the reactivity patterns of both 
MAbs in epithelial malignancies Normally, relatively more 
cases were (partly) positive for OV TL 12/30 than for RCK 
105 This is particularly striking in some cases of squa­
mous cell carcinomas and small cell carcinomas of the 
lung, Gl tract adenocarcinomas, and hepatocellular carci 
nomas These differences in the reactivity patterns of the 
individual keratin 7 antibodies likely can be explained by 
epitope masking Thus although OV-TL 12/30 detects 
keratin 7 expression more consistently than RCK 105, the 
latter antibody allows a better immunohistochemical dis 
tmction between adenocarcinomas and squamous cell 
carcinomas, on the one hand, and between different 
groups of adenocarcinomas on the other hand However, 
within the group of RCK 105 negative adenocarcinomas 
(for example those derived from the gastromlestmal tract 
or prostate), a positive reaction lor OV TL 12/30 may pro­
vide an indication of the origin of such neoplasms in cases 
of metastases or anaplastic growth Because OV-TL 12/ 
30 distinguishes belween surface epithelium and glandu­
lar structures in stomach and duodenum, m contrast to 
RCK 105. the OV-TL 12/30 antibody might point to 
whether a stomach cancer is derived from surface epithe­
lium or from glandular cells In addition OV TL 12/30 (in 
combination with RCK 105) refines the diagnosis of gas­
trointestinal trad cancer in showing their derivation from 
colon, small intestine, or stomach duodenum This phe 
nomenon of epitope masking can also explain the slightly 
different reaction patterns of the individual keratin 18 anti­
bodies (see also Franke et al23) 
In general, adenocarcinomas arising from the gastroin­
testinal tract are negative lor the keratin 7 antibodies Also 
metastases of such malignancies remain unstained, 
which is nicely illustrated by stomach and colon adeno­
carcinomas metastatic to the ovaries 
Similarly, prostate carcinomas, renal cell carcinomas, 
epithelial liver tumors, and carcinoids of several organs 
are normally negative for keralm 7 However, some tu­
mors within this group of normally keratin 7 negative neo­
plastic tissues may show keratin 7 reaclivily (also with 
53 
RCK 105), ranging from a few scattered positive cells wa 
positive tumor areas to homogeneously positive tumors 
In contrast, adenocarcinomas of the lung, pancreas, 
breast, and female genital tract, as well as transitional cell 
carcinomas and mesotheliomas are normally positive lor 
keratin 7 Again, exceptions to this rule are lound that 
showed positivity in only part of the tumor cells or which 
were even completely negative This became especially 
apparent in two cases of gynecologic malignancies, illus­
trating that these latter tumor types need further examina­
tion 
Although now we routinely use the keratin antibodies 
described above to help in Ihe differential diagnosis of 
(adeno)carcinoma of unknown origin, it is obvious that re­
sults obtained with these monoclonal antibodies should 
be interpreted with care and that exceptions to a general 
reactivity pattern should be kept in mind when applying 
these reagents in diagnostic histo and cytopathology 
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IMMUNOHISTOCHEMICAL DEMONSTRATION 
OF KERATIN 7 IN ROUTINELY FIXED 
PARAFFIN-EMBEDDED HUMAN TISSUES 
TATHARINA С VAN NltKFRK*, PAUL H К JAP*, hRANS ( S RAMAFkrRSt, TRID VAN 01 MOI ^ G R A H ' Î 
ANI) 1 AMBbRT O POPLS* 
*Dt'partnH ni о/ Cell Biologi aiul Htslologi Faiulli of Meditai Siitmes L ітегчт of \i/nieg(n \'i/nut>(n 
The Neihtrkmds tl)ipartimnlo/ UoUtular (ell Biologi I nn(r\il\ о/ Liinhurg Maasìndii Thi balurlaruls 
IDíparmicnt of Pathology MetlualСenttr Alkmaar Alkmaar Ли \ellnrlatids 
Reimt<ІП lamían IV9I 
Atti pit <П0 April IWl 
S U M M A R Y 
Thcimmunoreactivily ol OV-TL 12 Ì0 amonoclonil anti keratin 7 antibody (Mab) was investigated on Pro¿cn as 
well as paraflin-embcdded human tissues Its reactivity patterns were compared with another wtll-characlcn/cd 
monoclonal antibody to keratin 7 (RCK 105) and with broadly cross-reacting monoclonal (OV I L 12 5) as well as 
polyclonal (pKcr) keratin antiscra In frozen sections of normal and malignant human tissues both keratin 7 Mabs gave 
similar staining patterns The immunorcactivity for OV TL 12 Wand the polvclonal antibody (pKer) in tissue sections 
fixed m 4 per cent formalin or Bouin solution was completely restored when prctrealed with U 1 per cent pronase 0 1 
per cent trypsin in phosphate-buffered saline (PBS) or with 0 5 per cent pepsin in Ü 01 N HCl Lxtcpt lor loss of 
immunorcactivity on human normal stomach surface epithelium and glandular mucous cells Mab OV-TL 12 10 
reacted strongly positive with essentially all those formalin or Bouin-hxcd paraffln embedded tissues that had been 
shown to stain in non-hxed frozen sections In addition to the good correlation in normal human tissues a complete 
correlation between the reactivity on frozen and paralfin-cmbcddcd human carcinomas (л = 86) was lound as well 
While both RCK 105 (anti-kcratm 7)and OV IL 12 5 (anti-keratm 5 7 14 19) did not slain on parattin embedded 
sections the polyclonal control antiserum (pKer) lost immunorcactivity in some cell types (c g mucous cells in 
compound glands hepatocytes pancreatic aunar cells and proximal and distal convoluted tubules of the kidney) 
Our study shows that the keratin 7 Mab OV-TL 12 30 is an excellent marker for tumour histopalhology since it is 
reactive in paraffin embedded formalin-fixed human tissues 
Ktv WORDS Monoclonal antibodies, keratin 7, paralTm-embeddcd normal tissues, carcinomas 
I N T R O D U C I ION types of epithelium and t a r u n o m a s derived from 
ihcm 1 
Keratins are recognized as the main intermediate in frozen sections Mabs to keratin 7 recognize 
filaments of epithelial cells They comprise a family specific subtypes of adenocarcinoma and can, for 
of at least 20 different polypeptides,1 ^1 which are example, distinguish between ovarian carcinomas 
distributed in combinations in a more or less tissue- (keratin 7 positive) and carcinomas of the gastro-
spectfic fashion ' ' Malignancies derived from epi- intestinal tract (keratin 7 negative) or between iran-
thehal tissues have been shown to retain specific ¡.шета! <-ell carcinomas (keratin 7 positive) and 
keratins prostate cancer (keratin 7 negative) as described 
Monoclonal antibodies to these are of use in previously 1 Although both antibodies OV-TL 
diagnostic histopalhology, allowing the immuno- 12'30 and R C K 105 are directed to keratin 7, some 
his tochemical d i s t inct ion between different differences were found on frozen sections ^ A p p l i -
cation in paraffin-embedded tissues1 0 ' ' is limited by 
the lack of monoclonal antibodies reactive with 
formalin- or Bouin-fixcd рагаПіп-embedded sec­
tions p In this study we investigated the difference in 
0022 3417 91 100145-08 $05 00 
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Table I Reactivity of keratin 7 and polyclonal antibodies in normal human epithelial tissues 
Tissues 
Compound glands* 
Interlobular ducts 
Intralobular ducts 
Serous secretory units 
Mucous secretory units 
Myoepithelia 
Tongue 
Squamous epithelium 
Taste buds 
Gl.indst 
Oesophagus 
Squamous epithelium 
Glandst 
Stomach 
Surface epithelium 
Gastric glands 
Cardiac glands 
Duodenum 
Surface epithelium 
Brunnerglands 
Small intestine 
Epithelium 
Large intestine 
Epithelium 
Liver 
Hcpatocytcs 
Hering canal bile ducts 
Pancreas 
Acinar cells 
Ducts 
Islets of Langcrhans 
Lung 
Bronchial bronchiolarepuhelium 
Alveoli 
Glandst 
Prostate 
Columnar acinar cells 
Basal acinar cells 
Ducts 
RCK 
105 
fs 
+ 
+ 
+ 
+ 
+ 
-
+ 
— 
+ 
- 4 
-
3 
-
-
-
+ 
_ 
+ 
-
+ 
+ 
+ 1 
- 2 
-
+ 
Keratin 
fs 
+ 
+ 
+ 
h 
1 
+ 
+ 
t 
t 
+ 
- 5 
-
+ 
-
-
-
+ 
-
+ 
-
+ 
+ 
t 
-t 1 
+ 1 
+ 
7 
OV-TL 
12 10 
PS 
+ 
+ 
+ (H) 
-
+ 
-
+ (H) 
t 
— 
t 
- 4 
-
- 1 
-
-
± + 
_ 
+ 
-
+ 
+ 
t 
+ (H) 
+ (H) 
+ 
Broad-spccii 
fs 
+ 
+ 
+ 
-1-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
+ 
-
+ 
+ 
+ 
+ 
+ 
Polydona 
anli-
kcralm 
rum 
1 
11 
p s 
-t 
+ + 
+ (H) 
-
+ 
+ 
- 6 
t 
+ 
t 
+ 
-
+ 
-
+ 
-
+ 
+ 
+ 
+ 
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Tabic I {Continued) 
Tissues 
Keratin 7 
RCK 
105 
fs 
OV-TL 
12/30 
fs PS 
Broad-spectrum 
poljclonal 
anti-
keratin 
fs ps 
Ovary 
Surface epithelium + (H) 
F allopian tube 
Epithelium + (H) 
Uterine corpus 
Surface epithelium 
Glandular epithelium 
Cervix 
Surface epithelium 
Glandular epithelium 
Squamous epithelium 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
-
+ (H) 
+ (H) 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Placenta 
Trophoblast 
Vagina 
Squamous epithelium 
Mammary gland 
Inner epithelial cells 
Outer epithelial cells 
+ 
+ 
+ 
+ 
-l± 
Kidney 
Glomeruli 
Parietal epithelium 
Proximal convoluted tubules 
Loops of Hen le 
Distal convoluted tubules 
Collecting ducts 
Pelvis 
+ 1 
+§ 
+ 
+ 1 
+§ 
+ 
+ 
+ 
+ 1 
+§ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 1 
-t(H) 
+ 
+ 
Skin 
Acini 
Ducts (luminal) 
+ (H) 
+ 
Abbreviations f s =Гго/еп sections ρ s = paraffin embedded sections + positive, ±, weakly positive —, negative 1 partly 
positive 2 several cells (ad random) positive, 3 sporadic positive cells 4 occasionally small areas positive, 5 several basal cells 
positive 6 sporadically positive traces (H), hclcrogeneous (positive as well as negative) cells 
•With exception of mammary gland prostate, stomach, pancreas uterine corpusycervix 
tSec under compound glands 
JSomc Leih weakly positive 
ÇWiih exception ofthc proximal straight tubule and the macula densa 
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Fig I A G. Immunoperoxidase staminp with anli-kcralin 7 antibody (OV-TL 12 30) in normal human paratlin-
embeddcd tissues A. Negatively reacting colonic crypts B. C'. Semi serial sections of prostate negative reaction m 
sections without pronase pretreatmenl (B). positive reaction after pronase prelrcatmcnt (C) D. Submandibular gland 
with a positively reacting duct (D) Helerogeneously positive staining of serous cells (white arrow), and ol myoepithelial 
cells (black arrow), negative mucous cells (M) C. Cortex of kidney collecting duel stains intensely, (lop arrow) Note 
negative macula densa (arrowhead) m positively stained distal tubule (D) Proximal lubules (P) and glomerular tuft (G) 
are negative, except a few positive parietal cells (bottom arrow) К Heterogeneousl> positive staining of dilated acini in 
central region ol the prostate G. Liver: intra- and perilobular bile ductules reading strongly positive between negative-
stained hepatocytes Η К. lmniunoperoxidasestainingofanti-keratin7anlibody(OV-TL 12 10)on paraUìn embedded. 
human epithelial tumours H. Strong positive reactivity m serous ovarian cancer 1. Strong positive reactivity in nests of 
Brenner tumour J. Metastasis of a keratin 7 negative colon carcinoma (asterisk ) in the ovary Note the positive reaction of 
the mcsothclial lining (arrow) K. Negatively stained primary adenocarcinoma ol caecum 
immune reactivity of both anti-keratin 7 mono-
clonal antibodies (OV-TL 12 30 and RCK105) ver-
sus polyclonal (pKer) and a broadly cross-reacting 
keratin Mab (OV-TL 12 5) on formalin- or Boum-
fixed and paraffin-embedded human tissues. Our 
results show that Mab OV-TL 12 30 reacts strongly 
in proteolytically pretreated paraffin-embedded 
human tissues and will therefore become a strong 
tool in routine histopathology. 
use. Frozen sections (4 7/im) werecut on a cryostat 
and air dried Four percent neutral buffered forma-
lin" and Bouin solution-fixed" paraflin-embedded 
blocks of normal and neoplastic human tissues were 
used. The collection of fro/en tissues and paraffin-
embedded tissues was partly derived from identical. 
parallel samples, and partly from non-identical 
samples. 
MATERIALS AND METHODS 
Tissues 
Fresh normal and neoplastic human tissues were 
frozen in liquid nitrogen and stored at - 8 0 С until 
Immunohtstochemical assays 
The immunoperoxidase technique used on frozen 
sections was performed as described previously.14 
Paraffin-embedded sections were cut at 4/mi, 
picked up on tissue adhesived slides, dried on a 
thermal unit(lnvenlum type P61) for about 2 min at 
60 С and in an incubator at 37 С for one night. 
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Tabic I] RcMctiMlv patlerns o f jnt i -c>lokentt in 7 and polyclonal anli-cytokeralin antibodies in parafhn-cmbedded 
human epithelial (uimiui tissues 
I issues 
H n r o i d c a 
Squamous cell ca lung 
Moderaieh dilT adenoca stomach 
PoorK di l f adenoca stomach 
PoorK di l l adenoca stomach 
PoorK di l l signel ring cell ca stomach 
Anaplastic ca stomach 
Small intestine ca 
WelldiH adenoca colon 
Moderately di l l adenoca colon 
Poorly di l l adenoc.i colon 
Rectum ca 
Metastasis ol eoccum ca in the ovary 
Pancreasca 
Breast ca 
Ovarian lumors 
Lndometnal ca 
I ndocemcal ca m situ 
Mola 
Moderately poorly d i l l ca prostate 
Moderately poorly di l l ca prostale 
Renal célica 
Renal cell ca 
Malignant mesolhehoma 
Malignant melanoma 
Subsequently they were deparaffim/ed in xylol 100 
per cent and réhydratée) through graded alcohols 
I ndogenous peroxidase aclmly was blocked by a 
10-min incubation with 1 per cent Η,Ο, in 
methanol (Merck. Darmstadt. Germany) at room 
temperature 
In pilot experiments the optimal demasking con­
ditions (c g lime and temperature of incubation, 
concentration and type of proteolytic cn/ymes) 
were established and subsequently applied as 
lollows ЛГіеі washing in phosphate-bullercd saline 
(PBS), containing 0 05 per cent Tween-20 (Merck. 
Darmstadt. Germany), sections were treated fur 10 
mm at 17 С with 0 I per cent pronase (P5147 type 
XIV. Sigma. St Louis. MO. USA) in PBS Tween 
pH 7 4 and I per cent bovine serum albumin (BSA) 
in case ol pKer or pronase F (Serva) or 0 5 per cent 
pepsin in 0 01 N HCl lor ÜV- PL 12 30 The enzy-
Numbcr Monoclonal Broad-spectrum 
o f O V - T L 1 2 10 polyclonal 
specimens anti-keratin 7 anti-kcralm 
22 
1(H) 
KU) 
1 
+ 
-
- 3 
- 3 , 4 
- 3 . 4 
- 3 4 
- 3 . 4 
+ (H) 
+ 
+ (H) 
-KH) 
+ 
+ (H) 
t-4(2,i»„) 
3 
- ( I I ) 
+ 
+ (H) 
+ (H) 
+ 
+ 
+ (H) 
-KH) 
+ 
+ 
i/  made digestion step was terminated by washing 
with PBS Tween and an incubation with undiluted 
s normal rat serum for 15 mm in order to reduce 
  i  background staining 
   The sections were incubated with primary anti­
bodies for 60 mm. washed in PBS-Tween BSA 
- and incubated with pcroxidase-conjugated rabbtt-
c anti-mouse immunoglobulins (RAM-PO, Dako, 
l s) Denmark) diluted I 150 in PBS, for 30 mm After 
Uly three washing steps in PBS peroxidase reactivity was 
e- ll li  revealed with 3 т м 3,3 -diamino-benzidine (Sigma) 
\ , and 0 1 percent Η,Ο, in PBS Tween forSmin The 
:   o   shdeswerewashcdinrunningwaterandincubaledin 
l    0 5 per cent CuSOj in 0 9 per ceni N a d , for 5 mm 
) i    Sections were counterstamed with haematoxylin 
ι l i  ( ) and mounted in cukitt after dehydration 
ι) r   er ce t The lollowing ami-keratin antibodies were used 
12 30 The enzy- inthtsstudy 
\nbrc\iilums ->- poMlivc ± weakly positive — перліі е 1 partly positive 2 several cells (ad random) positive ^. sporadic 
posimetells 4 (H.casuHul/v small areas positive (H) licteroireneous (positivea·» well as negalive) cells 
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(1) The mouse monoclonal antibodies OV-TL 
12 10 and RCK 105 specific for keratin 7, as 
described previously18 
(2) An affinity-purified rabbit antiserum raised and 
purified against human skin keratins (pKer), 
prepared as described previously " 
(3) The broad spectrum keratin Mab OV-TL 12 5, 
reactive with keratins 5 7, 14 and 19'"' 
RESULTS 
Immunolmlochemu al reai /n il\ in normal human 
tissues 
The results of the immunoperoxidase assays for 
kcralin 7 Mabs (OV TL 12 30 and RCK 105) and 
the broad spectrum pKer using frozen and paraffin-
embedded normal human tissues are summarized in 
Table I and illustrated in Fig 1A G 
Our data show that no immunoreactivity was 
found with RCK 105 nor OV-TL 12 5 in paraffin 
embedded tissues The antibody OV TL 12 30 
reacted positively (Table I Fig ID G) with all 
paraffin embedded tissues (after pretreatment with 
proteolytic enz> me? Fig 1 B, C) that were positive 
in Irozen sections 
Although OV-TL 12 30 and RCK 105 showed a 
similar reactivity pattern on frozen sections differ­
ences between both antibodies were found in the 
digestive and genitourinary tract Large intestinal 
epithelium was negative for keratin 7 (Fig 1A). 
gastric and duodenal epithelium were positive for 
OV TL 12 30 but not for RCK 105 m frozen sec­
tions The reactivity of OV-TL 12 30 with gastric 
and duodenal epithelium was greatly reduced in 
paraffin sections A similar reduction in staining 
intensity was found in paraffin-embedded, normal 
mucous cell types in compound glands of some 
organs (Fig ID), while serous cells and myoepi­
thelial cells were unaffected RCK 105 stained the 
thin part of the loops of Henle and the collecting 
tubules but not the proximal and distal tubules in 
frozen sections whileOVTL12 30stainedthedislal 
tubules but not the macula densa of the distal tubules 
nor the proximal tubules (Table I Fig IF) Some 
samples of 4 per cent formalin-fixed human tissues. 
stored for about 30 years, still showed strong reac­
tivity with the О Л L 12 30antibodv About20per 
cent of the paraffin-embedded tissues were fixed in 
Bourn solution 
An affinity purified polvclonal antiserum directed 
against human skin keratins showed reactivity 
patterns in normal frozen sections as previously 
described1'' (Table I) Anti-pKer antibody stained 
virtually all paraffin-embedded epithelial cell types, 
although negative or weak staining was observed in 
the mucous cell types of compound glands, hepato-
cytes, acinar cells of the pancreas, proximal and 
distal convoluted renal tubules and the parietal 
cells 
In our study in some samples Pronase P5147 type 
XIV (Sigma) gave better results in combination with 
pKer than Pronase F (Serva) However, the latter 
gave strong positive results in combination with 
OV-TL 12 30 
Monoclonal keratin antibodi reactnit\ patterns in 
human tumours 
The results of our immunohistochemical studies 
on 86 formalin-fixed, paraffin-embedded human 
malignant epithelial tissues are summarized in 
Table II and illustrated in Fig IH К Within these 
tissues no reactivity with RCK 105 was found 
Adenocarcinomas of the small and large intestine 
(Table II Fig 1J,K) were negative with OV-TL 
12 30 apart from scattered possible endocrine cells 
Fig I Η-K illustrates that OV-TL 12 30 can be used 
in paraffin sections to discriminate between ovarian 
carcinomas (keratin 7 positive) and large intestine 
carcinomas (keratin 7 negative) The reactivity 
pattern of OV-TL 12 30 in paraffin sections was 
concordant with the results on frozen sections ' 
DISCUSSION 
In this study we have shown that keratin 7 can be 
stained by the immunoperoxidase technique in 
paraffin-embedded tissues routinely fixed in 4 per 
cent formalin or Bourn solution, after prelreatment 
with protease A number of antigens (e g immuno­
globulins) may be 'unmasked by proteolytic 
digestion of formaldehyde- or Bouin-fixed sections, 
but the mechanism for this rescue of antigenicity is 
unknown " ^ " 
In general the keratin 7 (OV TL 12 30) antibody 
reactivity patterns on normal human paraffin-
embedded tissues were similar to those seen on 
frozen sections, however some minor discrepancies 
were observed The difference between OV-TL 
12 30 and RCK 105 observ ed in frozen sections, was 
not detected in paraffin sections 
No discordance was found in the staining pattern 
of OV-TL 12 30 on paraffin-embedded and frozen 
65 
tissues 1 and wc conclude that OV-TL 12 ^0 will be a 
useful marker in routine diagnostic histopathology, 
eg OV-TL 12 Ю can be used to distinguish 
between ovarian carcinomas and colon carcinomas, 
in addition with monoclonal antibodies specific 
for ovanan tumour antigens 1 1 6 , 9 2 ( ) or between 
hepatomas and cholangiocarcinomas ^0 
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COMPARATIVE IMMUNOHISTOCHEMICAL STUDY 
OF FOUR MONOCLONAL ANTIBODIES DIRECTED 
AGAINST OVARIAN 
CARCINOMA-ASSOCIATED ANTIGENS ' 
Otto С Boerman, Catharina С. van Niekerk, Kardien Makkink, 
*Ton G. J. M. Hanselaar, -| Peter Kenemans and Lambert G. Poels 
Departments of Cell Biology & Histology, and *Pathology, University of Nijmegen, 
Nijmegen; and -| Department Obstetrics & Gynecology, Free University of Amsterdam, 
The Netherlands 
Summary: The monoclonal antibodies ОС 125, OV-TL 3, MOv 18, and OV-TL 23, which are 
directed against distinct ovarian carcinoma-associated antigens, are assessed in the present 
study for their diagnostic value. The expression of the antigens defined by these antibodies 
was studied in serial sections from 78 ovarian carcinomas and 103 nonovarian carcinomas 
obtained from 181 patients, using the immunoperoxidase technique. Immunoelectron microscopy 
demonstrated that the antigens were all localized on the tumor cell membrane. ОС 125, OV-TL 
3, and MOv 18 reacted positively with ~90% of the ovarian carcinoma samples (n=78), 
whereas OV-TL 23 stained 78% of these samples. ОС 125, OV-TL 3 and MOv 18 were also 
reactive with a majority of carcinomas derived from the cervix, endometrium and fallopian 
tube, while OV-TL 23 reactivity was primarily restricted to ovarian carcinomas. ОС 125 and 
OV-TL 3 reacted respectively with 11% and 14% of the nongynecologic carcinomas tested 
(n = 64). Positive cases included breast, colon, and lung carcinomas. The antibodies MOv 
18 and OV-TL 23 were found less reactive with nongynecologic carcinomas. Key Words: 
Monoclonal antibodies-Ovarian carcinoma-Immunohistochemistry. 
Approximately 90% of malignant ovarian tumors are of the common epithelial 
type. Epithelial ovarian cancers are thought to arise from modified peritoneal 
mesothelial cells covering the surface of the ovary (1,2). Since ovarian carcinomas 
This work was supported by a grant from the Dutch Praeventiefonds (no. 28-1248). 
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cause symptoms only late in the course of the disease, >75% of ovarian cancer 
patients have tumor in the pelvis or abdomen outside the ovary at the time of 
diagnosis (3). Oviductal, lymphatic, or hematogenous dissemination may spread 
ovarian cancer to fallopian tube, endometrium, distant nodes, liver, lung, pancreas, 
or skeleton (4). Although the histopathologic differential diagnosis between ovarian 
and nonovarian cancers is feasible in most cases, ~ 10% of poorly differentiated 
ovarian tumors cannot be positively identified on the basis of morphologic criteria 
(5). In addition, ~ 8% of ovarian tumors arise outside the ovary (6,7), the most 
common primary sites being breast, intestine, and stomach. These metastases 
from occult carcinomas may show an adenoid, papillary, or cystic structure, 
sometimes hardly distinguishable from carcinomas arising in the ovary (8,9). 
Since treatment and prognosis depend on the origin of the tumor (i.e., breast, 
colon, ovary) (10-12), reliable histopathologic typing of adenocarcinomas in the 
abdominal cavity is essential. 
Monoclonal antibodies against ovarian carcinoma-associated antigens have been 
developed in several laboratories (13-15). Immunohistochemical staining of 
carcinoma sections using monoclonal antibodies against ovarian carcinoma-associated 
antigens may be a useful supplementary method in surgical pathology in the 
discrimination between primary and metastatic ovarian carcinomas and other 
adenocarcinomas. The ideal target for an antibody for application to pathologic 
practice would be an antigen that is abundantly expressed in ovarian carcinomas, 
but is not expressed in those of nonovarian origin. In this study, we evaluated 
the reactivities of four antiovarian cancer monoclonal antibodies (OC 125, OV-TL 
3, MOv 18, and OV-TL 23) by assessing their immune reactivity on serial sections 
of multiple tumor types in order to compare directly their potential in occassionally 
encountered difficulties in surgical pathology. 
METHODS 
Tumors 
Tumors were obtained at the time of surgery from 181 patients. Small blocks 
of fresh tissue were frozen in liquid nitrogen and stored at -80oC. Diagnosis had 
been made from both cryostat and paraffin sections stained with hematoxylin/eosin. 
Epithelial tumors of the ovary (n=78) were histologically classified according 
to the World Health Organization (WHO) criteria. In addition, three adeno-
carcinomas of the fallopian tube, 21 endometrial carcinomas, 11 cervical car-
cinomas, and five gynecologic squamous cell carcinomas were tested. Furthermore, 
64 carcinomas from 10 different organs (including 16 breast, 11 colon, and 10 
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lung carcinomas) were studied. 
Monoclonal antibodies 
The following murine monoclonal antibodies2 were used in this study: (a) OC 
125 was raised against a serous ovarian carcinoma cell line (OVCA 433) (13). 
(b) OV-TL 3 was obtained after immunization with a cell suspension prepared 
from an endometrioid ovarian carcinoma specimen (14). (c) MOv 18 was raised 
against a crude membrane preparation of a poorly differentiated ovarian carcinoma 
(15). (d) OV-TL 23 was isolated after immunization with cyst fluid from a serous 
ovarian carcinoma (16). (e) OV-TL 12/5, an antikeratin antibody (directed against 
keratin 5, 7, 14 and 19) (17,18), was used as a positive control. The antibodies 
were purified from ascitic fluid using a Protein A-Sepharose column (19). For 
immunohistochemistry, purified monoclonal antibodies diluted in phosphate-buffered 
saline (PBS) (20 μg/ml) were used. 
Immunohistochemical studies 
Serial unfixed cryostat sections (4-6 μπι) were incubated with purified monoclonal 
antibody (20 μg/ml PBS) for 30 min at room temperature. The sections were 
then washed and treated with peroxidase conjugated rabbit-anti-mouse immunoglobu­
lins (DAKO, Denmark) diluted 1:100 in PBS, 0.05% Tween-20 (E. Merck, 
Darmstadt, Federal Republic of Germany). After washing, peroxidase was revealed 
with3 mM 3',3'-diaminobenzidine (Sigma, St. Louis, MO, U. S. A.) and 0.01 % 
HJOT in PBS, 0.05% Tween-20. The sections were counterstained with hematoxylin 
and mounted in Eukitt. Negative control staining was performed on adjacent sections 
by replacing the first antibody by PBS. Sections of an ovarian carcinoma sample 
(86-753) reactive with all antibodies used in this study served as a positive control 
in each staining session. 
Staining was scored arbitrarily by two independent observers as negative (-), 
weak (+), moderate (+), or strong (+ +), according to the intensity of the staining 
and the percentage of tumor cells in a section stained. The monoclonal antibody 
OV-TL 12/5, which stains all carcinoma cells in a section, was used as a reference 
in the estimations of the percentage of the positively stained cells. The sensitivity 
and specificity of the antibodies for staining ovarian carcinomas was calculated 
as follows: 
ПЪе monoclonal antibodies used in this study have not been submitted to the FDA for approval 
in diagnostic use in tumor pathology. 
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number of ovarian carcinoma samples stained positivelv 
sensitivity = χ 100% 
total number of ovarian carcinoma samples examined 
number of nonovarian carcinoma samples stained negative 
specificity = χ 100% 
total number of nonovarian carcinoma samples examined 
Immunoelectron microscopy 
A freshly obtained sample from a serous ovarian carcinoma was fixed in periodate-
lysine-paraformaldehyde-glutaraldehyde solution (PLPG), for Vh hr (20). Frozen 
sections (30 μπι) were cut and incubated with the monoclonal antibodies (20 /ig/ml) 
followed by incubation with anti-mouse IgG antibody conjugated with peroxidase 
(1:100) (DAKO, Denmark). Following a 10 min fixation in 2% glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.4), a second 15 min incubation was carried 
out using 1 % S'.S'-diaminobenzidine-HCl with 0.01 % HjOj. Sections were postfixed 
in 1 % osmium tetroxide, dehydrated in an ascending series of ethanols and 
embedded in Epon 812. After polymerization, ultrathin sections were cut with 
a diamond knife on a Reichert OM U3 ultramicrotome (Reichert, Vienna, Austria). 
Sections were double-contrasted with uranyl acetate and lead citrate, and examined 
in a Philips EM 300 electron microscope (Philips, Eindhoven, The Netherlands). 
RESULTS 
Immunohistochemical staining of ovarian carcinomas 
The four monoclonal antibodies were used to stain sections of epithelial ovarian 
cancers from 78 patients. Frozen sections were used because OV-TL 3, MOv 
18, and OV-TL 23 do not react on paraffin-embedded tissue. The results are 1 isted 
in Table 1. The highest sensitivity of staining for ovarian carcinomas was found 
for OV-TL 3 (94%), whereas OC 125 and MOv 18 scored 92% and 90%, respec­
tively. The lowest sensitivity (78%) was found for OV-TL 23. 
In addition to sensitivity, the intensity of the staining may also be a criterion 
for selecting antibodies for use in surgical pathology. Figure 1 summarizes the 
staining intensities of the antibodies in sections from the 78 ovarian carcinoma 
specimens. OC 125, OV-TL 3, and MOv 18 showed intense staining in >60% 
of the tissues, whereas OV-TL 23 reacted strongly with only 25% of the samples. 
Moreover, OV-TL 23 weakly stained ~ 2 0 % of the tissue specimens, whereas 
with the other antibodies a weak reaction was only observed in a small number 
(five to six) of samples. 
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TABLE 1. Immunohistochemical staining of 
ovarian carcinomas* 
Histological type 
Serous 
Mucinous 
Endometrioid 
Clear cell 
Mixed epithelial 
Undifferentiated 
Nonclassified 
Total 
OC 125 
41/42b 
2/5 
6/6 
4/6 
3/3 
3/3 
13/13 
72/78 
(92%) 
OV-TL 3 
41/42 
3/5 
5/6 
6/6 
3/3 
3/3 
12/13 
73/78 
(94%) 
MOv 18 
39/42 
3/5 
6/6 
3/6 
3/3 
3/3 
12/13 
70/78 
(90%) 
OV-TL 23 
36/42 
2/5 
5/6 
3/6 
3/3 
3/3 
9/13 
61/78 
(78%) 
"Specimens were assayed in an immunoperoxidase assay. Staining was scored by two independent observers. 
•"Number of positives/total number examined. 
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strong moderate weaK 
FIG. 1. Diagram showing for each MAb the percentage of ovarian carcinoma samples (n = 78) stained 
strongly positive, moderately positive, and weakly positive. 
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OC 125 stained 41 of the 42 serous carcinomas distinctly positively. An example 
of a positive reactivity is shown in figure 2A. One moderately differentiated serous 
ovarian carcinoma stained negatively. OC 125 showed a characteristic pattern 
of staining, with the intraluminal and peripheral cell surfaces reacting most 
intensively. The mucinous ovarian carcinomas showed less OC 125 reactivity 
than the other histologic types: one mucinous carcinoma stained distinctly positive, 
one sample stained focally, and three were negative. 
OV-TL 3 positively stained 41 of the 42 serous tumors. An example is shown 
in Fig. 2B. Additional staining of tumor stroma was observed occasionally, but 
was not scored. The serous tumor that was negative to OV-TL 3 reacted positively, 
however with the other three antibodies. OV-TL 3 stained ~ 60% of mucinous 
and 83% of endometrioid carcinomas. 
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MOv 18 positively stained 39 of the 42 serous carcinomas (Fig. 2C). In addition, 
three of five mucinous carcinomas stained distinctly positive, whereas only 50% 
(three of 6) of the clear cell tumors were positive. 
OV-TL 23 reactivity was found in 36 (86%) serous tumor samples (Fig. 2D). 
In addition, ~ 6 0 % (eleven of 19) of the nonserous tumors stained positively. 
In general, OV-TL 23 staining was heterogeneous, ranging from a localized to 
uniform distribution. This resulted in a less intense staining of most sections in 
comparison with that observed with the other antibodies (cf. Fig. 1). 
Immunoelectron microscopy on a sample of a serous ovarian carcinoma showed 
that all antibodies are directed against antigens localized in the membranes of 
the neoplastic cells (Fig. 3). OV-TL 23 reactivity appeared to be restricted to 
the luminal cell surface (Fig. 3D), whereas the antigens recognized by OC 125, 
OV-TL 3, and MOv 18 were demonstrated at the basal, the lateral, and the apical 
sites of the cells, resulting in circumferential staining (Fig. 3A-C). Additional 
cytoplasmic immune reactivity was not observed with any of the four antibodies, 
whereas the sections stained with the anti-keratin antibody (OV-TL 12/5) showed 
dense cytoplasmic reactivity (not shown). 
FIG. 3. Immunoelectron micrograph showing immunoperoxidase reaction on a sample of a serous 
ovarian carcinoma stained with OC 125 (A), OV-TL 3 (B), MOv 18 (C), and OV-TL 23 (D). The 
cell membranes are stained clearly positive with each of the antibodies. (Α-C: χ 3,500; D: χ 9,500). 
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Inimunohistochemical staining of nonovarian carcinomas 
OC 125, OV-TL 3, and MOv 18 showed positive staining with the majority 
of the 39 other gynecologic carcinomas examined (Table 2). OV-TL 23 showed 
markedly less reactivity with these samples than the other antibodies. OC 125, 
MOv 18, and OV-TL 3 stained the majority of the adenocarcinomas of the fallopian 
tube, endometrium, and cervix. Additionally, these antibodies positively stained 
some of the squamous cell carcinomas of the vagina and/or the vulva. The OV-TL 
23 antibody stained only 25% of the nonovarian gynecologic adenocarcinomas 
TABLE 2. Inimunohistochemical staining of nonovarian carcinomas' 
Gynecologic carcinomas 
Site 
Oviduct 
Endometrium 
Cervix 
Adenocarcinoma 
Squamous cell 
Vulva 
Vagina 
OC 125 
(η = 39) 
з/зь 
16/21 
2/4 
0/5 
2/5 
1/1 
Nongynecologic carcinomas (n = 64) 
Site 
Breast 
Stomach 
Ileum 
Colon 
Rectum 
Pancreas 
Lungc 
Kidney 
Urether 
Bladder 
Total 
3/16 
0/3 
0/1 
1/11 
0/4 
1/2 
2/10 
0/8 
0/1 
0/8 
31/103 
OV-TL 3 
3/3 
14/21 
3/4 
2/5 
3/5 
1/1 
5/16 
1/3 
0/1 
1/11 
1/4 
0/2 
1/10 
0/8 
0/1 
0/8 
35/103 
MOv 18 
3/3 
15/21 
2/4 
0/5 
2/5 
0/1 
1/16 
0/3 
0/1 
1/11 
0/4 
0/2 
0/10 
0/8 
0/1 
0/8 
24/103 
OV-TL 23 
3/3 
2/21 
2/4 
0/5 
0/5 
0/1 
0/16 
0/3 
0/1 
0/11 
0/4 
0/2 
0/10 
0/8 
0/1 
0/8 
7/103 
'Specimens were assayed in an immunoperoxidase assay. Staining was scored by two independent observers. 
'Number of positives/total number examined. 
Three small cell carcinomas, three squamous cell carcinomas, three adenocarcinomas and one carcinoid 
tumor were tested. 
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examined (seven of 28) and did not react with the squamous cell carcinomas of 
the cervix uteri, vulva, and vagina. 
The reactivity of the four monoclonal antibodies with 64 nongynecologic 
carcinomas (including 16 breast, 20 gastrointestinal, and 10 lung carcinomas) 
is reported in Table 2. OV-TL 23 showed no reactivity with these samples. 
Positivity for OC 125 was detected in adenocarcinomas of the breast (three of 
16), colon (one of 11), pancreas (one of 2) and lung (two of 10). OV-TL 3 
positively stained a third of breast cancer samples (five of 16), whereas (three 
of 19) gastrointestinal carcinomas and one adenocarcinoma of the lung also stained 
positively. MOv 18 reacted positively with two nongynecologic cancer samples: 
one ductal breast carcinoma and one mucinous adenocarcinoma of the colon. 
The highest specificity (93%) was found for OV-TL 23, whereas the specificities 
of OC 125, OV-TL 3, and MOv 18 were significantly lower: 70%, 66% and 
77%, respectively. The relevance of the absolute value of these calculated 
specificities is limited since the range of nonovarian carcinomas we used in this 
study does not reflect population-based incidence figures. However, the reported 
specificities represent a relative indication of the specificity of the antibodies for 
staining ovarian carcinomas. 
DISCUSSION 
We studied the immune reactivity of four anti-ovarian carcinoma monoclonal 
antibodies in sections from a broad series of carcinomas, in order to investigate 
their application in histopathological differential diagnosis of cancer. 
The immunohistochemical reactivity with cancer tissues of each of these four 
monoclonal antibodies has been previously described (14-16,21,22). However, 
an actual com-parison of their immunohistochemical reactivities requires an 
evaluation on serially cut sections from a wide range of cancer samples. 
Immunohistochemical study of 78 ovarian carcinoma specimens revealed that 
OC 125, OV-TL 3, and MOv 18 each reacted with ~ 90% of the ovarian carcino-
mas examined, whereas each antibody stained 98 %, 98 %, and 93 % of the serous 
ovarian carcinomas, respectively. In the present study, the frequencies of OC 
125 and MOv 18 positivity were higher than reported earlier: 62% for OC 125 
(21) and 69% for MOv 18 (15). However, more recent studies with OC 125 are 
in line with our observations (90%) (23,24). The sensitivity of OV-TL 23 for 
staining ovarian carcinomas was significantly lower than the sensitivity of the 
other antibodies, and is in agreement with earlier observations (16). 
It was originally reported that OC 125 was unreactive with mucinous ovarian 
77 
carcinomas (21), however, in this study OC 125 positivity was found in a proportion 
of the mucinous samples. CA 125 expression in mucinous ovarian tumors has 
been reported in previous studies (25,26) and is in line with the high CA 125 
levels in cyst fluids from mucinous ovarian tumors (27,28) and in sera from patients 
bearing mucinous ovarian carcinomas (29). We found the mucinous samples also 
reactive with MOv 18. Probably as a result of the limited number of mucinous 
samples previously examined, this reactivity has not been observed earlier (15). 
For application in surgical pathology, the antibodies should not only stain ovarian 
carcinomas, but should also be nonreactive with nonovarian carcinomas with similar 
histologic appearances. The epithelia of normal endometrium, fallopian tube and 
endocervix have been shown to weakly express the antigenic determinants re-
cognized by OC 125 (22), OV-TL 3 (14), and MOv 18 (30). In this study, the 
majority of adenocarcinomas originating from these epithelia also showed OC 
125, OV-TL 3, and MOv 18 positivity. Consequently, these antibodies do not 
facilitate discrimination between the various adenocarcinomas arising from the 
gynecologic tract. Although OV-TL 23 reacted with only 10% of the endometrial 
carcinomas, this antibody docs not discriminate sufficiently to be a useful tool 
to distinguish endometrial cancers from ovarian cancers. 
The expression of the antigens defined by OC 125, OV-TL 3, and MOv 18 
in carcinomas of the vagina and/or vulva shows that their expression is not restricted 
to adenocarcinomas, but also can be observed in squamous cell carcinomas. 
The immune reactivity of OC 125 with breast and colon carcinomas corresponds 
with that of earlier reports (22,24,31). OV-TL 3 positivity in breast carcinomas 
has not been reported previously (24,32), but sample numbers in these investigations 
were limited. The reactivity of OC 125 and OV-TL 3 with carcinomas of the 
breast, colon, and lung limits the use of these antibodies in differential diagnosis, 
since these carcinomas comprise a major proportion of the secondary ovarian 
tumors. 
MOv 18 showed only very limited reactivity with the nongynccologic carcinomas 
(3 % positive), whereas OV-TL 23 was completely unreactive with these samples, 
making these antibodies suitable tools for application in gynecologic pathology 
practice. 
The monoclonal antibodies OC 125, OV-TL 3, and MOv 18 are useful adjuncts 
for discriminating ovarian carcinomas from nongynccologic carcinomas. OC 125, 
MOv 18, and OV-TL 3 display very high sensitivity for staining ovarian carcinomas, 
and thus a negative reactivity with these antibodies in an adenocarcinoma section 
makes it unlikely to be an ovarian carcinoma. However, the occasional reactivity 
of OC 125 and OV-TL 3 (and, to a lesser extent, MOv 18) with nongynccologic 
carcinomas must be kept in mind when interpreting positive reactivities. 
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OV-TL 23 displayed the lowest sensitivity for staining ovarian carcinomas and 
mostly revealed heterogeneous staining patterns. On the other hand, OV-TL 23 
was the only antibody used in this study to be completely unreactive with the 
64 nongynecologic carcinomas. Therefore, a carcinoma sample displaying a positive 
reactivity with OV-TL 23 is likely to be a carcinoma originating from the female 
genital tract (i.e., ovary, endometrium, fallopian tube). 
From the immunohistochemical characteristics of these antibodies, it can be 
concluded that the value of only one antibody as a diagnostic tool in surgical 
pathology is limited, because the antibody occasionally is reactive with nonovarian 
carcinomas (OC 125, OV-TL 3, MOv 18), or because the antibody frequently 
stains ovarian cancer sections only weakly or focally (OV-TL 23). Therefore, 
a panel of antibodies seems more informative. For example, although a positive 
reactivity with breast cancer specimens is observed occassionally with these 
antibodies (19% with OC 125, 31 % with OV-TL 3, 6% with MOv 18), a postive 
reactivity of a cancer specimen with each of the three antibodies strongly suggests 
that the tumor does not originate from mammary epithelium. Analogously, this 
panel of antibodies can be used to distinguish colonic cancer from ovarian cancer. 
For this purpose an anti-keratin 7 antibody could be added to the panel, since 
application of a combination of anti-ovarian carcinoma antibodies and anti-keratin 
7 antibodies has been shown to facilitate the discrimination between ovarian and 
colon carcinomas (17,18). 
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CHAPTER SEVEN 
MARKER PROFILE OF DIFFERENT PHASES IN THE TRANSITION OF 
NORMAL HUMAN OVARIAN EPITHELIUM TO 
OVARIAN CARCINOMAS. 
С. C. van Niekerk, О. C. Boerman, F. С. S. Ramaekers and L. G. Poels. 
Am J Pathol 1991, 138: 455-463 
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Marker Profile of Different Phases in the 
Transition of Normal Human Ovarian 
Epithelium to Ovarian Carcinomas 
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To investigate whether early changes in the transfor 
motion of normal ovarian epithelial cells into tumor 
cells can be detected и ith monoclonal antibodies a 
comparative immunohistochemical study was per 
formed on normal human ovarian mesotheltal cells, 
cystomas cystadenomas ovarian carcinomas as 
well as granulosa cell tumor t'slng monoclonal an 
ttbodies against different keratin subtypes it was 
shown that mesothelial cells ovarian cysts cystade 
nomas, and carcinomas all reacted positively with 
broad spectrum anti keratin monoclonal antibodies 
(MAbs) as well as with MAbs to keratins * 8 18 and 
19 Keratins 4 and 13 were not found m mesothelial 
cells, but positive groups of cells were identified in 
several cystomas adenomas, and carcinomas While 
mesothelial cells did not react with the panepithetial 
marker B№ 495 i6 invaginating metaplastic meso 
thelial cells, inclusion cysts cystomas, adenomas, 
and carcinomas showed an increasing reactivity 
with BW495I36 with an increasing degree of malig 
nancy The reactivity of MAbs against ovarian carci 
noma associated antigens (OV TL 3 ОС ¡25 MOv 
18, and OV TL 10) was limited to weak staining re 
action in some mesothelial cells but were found to be 
positive on more than 50% of the ovanan cystade 
nomas and more than 90% of the ovanan carcino 
mas Thecal and granulosa cells of primordial, pn 
тагу and secondary follicles all reacted positively 
with antibodies to the broad spectrum keratins OV 
TI 1215 and RCK 102 and to keratins 8 and 18, but 
not with keratins 4 7 13 and 19 These keratins 
decreased or disappeared in granulosa cells of ma 
ture follicles (Graafian follicles) whereas granulosa 
cell tumors did not react with anti keratin antibod 
íes The reactivity ofBW 49536 was negative or lim 
tied to traces in some granulosa cells. Ovanan car 
ctnoma associated antigens were not expressed in 
granulosa cells or granulosa cell tumors. The data 
indicate that mesothelial cells undergoing metaplas 
tic changes finally resulting in ovarian cystade 
nomas (and carcinomas) initiate the synthesis of a 
2<X) kd glycoprotein recognized by MAb (BW 4951 
36) the production ofoianan carcinoma associated 
antigens m addition to focal production of keratin 4 
and/or lì as seen in several samples The granulosa 
cell tumors decrease or switch off their keratin pro 
auction and remain negative for the 200 kd glyco 
protein and the ovanan carcinoma associated anti 
gem. (Am J Fathol 1991 138 455^463) 
The normal ovarian surface is covered by a single layer of 
flat or cuboidal epithelial cells that histologically corre-
spond to the mesothelial lining of the pleural the pencar 
dial and the penloneal cavities The coelomic epithelium 
is thought to contribute during embryogenesis to the 
formation of the Mullenan duct Irom which the upper gen-
ital organs develop and in later life it can contribute to 
the formation of the maprity of benign and malignant ep-
ithelial neoplasms of the ovary ' The lormalion of crypts 
inclusion cysts and papillary structures are considered 
steps in differentiation proliferation and possible hor 
mone-mediated malignant transformation of entrapped 
ovarian epithelium23 To investigate whether early 
changes in the transformation of normal ovarian cells to 
tumor cells could be recognized with monoclonal anti-
bodies we carried out a comparative immunohistochem-
ical study on normal human ovanes lined with mesothelial 
cells cystomas cystadenomas ovarian carcinomas as 
well as granulosa cells and granulosa cell tumors The 
results indicate that the ovarian carcinomas derived from 
mesothelial cells have a phenotype that is distinct from 
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the granulosa cell tumors as marked by monoclonal an­
tibodies to keratins by BW495/36 and by monoclonal 
antibodies to ovarian carcinoma-associated antigens 
Material and Methods 
Tissues 
Normal and neoplastic human ovarian tissues were snap 
frozen immediately after surgery and stored at - 80°C 
For use in the indirect immunofluorescence and immu-
noperoxidase technique 4- to 5-μΓη thick cryostat sec­
tions were air dried and used unfixed in all immunohisto-
chemical assays Parallel samples were processed lor 
histologic examination (hematoxylin and eosm staining) 
Immunohistochemical Techniques 
Unfixed air-dried sections were incubated with optimally 
diluted monoclonal antibodies for 30 minutes at room 
temperature After repeated washings in phosphate-
buffered saline (PBS) containing 0 5% Tween-20 (Merck 
Darmstadt. FRG), pH 7 4 sections were further incu­
bated for 30 minutes at room temperature with peroxi­
dase conjugated rabbit anti-mouse Ig (1 100 Dako 
Glostrup Denmark) washed in PBS-Tween, and perox­
idase activity detected with 0 1% 3'-3-diamino-
benzidme-HCI (Sigma Chemical Co, St Louis MO) and 
0 01 % H 2 0 2 for 5 minutes Sections were counterstained 
with hematoxylin and eosm according to standard pro­
cedures 
The indirect immunofluorescence assay on cryostat 
sections was performed as described previously * The 
following antibodies were used in this study 
1 ) Mouse monoclonal antibodies against ovanan car­
cinoma OC 125,5 OV-TL 3,4 OV-TL 10,6 and MOv 1Θ 7 
2) Mouse monoclonal antibodies against intermediate 
filament proteins broad-spectrum keratin antibodies 
OV-TL 12/5 against keratins 5, 7, 14 and 19, RCK 102 
against keratins 5 and 8, в э keratin 7 OV-TL 12/30 and 
RCK 1 0 5 e D keratin 18 RGE 53, RCK 106. CK18-2 
2 С 8 1 0 в э keratin 4 бВЮ," keratin 8 CAM 52 and 
M20,12 keratin 13 1C7 and 2D7 " keratin 19 LP2K ' 3 
3) Mouse monoclonal antibodies BW 431/31 against a 
carcinoembryomc antigen (CEA) epitope,1" and BW 
495/36 against a 200-kd glycoprotein in epithelial cell 
types 1 5 1 6 The fluorescence intensity as well as the num­
ber of positive cells were arbitrarily scored as ~ negative, 
''"'"weakly positive. + positive, or + + strongly positive 
The immunoperoxidase reaction was scored similarly 
Both the IPO and IFA technique have been applied to 
all normal and tumor cases 
Results 
Immunocytochemcal Studies on 
Mesothelial Cell Ovarian Cysts(adenomas) 
and Carcinomas 
The immunohistochemical finding of the marker profile of 
ovarian mesothelium and ovarian tumors are summa­
rized in Table 1 and depicted in Figures A to L It is ob­
vious that all stages of malignant transformation contain 
keratins as concluded from their reaction with the broad-
spectrum antibodies OV-TL 12/5 and RCK 102 
Table 1 shows also that mesothelial cells contain ker­
atins 7, 8 18 (Figure A) and 19 Keratin 4 and 13 nor the 
200-kd glycoprotein defined by the panepithelial marker 
BW495'36 (Figure B) were expressed in these cells The 
keratins expressed in mesothelial cells were also found in 
ovarian cysts (Figure D) cystadenomas as well as ovar­
ian carcinomas (Figure G) Incidentally heterogeneity 
was noticed in the group of adenomas and/or carcino­
mas assayed with the four different monoclonal antibod­
ies to keratin 18 and the two different MAbs against ker­
atin 8 (Table 1 ) The strong fluorescence or peroxidase 
staining reaction as observed in mesothelial cells (Figure 
C) was reduced or negative in cysts (Figure F) and ad­
enomas. but again strongly expressed in carcinomas 
Keratins 4 and 13. being absent in mesothelial cells be­
came expressed in focal groups of carcinoma cells (Fig­
ure I) in about one half of the samples 
The monoclonal antibody BW 49536 did not stain 
ovarian mesothelial cells (Figure B) Within the group of 
ovarian cysts both negative as well as positive cases 
were found (figure E2 and El ) and even heterogeneous 
staining was observed within the epithelial lining of a cyst 
All ovanan aoenomas as well as all carcinomas (Figure 
H) were clearly positive This means that BW 495/36 dis­
criminates between mesothelial cells and ovarian adeno­
mas с q carcinomas, while the group of ovarian cysts 
constitutes an intermediate mixed group 
The markers OV-TL 3. OC 125 and MOv 18 were 
found at low expression levels in a minor number of sam­
ples of mesothelial cells but the expression level in­
creased in cysts and in adenomas 
They were strongly positive in more than 90% of the 
ovarian carcinomas (Figures J, K, and L) while OV-TL 10 
reacted with 60% of the carcinomas 
Although nearly all cystadenomas were stained posi­
tively with OV-TL 3, OC 125, and MOv 18, OV-TL 3 
scored strongly positive with 2 of 12 samples of cystad­
enomas, OC 125 with 6 of 12, and MOv 18 with 6 of 11 
samples OV-TL 10. which reacted with only 60% of ovar­
ian carcinomas, displayed also less reactivity with the 
benign tumors (3 of 10) The staining pattern of anti-CEA 
(BW431/31) was not discriminative between the groups 
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Table 1 Marker Fro/tie о/Оімгшп Me^othelium and Оіагшп fuman 
МАЬ 
RGE53 
RCK 106 
СК'8 2 
2С8 
О TL 12/5 
О TL 12/30 
RCK 105 
CAM 5 2 
M 20 
RCK 102 
LP2K 
6B10 
2D7 
IC7 
BW 495 36 
O V T L 3 
OC 125 
MOv 18 
O V T L 1 0 
BW 431/31 
Antigen 
Keratin 
18 
Keratins 
5'7 14/19 
Keratin 
7 
Keratin 
8 
Keratins 
5/8 
Keratin 
19 
Keratin 
4 
Keratin 
13 
Panepith 
Ovar care 
OA3 
CA 125 
Glycoprot 
38 40 kDa 
OA10 
CEA 
Mesothelium 
+ ' + + 6/6 
+ + 6/6 
+ 4/4 
- - / + 4/4 
+ + 
+ + 
+ + 
-t + 
+ + 
τ -г 
+ ' + + 
— 
— 
— 
+ -
— 
— 
— 
+ -
+ -
— 
— 
-г -
6/6 
6/6 
6/6 
4/4 
4/4 
6/6 
6/6 
6/6 
6/6 
6/6 
6/6 
6/6 
5 6 
16 
5/5 
1/6 
4/6 
2/6 
4,6 
2/6 
Cystoma S 
* - / + + 
+ τ 
+ + 
+ Η 
-t + 
+ + 
+ + 
+ /-·- + 
-t + 
+ f 
f - / + 
+ + 
+ -
+ -
+ -
+ 
+ 
•b -
+ / + "Г 
1- -
-t - / + 
f + + 
1-/+ + 
+ 
--
implex 
11/11 
8/8 
9/9 
9/9 
12/12 
'2/1? 
5/5 
3 3 
3/3 
9/9 
6/8 
2'8 
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the results of IPO as well as IFA 'echmque applied to all normal and lumor cases 
of ovarian cystomas adenomas and carcinomas be­
cause of its variable staining pattern 
Immunocytochemical Studies on Granulosa 
Cells and Granulosa Cell Tumors 
Table 2 summarizes the marker profile of granulosa cells 
and granulosa cell tumors which are depicted in Figures 
M to Ρ Several keratins were found in primary (Figure M) 
and growing follicles (Figure N) of the ovaries while the 
expression of keratins in mature Graafian follicles was 
usually reduced to traces (Figure О and P) or undetect­
able The thecal cells of the primordial follicle as well as 
the granulosa cells up to the stage beyond the secondary 
follicles reacted with MAbs to keratin 8 18 and with two 
broad spectrum antibodies OV-TL 12/5 and RCK 102 
Keratins 7 and 19 were not observed in granulosa cells 
except for traces in a single sample Keratins 4 and 13 
also were absent in granulosa cells No or sporadic re­
activity of BW 495/36 and of the markers OV TL 3 ОС 
125 MOv 18 and OV-TL 10 was found in sporadic gran­
ulosa cells 
Although a limited number (n = 2) of granulosa cell 
tumors were available none of them showed significant 
reactivity with the monoclonal antibodies used Slight 
staining was observed on ovanan stroma in some sam­
ples with OV TL 3 
Discussion 
The ovanan surface epithelium or mesothelium is the site 
of origin of the largest group of ovarian tumors16 The 
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formation of crypts inclusion cysts cystadenomas and 
papillary structures are considered to represent steps in 
differentiation proliferation and possible malignant trans­
formation of entrapped ovarian germinal epithelium 
thought to be mediated through hormones 2 
To investigate whether early changes in the transfor­
mation of normal ovarian epithelial cells into tumor cells 
can be detected with monoclonal antibodies we com­
pared the marker profile of normal ovaries ovarian cys­
tomas adenomas carcinomas as well as granulosa 
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diflerences we'e observed in the resul's ol IPO as well as ΙΓΑ technique applied to al1 norma and tumo' cases 
cells and granulosa cell tumors Using monoclonal anti 
bodies to diiferent keratin subtypes ovarian mesottielial 
cells cystomas, adenomas and carcinomas displayed 
virtually identical keratin expression patterns although 
within some ovarian carcinoma subtypes helerogeneous 
reactivities were observed Positive staining was seen in 
all cases with the broad-spectrum monoclonal antibodies 
OV-TL 12/5 (keratins 5 7 14 and 19) RCK 102 (keratins 
5 and 8) OV TL 12/30 and RCK 105 (keratin 7) RGE53 
RCK 106 CK 18-2 2C8 (all four keratins 18) CAM 5 2 
and M20 (keratin 8) 
From these results we conclude that normal ovarian 
mesothelium and ovanan carcinomas contain keratins 7 
8 18 and 19 as their epithelial mlermediale filament con 
stituents in accordance with earlier reports in the 
literature 1 7 1 β The ovarian cystomas and adenomas 
however also containing keratins 7 8 and 18 are vari­
able in the expression of keratin 19 
Although keratin 19 as detected by LP2K was found 
m all mesothelial cells expression in cysts and cystade-
nomas was less (ie two of eight and four of eight cases 
positive respectively) All ovarian carcinomas were found 
(heterogeneously) positive for LP2K 
Although keratin 4 and 13 were not found m simple 
ovarian mesothelial cells both keratins were expressed in 
scattered cells or groups of cells m several samples of 
the cystadenomas and carcinomas while in one of nine 
ovarian carcinomas all tumor cells were strongly positive 
with the keratin 4 antibody These keratins are character­
istic of complex epithelia " , 7 
Whether ihe expression of keratins 4 and/or 13 in 
some cystoma simplex samples might indicate an early 
metaplasia of benign epithelial cells remains to be eluci-
aated 
As shown previously 6 the antibody BW495/36 recog 
mzmg a 200-kd glycoprotein perfectly discriminated be­
tween ovarian mesothelial cells negative for BW 495/36 
and ovarian carcinomas positive for BW 495/36 We have 
now extended this observation by showing that also all 
ovarian adenomas stained strongly positive with BW 495.' 
36 Within Ihe group of ovarian cysts however some 
samples were positive while other samples showed only 
focal positive staining or a completely negative reaction 
This suggests that generation of adenoma from cystic 
epithelium is marked by the initiation expression of the 
200-kd glycoprotein defined by the BW 495/36 Although 
antibodies HMFG1 and HMFG2 have been described to 
discriminate between mesothelial cells (negative) and 
ovarian carcinoma cells (positive) the expression on 
ovarian cysts and adenomas (distinctive by proliferation 
of glandular elements) was much less marked than 
shown here for BW 495/36 1 8 
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As a result, the latter antibody seems to be a better 
candidate to discriminate between normal and atypical 
mesothelial cells on the one hand and (pre)malignant 
ovarian cells on the other hand in for example cytologic 
specimens of patients 
The ovarian carcinoma associated antigens 0A3 CA 
125 and the MOv 18 defined antigen all were strongly 
expressed in more than 90% of the ovarian carcinomas 
examined while the reactivity with OV-TL 10 reached a 
level of approximately 60% The number of positively 
scored samples was also high in the group of cysts and 
adenomas although the immunofluorescence reaction 
usually was weak The mesothelial cells lining the ovary 
showed in one or more samples only weak reactivity with 
antibodies OV-TL 3 ОС 125. MOv 18, and OV-TL 10 
One can argue therefore that these markers are increas­
ingly expressed in the transformation of mesothelial cells 
through adenoma to carcinoma rather than being ex­
pressed exclusively in ovarian cancers Local invagina­
tion and proliferation of the germinal epithelium might 
therefore be considered as the time of initiation of tumor 
antigen expression as was suggested originally for CA 
125 1 8 
Carcmoembryonic antigen expression was not dis­
criminative between all stages from mesothelial cells to 
ovarian carcinomas Its expression may reflect differenti 
ating and/or proliferative state of cells by analogy with the 
expression of CEA in transitional epithelial cells'9 and by 
mesothelial cell strains in culture6 
A limited number of granulosa cell tumors was inves­
tigated and found to be negative for all the keratin mono­
clonal antibodies examined Also the BW 495/36 antigen 
could not be detected Although this observation con­
firms the assumption that granulosa cell tumors are not 
carcinomas our study has indicated that the correspond­
ing normal granulosa cells at least transiently expressed 
keratins 8 and 18 and traces of keratin 7 and 19 in a 
single sample These keratins gradually disappeared on 
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maturation of the granulosa cells into Graafian follicles 
thus extending the results described by Czernobilsky el 
a l ' and B e n Z e e v and Amsterdam' '" using different 
monoclonal keratin antibodies In addition to the absence 
of keratins in granulosa cell tumors the panepithelial 
marker BW 495/36 gave hardly any delectable reaction 
in both granutosa cell tumors as well as in normal gran 
ulosa cells or any other cell type in the ovary 
As discussed by Czernobilsky ' granulosa cells could 
develop from the coelomic epithelium ( - mesothelium) 
the ovarian mesenchym or the mesonephric tubules 
which transform into the rete ovarii cords All three cell 
types have been shown to coexpress keratins and 
vimentm ?' thus making a granulosa cell histogenesis 
from epithelial cell types ( = mesothelium or relè ovarii) 
plausible The absence of BW 495'36 reactivity in both 
mesothehal and granulosa cells supports such a hypoth 
esis The keratin pattern ol granulosa cells however was 
distinct partly from that of the mesothelial cells In addition 
to keratins 8 and 18 in both cell types mesothelial cells 
also expressed keratins 7 and 19 The absence of the 
latter two keratins in human granulosa cells might how 
ever be associated with steroid levels as recenlly has 
been shown by Ben Ze ev and Amsterdam'4 for human 
granulosa cells in culture in the presence of human cho-
rionic gonadotrophm 
Comparing the changes from mesothelial cells to 
ovarian carcinomas with the changes of granulosa cells 
to corresponding tumors the ovarian carcinomas acti 
vated Ihe synthesis of the 20O-kd glycoprotein as well as 
the production of several ovarian carcinoma associated 
antigens The granulosa cell tumors on the other hand 
deactivated the keratin synthesis and did not initiate any 
significant synthesis of the 200 kd glycoprotein or of the 
ovarian carcinoma-associated antigens 
In the future these findings may be used as diagnostic 
criteria although it must be examined to what extent ste-
roid levels influence the expression levels of all these an-
tigens 
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CHANGES IN EXPRESSION OF DIFFERENTIATION 
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DERIVED TUMORS 
С. C. van Niekerk, * F . C. S. Ramaekers, **A. G. J. M. Hanselaar, 
**J. Aldeweireldt and L.G. Poels 
Departments of Cell Biology & Histology, and **Pathology, University of Nijmegen, 
Nijmegen; and *Department of Molecular Cell Biology & Genetics, University of 
Limburg, Maastricht, The Netherlands 
Summary: The marker profile of 18 samples of normal human ovarian tissues and 138 
samples of their derived tumors was established using 44 monoclonal antibodies directed 
against intermediate filaments, ovarian carcinoma specific antigens, general tumor-as­
sociated antigens and MHC-I/II antigens. Our data show that : 
1) Keratin expression is not limited to the group of epithelial tumors, but is also found in 
some gonadal as well as in germ cell tumors. 
2) The expression of the different subtypes of keratins in tumors does not always reflect 
the keratin pattern in the corresponding normal cells. 
a) In addition to keratin nos. 7, 8, 18 and 19, keratins 4, 13, 10 and 14 were expressed 
in a variable number of cells in cystomas, mucinous adenomas and carcinomas but not 
found in the mesothelial cells. 
b) In the group of gonadal stromal tumors keratins 7, 8, 18, and 19 were expressed in 
granulosa theca cell tumors, Sertoli-Leydig cell tumors, and in <10% of the cells in one 
case of granulosa cell tumors, while keratin 7 showed only expression in the one case of 
Leydig cell tumor. The expression of keratins 7, 8, 18 and 19 was also found in primor­
dial and primary follicles. To a lesser extent keratins 7, 8 and 18 became expressed in the 
(pre)anthral follicles. 
c) Germ cell tumors showed a variable expression of keratins, 7, 8, 18, 19 (and to a 
lesser extent keratins 4, 13) and 14 for epithelial cysts. Keratin 14 was found in squamous 
cell differentiation of dermoid cysts, and keratin 10 in cornified squamous epithelium. The 
dysgerminomas contained keratins 7, 8, and 18 only, while the endodermal sinus tumor 
contained keratins 7, 8, 18, 19 and 13, and to a lesser extent keratins 4 and 10. 
3) Vimentin expression was seen in most ovarian tumors indicating that this intermediate 
filament protein does not discriminate between epithelial and mesenchymal derived 
tumors. Expression of desmin was seen in about half of the mucinous adenomas and 
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carcinomas, albeit in minor cell populations. 
4) BW 495/36 usually followed the expression of keratins in all ovarian tumors, except for 
2 out of 3 cases of granulosa cell tumors, 1 Leydig cell tumor and the squamous cells in 
dermoid cyst tumors. The antibody discriminates, between positive ovarian tumors and 
negative normal mesothelium. 
5) HMFG-2 showed in most cases a similar, but ofien a weaker reactivity pattern as 
compared to BW 495/36, except for a negative reaction in all gonadal tumors and 
corresponding normal cells as well as the dysgerminomas. 
6) TAG-72 was positive in most mucinous ovarian adenomas and most ovarian carcino-
mas, but negative in mesothelial cells, most cystomas and serous adenomas. None of the 
gonadal tumors were stained positive. In the germ cell tumors which were mostly positive, 
the antibody did not discriminate between benign and malignant cases. Squamous cells in 
the dermoid cysts remained negative. 
7) The ovarian tumor markers (OC 125, OV-TL 3, OV-TL 16 and MOv 18) reacted with 
almost all samples of the epithelial ovarian tumors with an increasing expression from 
benign cases to carcinomas. Antibody OV632 was negative for mesothelial cells, cystomas 
and serous adenomas, while MOv 18 hardly reacted with mesothelial cells. Most ovarian 
carcinoma markers were found positive in the endoderma! sinus tumor but virtually 
negative in the group of dysgerminomas and dermoid cysts. OV-TL 3 and OV-TL 16 
reacted also with gonadal stromal tumors and corresponding normal ovarian cells. 
8) HLA-1 was found to be expressed in almost all nucleated cells, although loss of HLA-1 
expression was seen in areas of tumor cells. HLA-DR was negative on normal ovarian 
mesothelium, while heterogeneously expression was observed in most of the epithelial 
benign and malignant ovarian tumor samples. Key Words: Ovarian cystoma-Adenoma-
Carcinoma-Gonadal stromal tumors-Ovarian tumor markers-Keratins-Vimentin. 
In the Western world ovarian cancer is the most lethal of all gynecological 
neoplasms and responsible for approximately 50% of all deaths resulting 
from malignancies of the gynecological tract.1 
Ovarian tumor histogenesis can be understood on the basis of elements that 
constitute the normal ovary, i.e. the surface epithelium, the supporting 
stroma and the germ cells. During embryogenesis the coelomic epithelium is 
thought to contribute to the formation of the Miillerian duct from which the 
upper genital organs develop2. Epithelial ovarian tumors are thought to arise 
from this germinal epithelium, that consists of modified peritoneal mesotheli-
al cells covering the surface of the ovary2,3. Different types of epithelial 
ovarian tumors can be distinguished. The epithelium of the serous tumors 
resembles the epithelium of the fallopian tube, that of the mucinous tumors 
resembles the endocervical epithelium and the epithelium of the endometrioid 
and clear cell tumors resembles that of the uterine endometrium. The 
Brenner tumor resembles the urothelium, and it therefore appears that cells 
of the ovarian surface epithelium also have the potential for differentiation 
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along Wolffian lines.2 Amongst the epithelial ovarian carcinomas, serous and 
endometrioid cystadenocarcinomas are most frequently observed, while 
mucinous and clear cell adenocarcinomas are the least common'. Sex cord 
stromal tumors, which account for less than 10% of all ovarian tumors may 
show differentiation toward female or male structures. Germ cell tumors 
(constituting 20% of all ovarian tumors)1 may proliferate as undifferentiated 
neoplastic germ cells derived from primordial germ cells. These tumors may 
develop both in the gonads or at extra gonadal sites along the line of migra-
tion of these cells. 
Monoclonal antibodies (Mabs) specific for ovarian cancer, and general tumor 
or tissue differentiation antigens can be used in diagnostic pathology to 
establish the nature of ovarian neoplasia. It is important to distinguish the 
different primary ovarian tumors of epithelial, sex cord-stromal or germ cell 
origin, because the therapeutic modalities used for treatment of disseminated 
ovarian tumors differ between the different types and different stages of 
(p^malignancy3·'' as well from that used in the treatment of other malignan-
cies1. Furthermore, the prognosis of the different ovarian tumors differs 
considerably2. The purpose of this study is to review the specificity and 
sensitivity of monoclonal antibodies to antigens of normal ovarian cells, 
ovarian tumor-associated antigens as well as more general tissue markers in 
immunohistochemically distinguishing ovarian tumors and for the detection 
of early changes in the transformation of normal ovarian cells to tumor cells. 
MATERIALS AND METHODS 
Normal and neoplastic human ovarian tissue samples were obtained at the 
time of surgery from 156 patients. Small fresh tissue blocks were immediate-
ly snap-frozen in liquid nitrogen and stored at -80° C. Tissue sections (4-7 
micron thick) were fixed in acetone (10 min at room temperature) and used 
in the immunoperoxidase technique as described previously5. 
The following antibodies were used in this study: 
1. As antibodies against intermediate filament proteins, mouse monoclonals 
6B10 against keratin 46; OV-TL 12/30 and RCK 105 against keratin 7 7·8·9; 
M2010, LE4110, and CAM 5.2" against keratin 8; RKSE 6011 against keratin 
10; 1C7 and 2D76 against keratin 13; LL00210 and RCK 10712 against 
keratin 14; RGE53, RCK 106, CK 18-2 and 2C87·10·13 against keratin 18; 
I ^ K 1 4 against keratin 19; the broad-spectrum keratin antibodies RCK 102 
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against keratins 5 and 87·8; and OV-TL 12/5 against keratins 5, 7, 14, 195'7; 
were used. RCK 103" is a mouse monoclonal antibody which stains several 
types of glandular and squamous epithelia as well as transitional epithelium. 
Most importantly is its reaction with basal cell compartments and myoepithe-
lial cells. Since such cells have been described to contain keratins 5 and 14, 
one of these two proteins may be among the candidates of being antigens for 
RCK 103. Besides a reaction in epithelial cells, neural tissues are stained 
also by this antibody. Vimentin was detected by RV2028·11, while desmin 
was stained by RD 301 "^5. 
2. As antibodies against cell surface antigens, mouse monoclonals BW 
495/364·16'17 against an epithelial cell type 200-kDa glycoprotein, antibody 
HMFG-218 directed against a human milk fat globule antigen, B72.3 reactive 
with a high-molecular-weight mucin like glycoprotein complex TAG (tumor-
associated glycoprotein)-7219 and BW 431/315'20 directed against a CEA 
epitope, were used. 
3. As antibodies against ovarian carcinoma tissues, mouse monoclonals OV-
TL 3 directed against an ovarian carcinoma surface antigen,5,21 ·22, and OV-TL 
10 directed against a cytoplasmic antigen, present in about 60% of serous 
ovarian carcinomas5, were used. 
OV-TL 1523, OV-TL 3023 and OV-TL 3123 were obtained after immunizing 
mice with undifferentiated human ovarian cystadenoma extract and are 
directed against human ovarian carcinomas. 
OV-TL 1624, OV-TL 1724, OV-TL 192\ OV-TL 2224, OV-TL 2324, OV-TL 
2424 and OV-TL 2724 directed against human ovarian carcinomas, have been 
prepared by intrasplenic immunization of ovarian tumor derived cyst fluids. 
OC 125 is directed against the CA 125 antigenic determinant and was 
obtained after immunizing mice with the OVCA 433 ovarian carcinoma cell 
line25. 
MOv 18 is directed against an ovarian cancer-associated antigen, identified 
as a high-affinity folate-binding protein26, while OV632 is secreted by a 
hybridoma cell line which was produced from mice immunized with cyst 
fluid from a serous cystadenocarcinoma of the ovary27. 
4. As antibodies directed against MHC class antigens, HLA-I (Sera lab clone 
W6-32) directed against nucleated cells and anti-HLA-DR antigen marker 
(Becton and Dickinson clone L-243, Etten-Leur, The Netherlands) directed 
against a human monomorphic MHC class II antigen (molecular weight 28-
34 Kd with haplotypic variation), were used. Anti-HLA-DR antigen marker 
does not cross react with HLA-DQ or HLA-DP molecules. 
1 0 0 
The immunoperoxidase reaction was arbitrarily scored and expressed as the 
number of positive cases over the total number of cases tested. Samples were 
considered as positive when the number of positive cells ranged between 10-
100% in a section (without symbol); (+/-): less than 10% positive tumor 
cells; (+): > 10% weakly positive cells. 
RESULTS 
The imunocytochemical reactivity patterns of the monoclonal antibodies in 3 
groups of ovarian tumors and the corresponding normal ovarian cells, are 
described below, summarized in Tables I-III and depicted in Figs. 1-4. 
1. Germinal epithelium and derived tumors (Table I; Figs. 1 and 2) 
Table I shows that the normal germinal epithelium of the ovary as well as all 
stages of both benign and malignant transformation contain keratins 8 and 
18. The reactivity of the anti-keratin 8 Mab LE41 and anti-keratin 18 Mab 
2C8 is not as consistent as that of the other keratin 8 and 18 antibodies, 
while the reactivity pattern of RGE53 is more heterogeneous than RCK 106 
and CK 18-2. Keratins 7 (Fig. 1A) and 19 have been shown to be expressed 
in all mesothelial cells and the different stages of malignant transformation 
with only one negative case for keratin 7 as detected by OV-TL 12/30 in the 
adenocarcinoma group and keratin 19 in the ovarian endometrioid carcinoma 
group. Keratin 4 is absent in mesothelial cells, hardly expressed in cystomas 
and serous adenomas, while expression in serous carcinomas as well as in 
mucinous adenomas and carcinomas was found in about 50% of the samples 
in varying numbers of cells (Fig. IB). In the other subgroups of epithelial 
ovarian tumors keratin 4 was found to a much lesser degree. Keratin 13, also 
being absent in mesothelial cells, was expressed in part of the mucinous 
group of adenomas and carcinomas (Fig. 1С), while the expression in the 
other groups of adenomas and carcinomas was much less pronounced. In one 
case of a mucinous cystadenoma, keratin 13 positive metaplastic transitional 
cells were found strikingly. Keratin 10 expression was found in cell groups 
within approximately one-third of the mucinous tumor cases (Fig. ID), while 
no or hardly any expression was found in mesothelium, or any of the other 
epithelial ovarian tumor groups. Keratin 14 showed an expression pattern 
similar to keratin 4 in most tumor cases (Fig. IE). While LL002 defined 
keratin 14 was expressed in over 40% of the serous carcinomas, RCK 107 
detected keratin 14 in only 1 out of 16 serous carcinomas. Both monoclonal 
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Table I. Intermediate filament - and tumor marker profile of normal ovarian epithelium and germinal epithelial tumors' 
1 
Mab 
6B10 
OV-TL 
12/30 
Antigen 
Keratin 4 
Keratin 7 
RCK 105 Keratin 7 
M 2 0 Keratin В 
LE41 
CAM 5.2 
RKSE 60 
1C7 
2D7 
LL002 
RCK 107 
Keratin 8 
Keratin S 
Keratin 10 
Keratin 13 
Keratin 13 
Keratin 1 4 
Keratin 14 
Normal 
Mesolhelium 
0/7 
7/7 
Benign 
Cystoma 
2/16 
15/15 
7/7 16/16 
7/7 
6/6 
7/7 
0/7 
0/7 
0/7 
0/7 
0/7 
Serous 
Benign | B.M. 
Cyst- ' Cyst-
adenoma adenoma 
2/6 ' + / - 1/1 
Carcinoma 
9/16 
+ / - 5 / 1 6 
6/6 1/1 16/16 
6/6 1/1 
1 
16/16 5/6 
+ / - 1/6 
15/15 
16/16 
0/16 
+ / - 1 / 1 6 
1/16 
2/16 
2/16 
5/6 
+ 1/6 
6/6 
1/6 
0/6 
0/6 
0/6 
0/6 
1/1 
1/1 
1/1 
0/1 
+ / - 1/1 
+ / - 1/1 
+ / - 1/1 
0/1 
16/16 
16/16 
15/16 
± 1/16 
15/16 
+ / - 1 / 1 6 
+ / - 2 / 1 6 
+ / - 7 / 1 6 
2/16 
+ / - 4 / 1 6 
± 1/16 
7/16 
+ / - 5 / 1 6 
1/16 
+ / - 1 / 1 6 
Mucinous 
Benign 
Cyst-
adenoma 
10/19 
+ / - 2 / 1 9 
± 1/19 
19/19 
19/19 
19/19 
19/19 
18/19 
± 1/19 
4/19 
+ / - 1 / 1 9 
± 3/19 
7/19 
+ / - 1 / 1 9 
8/19 
+ / - 3 / 1 9 
± 1/19 
6/19 
+ / - 2 / 1 9 
7/19 
+ /-3/1Э 
B.M. 
Cyst-
adenoma 
1/3 
+ / - 1/3 
3/3 
3/3 
3/3 
3/3 
3/3 
1/3 
+ / - 1/3 
2/3 
2/3 
Carcinoma 
3/9 
+ / - 4/9 
9/9 
9/9 
9/9 
9/9 
9/9 
3/9 
+ / - 1/9 
5/9 
+ / - 2/9 
6/9 
± 1/9 
1/3 3/9 
+ / - 1/3 + / - 1/9 
1/3 
+ / - 1/3 
4/9 
+ / - 2/9 
Benign 
Brenner 
Tumor 
+ / - 1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
0/1 
1/1 
1/1 
0/1 
0/1 
Endo­
metrioid 
Carcinoma 
2/14 
+ / - 5 / 1 4 
13/14 
+ / - 1 / 1 4 
14/14 
14/14 
11/14 
± 2/14 
14/14 
+ / - 2 / 1 4 
+ / - 4 / 1 4 
± 1/14 
+ / - 5 / 1 4 
2/14 
+ / - 5 / 1 4 
+ / - 5 / 1 4 
Clear cell 
Carcinoma 
1/11 
11/11 
11/11 
Adeno­
carcinoma 
N O.S. 
2/10 
+ / - 3 / 1 0 
9/10 
+ / - 1 / 1 0 
10/10 
11/11 10/10 
9/11 
11/11 
0/11 
± 1/11 
± 1/11 
1/11 
+ / - 1 / 1 1 
± 1/11 
1/11 
+ / - 1 / 1 1 
9/10 
± 1/10 
10/10 
+ / - 1 / 1 0 
1/10 
+ / - 1 / 1 0 
1/10 
+ / - 2 / 1 0 
2/10 
+ / - 2 / 1 0 
+ / - 4 / 1 0 
Mixed 
Mullenan 
Carcinoma 
+ / - 1/2 
2/2 
2/2 
2/2 
2/2 
2/2 
0/2 
+ / - 1/2 
+ / - 1/2 
0/2 
0/2 
Table I. (continued 1) 
II 
Mab 
RGE53 
RCK 106 
CK 18-2 
2C8 
LP2K 
RCK 102 
OV-TL 
12/5 
RCK 103 
R V 2 0 2 
R D 3 0 1 
BW 
495/36 
HMFG 2 
Antigen 
Karatin 18 
Keratin 18 
Keratin 18 
Keratin 18 
Keratin 19 
Keratins 
5 + 8 
Keratins 
5 + 7 + 
14 + 19 
Normal 
Mesothelium 
7/7 
7/7 
7/7 
7/7 
6/Θ 
7/7 
7/7 
Keratins ' 7/7 
Vimentm 
Desmin 
Panepith. 
200 kDa 
HMFG 
7/7 
0/6 
0/7 
0/7 
Benign 
Cystoma 
16/16 
16/16 
15/15 
16/16 
16/16 
16/16 
14/14 
16/16 
14/16 
1/16 
11/15 
± 3/15 
7/15 
± 1/15 
Serous Mucinous | | 
Benign 
Cyst-
adenoma 
6/6 
6/6 
6/6 
S/6 
6/6 
6/6 
6/6 
5/6 
+ / - 1/6 
5/6 
± 1/6 
0/6 
6/6 
6/6 
B.M. 
Cyst-
adenoma 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
0/1 
1/1 
1/1 
Carcinoma 
16/16 
16/16 
16/16 
12/16 
± 4/16 
16/16 
16/16 
16/16 
15/16 
± 1/16 
11/16 
+ / - S / 1 6 
+ / - 1 / 1 6 
16/16 
16/16 
Benign 
Cyst-
adenoma 
19/19 
19/19 
19/19 
19/19 
19/19 
19/19 
19/19 
19/19 
12/19 
+ /-2/1Э 
± 2/19 
9/19 
19/19 
18/19 
± 1/19 
B M . 
Cyst 
adenoma 
3/3 
3/3 
3/3 
3/3 
3/3 
3/3 
Carcinoma 
9/9 
9/9 
9/9 
9/9 
9/9 
9/9 
Benign 
Brenner 
Tumor 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
3/3 9/9 1/1 
3/3 
3/3 
1/3 
+ / - 1/3 
3/3 
3/3 
9/9 
8/9 
+ / - 1/9 
5/9 
+ / - 1/9 
9/9 
9/9 
1/1 
+ / - 1/1 
0/1 
1/1 
1/1 
Endo-
metnoid 
Carcinoma 
14/14 
14/14 
14/14 
13/14 
13/14 
14/14 
13/14 
12/14 
+ / - 2 / 1 4 
10/14 
+ / - 4 / 1 4 
+ / - 2 / 1 4 
14/14 
11/14 
± 2/14 
Clear cell 
Carcinoma 
11/11 
11/11 
11/11 
10/11 
± 1/11 
11/11 
11/11 
11/11 
n/n 
9/11 
+ / - 2 / 1 1 
+ / - 1 / 1 1 
11/11 
11/11 
Adeno­
carcinoma 
N O S 
10/10 
10/10 
10/10 
8/10 
+ / - 1 / 1 0 
± 1/10 
10/10 
9/9 
10/10 
10/10 
8/10 
+ / - 2 / 1 0 
+ / - 1 / 1 0 
10/10 
9/10 
+ / - 1 / 1 0 
Mixed 
Mullerian 
Carcinoma 
2/2 
2/2 
2/2 
2/2 
2/2 
2/2 
2/2 
2/2 
2/2 
0/2 
2/2 
2/2 
Table I. (continued 2) 
II 
Mab 
В 72.3 
BW 
431/31 
OV-TL 3 
OV-TL 10 
OV-TL 1 5 
OV-TL 16 
OV-TL 17 
OV-TL 19 
OV-TL 22 
OV-TL 23 
OV-TL 24 
OV-TL 27 
OV-TL 30 
Antigen 
TAG-72 
CEA 
OA 3 
OA 10 
Normal Benign 
Mesotheliumi Cystoma 
0/6 
2/6 
± 2/6 
± 6/7 
1/6 
± 2/6 
O A 1 5 0/7 
OA 16 
OA 17 
OA 19 
OA 22 
OA 23 
OA 24 
O A 2 7 
0 А Э 0 
2/6 
± 1/6 
± 2/6 
± 2/7 
0/5 
± 2/6 
2/15 
9/15 
± 1/15 
13/15 
± 1/15 
8/14 
± 3/14 
5/16 
± 1/16 
8/15 
± 5/15 
1/13 
± 8/13 
± 5/14 
1/14 
± 3/14 
2/15 
± 3/15 
0/6 ' 1/13 
± 4/13 
1/6 
3/6 
± 1/6 
6/13 
± 1/13 
8/16 
+ / - 2 / 1 6 
Serous | Mucinous 
Benign 
Cyst-
adenoma 
0/6 
6/6 
6/6 
3/6 
± 3/6 
6/6 
4/6 
± 2/6 
2/4 
± 2/4 
± 3/4 
4/4 
6/6 
3/4 
+ / - 1/4 
4/4 
3/6 
B.M. 
Cyst-
adenoma 
+ / - 1/1 
+ / - 1/1 
+ / - 1/1 
+ / - 1/1 
+ / - 1/1 
1
 Benign B.M. 
Carcinoma Cyst- Cyst-
adenoma adenoma 
13/16 16/19 3/3 
+ / - 2 / 1 β + / - 2 / 1 9 
Β/16 17/19 3/3 
+ / - 3 / 1 6 
± 1/16 
15/16 
± 1/16 
6/16 
+ / - 2 / 1 6 
± 2/16 
16/16 
15/16 
± 1/16 
13/16 
± 3/16 
14/16 
+ / - 1 / 1 6 
± 1/16 
15/16 
+ / - 1 / 1 6 
14/16 
± 2/16 
13/16 
+ / - 3 / 1 6 
16/16 
14/16 
+ / - 1 / 1 6 
16/19 
± 2/19 
13/19 
± 2/19 
12/19 
+ / - 2 / 1 9 
± 1/19 
19/1Э 
13/15 
± 1/15 
9/15 
+ / - 1 / 1 5 
± 1/15 
7/15 
+ / - 2 / 1 5 
± 1/15 
11/19 
± 1/19 
5/15 
+ / - 2 / 1 5 
± 2/15 
8/15 
+ / - 3 / 1 5 
9/19 
+ / - 4 / 1 9 
± 1/19 
3/3 
1/3 
+ / - 1/3 
± 1/3 
1/3 
± 1/3 
3/3 
2/3 
± 1/3 
1/2 
+ / - 1/2 
1/2 
Carcinoma 
9/9 
7/9 
+ / - 1/9 
9/9 
5/9 
+ / - 2/9 
± 1/9 
7/9 
9/9 
8/8 
4/7 
+ / - 2/7 
5/8 
+ / - 2/8 
1/3 5/9 
+ / - 2/9 
1/2 
± 1/2 
2/2 
2/3 
+ / - 1/3 
5/8 
± 1/8 
6/8 
5/9 
+ / - 2/9 
Benign 
Brenner 
Tumor 
1/1 
1/1 
1/1 
+ / - 1/1 
0/1 
1/1 
0/1 
1/1 
0/1 
+ / - 1/1 
0/1 
0/1 
+ / - 1/1 
Endo- { Clear cell 
metnoid Carcinoma 
Carcinoma 
11/14 
+ / - 1 / 1 4 
± 1/14 
4/14 
+ / - 5 / 1 4 
± 1/14 
13/14 
± 1/14 
6/14 
± 4/14 
11/14 
± 1/14 
13/14 
7/8 
+ / - 1/8 
5/8 
+ / - 1/8 
± 2/8 
5/8 
+ / - 2/8 
10/14 
+ / - 2 / 1 4 
± 1/14 
6/8 
+ / - 1/8 
5/8 
+ / - 2/8 
± 1/8 
9/14 
+ / - 4 / 1 4 
± 1/14 
8/11 
+ / - 2 / 1 1 
8/11 
+ / - 3 / 1 1 
9/11 
± 2/11 
6/11 
+ / - 1 / 1 1 
8/11 
+ / - 1 / 1 1 
9/11 
± 2/11 
3/6 
+ / - 1/6 
3/6 
2/6 
+ / - 1/6 
8/11 
2/6 
+ / - 2/6 
3/6 
+ / - 2/6 
8/11 
+ / - 1 / 1 1 
± 1/11 
Adeno­
carcinoma 
N.O.S. 
7/10 
+ / - 3 / 1 0 
4/10 
+ / - 1 / 1 0 
± 1/10 
9/10 
± 1/10 
4/10 
+ / - 1 / 1 0 
± 1/10 
8/10 
+ / - 1 / 1 0 
8/10 
± 2/10 
6/10 
± 3/10 
8/10 
+ / - 1 / 1 0 
± 1/10 
5/10 
+ / - 4 / 1 0 
6/10 
+ / - 3 / 1 0 
6/10 
+ / - 2 / 1 0 
7/10 
+ / - 1 / 1 0 
± 1/10 
8/10 
+ / - 2 / 1 0 
Mixed 
Mullenan 
Carcinoma 
0/2 
+ / - 1/2 
± 1/2 
+ / - 1/2 
0/2 
± 1/2 
0/1 
± 1/1 
0/1 
0/2 
0/1 
0/1 
1/2 
Table I. (continued 3) 
II 
Mab 
OV-TL 31 
ОС 125 
MOv 18 
OV632 
HLA-I 
HLA-DR 
Antigen 
O A 3 1 
Ca 125 
Glycoprot. 
38-40 kDa 
Non-muc. 
ov. care. 
MHC-I 
MHC-II 
Normal 
Masothehum 
2/6 
± 1/6 
± 2/7 
0/7 
0/6 
6/6 
+ / - 1/5 
Benign 
Cystoma 
4/15 
± 1/15 
8/14 
± 2/14 
6/14 
+ / - 1 / 1 4 
± 1/15 
14/15 
± 1/15 
9/15 
Serous 
Benign 
Cyst-
adenoma 
5/6 
+ / - 1/6 
6/6 
6/6 
+ / - 2/6 
6/6 
5/6 
+ / - 1/6 
B.M. 
Cyst-
adenoma 
0/1 
1/1 
1/1 
0/1 
1/1 
1/1 
Carcinoma 
11/16 
+ / - 3 / 1 6 
± 2/16 
16/16 
16/16 
14/16 
+ / - 2 / 1 6 
16/16 
15/16 
+ / - 1 / 1 6 
Mucinous 
Benign 
Cyst-
adenoma 
7/19 
± 1/19 
10/19 
± 1/19 
16/19 
+ / - 2 / 1 9 
9/19 
+ / - 1 / 1 9 
± 1/19 
19/19 
16/19 
B.M. 
Cyst-
adenoma 
1/3 
2/3 
2/3 
2/3 
3/3 
2/3 
Carcinoma 
3/9 
+ / - 2/9 
± 1/9 
8/9 
+ / - 1/9 
7/9 
+ / - 2/9 
- · 1/9 
7/9 
9/9 
9/9 
Benign 
Brenner 
Tumor 
0/1 
+ / - 1/1 
0/1 
0/1 
1/1 
+ / - 1/1 
Endo­
metrioid 
Carcinoma 
3/14 
+ / - 4 / 1 4 
± 2/14 
11/14 
+ / - 1 / 1 4 
13/14 
6/14 
+ / - 2 / 1 4 
13/14 
13/14 
+ / - 1 / 1 4 
Clear cell 
Carcinoma 
3/11 
+ / - 2 / 1 1 
± 2/11 
6/11 
± 1/11 
11/11 
s/n 
7/11 
+ / - 3 / 1 1 
± 1/11 
S/11 
+ / - 4 / 1 1 
± 1/11 
Adeno­
carcinoma 
N.O.S. 
3/9 
+ / - 3/Э 
± 2/9 
7/10 
+ / - 1 / 1 0 
± 1/10 
9/10 
7/10 
± 1/10 
9/10 
± 1/10 
9/10 
+ / - 1 / 1 0 
Mixed 
Mullenan 
Carcinoma 
0/2 
2/2 
2/2 
+ / - 1/2 
2/2 
0/2 
'The number of positive cases over the total number of cases tested in an immunoperoxidase assay. No symbol: 10-100 % positive tumor cells in a section; 
( + / - ) : less than 10 % of positive tumor cells; ( ±) : weakly positive cells in more than 10 % of the tumor cell population. 
^ м ^ ? ? * 
A •f·^;** 
Fig. 1. Immunoperoxidase staining patterns of intermediate filaments in serous ovarian carcinomas 
(A, B, F, G), mucinous ovarian carcinomas (C, D, E) and a mucinous ovarian adenoma (H), 
incubated with antibodies OV-TL 12/30 (A), 6B10 (B), 2D7 (C), RKSE60 (D), RCK 107 (E), 
RCK 102 (F), RV 202 (G), and RD 301 (H). 
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antibodies however, detected equally well the keratin 14 in about one-third 
of the mucinous tumor groups. 
As expected, all samples ranging from mesothelium to ovarian carcinomas 
reacted positively with both broad-spectrum anti-keratin Mabs (Fig. IF), 
although one serous cystadenoma sample reacted negative with RCK 103, 
and one endometrioid carcinoma sample showed no reactivity with the broad-
spectrum keratin antibody OV-TL 12/5. 
Vimentin was found strongly positive in all mesothelial cells, in most 
cystomas and serous adenomas, but to a lesser extent in serous carcinomas 
(Fig. IG). Half of the mucinous adenomas and almost all mucinous carci-
nomas expressed vimentin heterogeneously in up to 50% of the cells. In the 
remaining group of carcinomas vimentin expression was scattered or focal, 
in more than 50% of the samples. The expression of desmin was found in 
the tumor cells of half of the mucinous adenomas (Fig. IH), half of the 
mucinous carcinomas, and one cystoma sample. 
The pan-epithelial marker BW 495/36, described earlier for its reaction in a 
smaller group of tumors5, did not react with normal mesothelial cells. Within 
the group of ovarian cysts both negative as well as positive cases were found 
and even heterogeneous staining within one case was observed in the 
epithelial lining of a cyst, in accord with previous observations5. Usually all 
adenomas and carcinomas reacted strongly with this Mab (Fig. 2A), except 
for a weak reactivity in metaplastic transitional cells in one case of a muci-
nous adenoma. 
HMFG-2 also did not react with mesothelial cells, while heterogeneous 
reactivity was observed in the group of cystomas. In several cases, HMFG-2 
stained less cells than BW495/36. Although the antibody detected all other 
adenomas and carcinomas also, the reactivity was often weaker than recor-
ded for BW 495/36 (Fig. 2B), while in the group of endometrioid carcino-
mas one negative sample was found. Antibody B72.3 discriminated between 
positively stained serous carcinomas and negative mesothelial cells, cystomas 
and serous adenomas (Fig. 2D). Only two (slightly) positive cystomas were 
observed. The antibody did not differentiate between positive mucinous 
adenomas (Fig. 2C) and mucinous carcinomas. 
Since CEA was expressed heterogeneously throughout all categories of 
samples, with a slightly stronger expression in the mucinous tumors, the 
marker was not considered as discriminative for any subtype of ovarian 
epithelial tumor. 
The ovarian tumor-associated antigen CA 125, as detected by antibody OC 
125, was found to be expressed in some mesothelial samples, most cystomas, 
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Fig. 2. Immunoperoxidase staining patterns for tumor markers and HLA markers of serous 
ovarian carcinomas (A, B, I), mucinous ovarian adenoma (C, G), serous adenoma (D), mixed 
serous/endometrioid ovarian carcinoma (E, F), and a clear cell carcinoma (Ή), incubated with BW 
495/36 (A), HMFG-2 (B), B72.3 (C, D), OC 125 (E), OV-TL 3 (F), OV-TL 30 (G), HLA-I (H), 
and HLA-DR (I). 
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all serous tumors, about half of the mucinous adenomas and most carcinomas 
(Fig. 2E). This marker, however, did not stain the complete group of other 
ovarian carcinoma subtypes. Antibody MOvlS was more sensitive than OC 
125 in that it stained considerably more ovarian epithelial tumors. 
Both antibodies OV-TL 3 and OV-TL 16 showed similar immunohisto-
chemical reactivity patterns. Mesothelial cells were stained only slightly, 
while most of the benign and malignant ovarian tumors were positive for 
both antibodies (Fig. 2 F). In this study both antibodies were found positive 
already in very early stages of ovarian tumor development, and remained 
positive in most cases of ovarian carcinomas. However, the OA3 and OA16 
antigens were also found (weakly) expressed in most ovarian stromal cells in 
contrast to OC 125 and OV632. Although some of the remaining OV-TL 
antibodies showed a low or no reactivity in the group of cystomas, most of 
these markers (OA 17, 19, 22, 23 and 24) became increasingly expressed in 
benign and malignant tumors. None of the OV-TL antibodies however, dis-
criminated completely between benign ovarian tumors and carcinomas (Fig. 
2G), nor between any subclass of carcinoma. Interestingly, the Brenner 
tumor was stained only by OV-TL 3, OV-TL 16, OV-TL 19, and by TAG-
72. 
The antibody OV632 discriminated between positive serous carcinomas and 
negative serous adenomas, cystomas and mesothelial cells, but did not distin-
guish between mucinous adenomas and mucinous carcinomas, which are 
generally positive. The antibody did not react with a considerable number of 
samples of endometrioid, clear cell and adenocarcinomas. The tumor 
markers OC 125, OV-TL 3 and OV-TL 16, MOv 18 reacted with an increa-
sing number of samples when going from cystomas to ovarian carcinomas. 
Therefore, they can be considered as general markers for ovarian tumors of 
epithelial origin, with increasing expression from benign epithelial tumor to 
carcinomas. MOv 18 showed lowest reactivity with normal ovarian mesothe-
lial cells. HLA-I was found to be expressed in almost all nucleated cells, 
except for one negative endometrioid and three clear cell carcinoma samples 
(Fig. 2H). Also loss of HLA-I expression was seen in foci of tumor tissue 
and in a number of cases of other ovarian neoplasias areas of negative tumor 
cells were observed. HLA-DR was not expressed in normal ovarian mesothe-
lium, but was found heterogenously in most cases of the benign and malig-
nant samples (Fig. 21), while a direct correlation with the presence of 
inflammatory cells was not observed. 
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2. Gonadal stroma and derived tumors (Table II; Fig. 3) 
Although follicle cells are not considered primarily as epithelial cells, 
keratins nos. 8, 18 and 19 (and traces of keratin 7, as stained with OV-TL 
12/30) were found in ovarian follicle cells, diminishing towards mature 
granulosa cells in Graafian follicles and corpus luteum. Granulosa cell 
tumors were generally negative for keratin, although remarkably one granu­
losa cell tumor was stained with both antikeratin 7 antibodies. Scattered 
stromal cells in normal ovaries were found positive with some keratin anti­
bodies. In some fibroma samples keratin 7 and 8 were also found weakly 
expressed. Normal theca cells were devoid of keratins, but in some fibro-
thecomas expression of keratins nos. 7, 8, 18 and 19 was found. A similar 
positive keratin expression pattern was found in the granulosa-theca cell 
tumor (Fig. ЗА), in which both cell populations (identified by silverstaining 
and sudan fat staining method) appeared to contain keratins. The Sertoli-
Leydig cell tumors contained keratins 7, 8, 18, and 19 (Fig. 3B), while 
strikingly again, the Leydig cell tumor displayed keratin 7 expression only. 
Vimentin was expressed in both keratin positive and keratin negative normal 
and tumor cells. Desmin expression remained limited to 2 cases of fibroma-
thecomas. 
Except for the negative reacting Leydig cell tumor, the expression of the 
pan-epithelial BW495/36 marker again followed the keratin expression within 
the group of malignant gonadal tumors (Fig. 3C), while HMFG-2 remained 
negative on all samples. Both HMFG-2 and BW495/36 did not react with 
fibromas. TAG-72 showed no reactivity within the group of gonadal tumors 
or the corresponding normal ovarian cells. Most tumor markers were 
negative in gonadal stromal tumors, but OV-TL 3 and OV-TL 16 were 
moderately positive in most samples and MOv 18 reacted with two fibro-
thecomas and the Leydig cell tumor. OV632 reacted with 2 out of 3 granu­
losa cell tumors. Four Mab's (MOv 18, OV-TL 15, OV-TL 22 and BW495/ 
36) reacted also with the zona pellucida of the oocyte (Fig. 3D). HLA class I 
was expressed in (almost) all nucleated cells and HLA-DR was found (weak­
ly) expressed in some primary and primordial follicle cells, in corpus luteal 
cells and granulosa cell tumors. 
3. Germ cell tumors (Table III; Fig. 4) 
The group of ovarian teratomas consisted of four cases of dermoid cysts, two 
containing simple epithelium, one containing (comified) squamous epitheli­
um, and one with possible epithelial elements. 
Both simple epithelial cysts contained keratins 7, 8, 14, 18 and 19, while 
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Table II. Intermediate filament - and tumor marker profile of gonadal stroma and gonadal stroma tumors ' 
Mab 
6B10 
OVTL 
12/30 
RCK 105 
M20 
LE41 
CAM 5 2 
RKSE 60 
1C7 
207 
LL002 
RCK 107 
RGE53 
RCK 106 
CK 18-2 
2C8 
LP2K 
RCK 102 
OVTL 
12/5 
RCK 103 
R V 2 0 2 
RD301 
BW 
495/36 
| H M F G - 2 J 
' Normal 
Antigen 
Keratin 4 
Keratin 7 
Keratin 7 
Keratin 8 
Keratin 8 
Keratin 8 
Keratin 10 
Keratin 13 
Keratin 13 
Keratin 14 
Keratin 14 
Keratin 18 
Keratin 18 
Keratin 18 
Keratin 18 
Keratin 19 
Keratins 
5 + 8 
Keratins 
5 + 7 + 
1 4 + 1 9 
Keratins 
Vimentm 
Desmin 
Panepith 
200 kDa 
HMFG ' 
pnmord/pnm 
follicle 
0/14 
+ / - 2 / 1 3 
± 7/13 
2/15 
+ 1/15 
15/15 
6/16 
± 2/16 
16/16 
0/15 
0/15 
0/14 
0/15 
0/16 
13 /13^ 
14/15 
15/15 
3/16 
± 6/16 
8/15 
± 4/15 
12/13 
8/13 
± 3/13 
1/16 
15/15 
0/16 
a
 7/13 
± 3/13 
0/15 
(Pre)anth 
granulosa 
cells 
0/8 
± 5/8 
0/8 
8/8 
± 1/8 
2/7 
+ 5/7 
0/8 
0/8 
0/8 
0/8 
0/8 
4/8 
+ / - 1/8 
± 3/8 
7/8 
+ / - 1/8 
8/8 
± 3/8 
0/8 
8/8 
0/8 
0/8 
8/8 
0/8 
0/8 
0/8 
ral follicle 
theca 
cells 
0/8 
± 1/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
0/8 
8/8 
0/8 
± 1/8 
0/8 
Corpus 
granulosa 
cells 
0/3 
1/3 
± 2/3 
0/3 
3/3 
0/3 
3/3 
0/3 
0/3 
0/3 
0/3 
0/3 1 
2/3 
± 1/3 
3/3 
3/3 
0/3 
0/3 
3/3 
0/3 
0/3 
3/3 
0/3 
1/3 
0/3 
luteum 
theca 
cells 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
3/3 
0/3 
± 1/3 
0/3 
Benign 
Fibroma 
0/3 
± 1/3 
± 1/3 
+ / - 1/3 
0/3 
+ / - 1/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0/3 
+ / - 1/3 
0/3 
0/3 
+ / - 1/3 
0/3 
o/s 
0/3 
3/3 
0/3 
0/3 
0/3 
Fibro 
Thecoma 
0/11 
4/11 
+ / - 3 / 1 1 
± 1/11 
+ / - 1 / 1 1 
± 8/11 
1/11 
+ / - 4 / 1 1 
± 1/11 
0/11 
1/11 
± 1/11 
0/11 1 
0/11 
0/11 
0/11 
0/11 
1 / 1 1 H 
1/11 
+ / - 2 / 1 1 
1/11 
+ / - 2 / 1 1 
0/11 
1/11 
- / - 1 / 1 1 
1/11 
+ / - 1 / 1 1 
1/11 
+ / - 1 / 1 1 
0/11 
U / H 
2/11 
i n i 
0/11 
Malignant 1 
Granulosa 
cell tumor 
0/3 
1/3 
+ / - 1/3 
± 1/3 
1/3 
+ / - 1/3 
0/3 
0/3 
0/3 
0/3 
0/3 
0'3 
0/3 
0/3 
+ / - 1/3 
+ / - 1/3 
0/3 
+ / - 1/3 
+ / - 1/3 
0/3 
0/3 
3/3 
+ / - 1/3 
1/3 
0/3 
Granulosa ' Sertoli 
theca cell Leydig cell 
tumor tumor 
0/2 
1/2 
± 1/2 
1/2 
2/2 
+ / - 1/2 
± 1/2 
2/2 
0/2 
0/2 
0/2 
0/2 
0/2 
2/2 
2/2 
2/2 
+ / - 1/2 
2/2 
2/2 
2/2 
1/2 
± 1/2 
2/2 
± 1/2 
2/2 
0/2 
0/2 
1/2 
2/2 
2/2 
1/2 
2/2 
0/2 
0/2 
0/2 
0/2 
0/2 
2/2 
2/2 
2/2 
1/2 
2/2 
2/2 
1/2 
1/2 
2/2 
0/2 
2/2 
0/2 
Leydig cell 
tumor 
0/1 
1/1 
1/1 
0/1 
0/1 
0/1 
0/1 
0/1 
0/1 
o/i 
0/1 
0/1 
0/1 
0/1 
0/1 
0/1 
0/1 
0/1 
0/1 
1/1 
0/1 
0/1 
0/1 
Table II. (continued 1) 
Il 
Il Mab 
В 72.3 
BW 
431/31 
OV-TL 3 
OV-TL 10 
OV-TL I S 
OV-TL 16 
OV-TL 1 7 
OV-TL 1 9 
OV-TL 22 
OV-TL 23 
OV-TL 24 
OV-TL 27 
OV-TL 30 
OV-TL 31 
ОС 125 
MOv 18 
0 V 6 3 2 
H LAI 
HLA-DR 
Antigen 
TAG-72 
CEA 
OA 3 
OA 10 
OA 15 
OA 16 
OA 17 
OA 19 
OA 22 
OA 23 
O A 2 4 
O A 2 7 
O A 3 0 
0 A 3 1 
Ca 125 
Glycoprot. 
38-40 kDa 
Non-muc. 
ov. care. 
MHC-I 
Normal Benign 
pnmord/prim 
follicle 
0/15 
0/15 
4/12 
± 1/12 
0/16 
α
 3/15 
±3 4/15 
2/13 
± 2/13 
± 2/9 
± 1/11 
c
 4/13 
5/15 
± 1/15 
0
 1/11 
D
 1/10 
± 2/10 
9/15 
± 3/15 
± 5/15 
0/15 
α
 11/15 
± α 1/15 
(Prelanthral follicle 
granulosa theca 
cells cells 
0/7 
0/7 
± 8/8 
0/7 
0/8 
± 7/7 
± 3/7 
0/7 
0/6 
0/7 
0/7 
0/7 
0/7 
± 8/8 
0/7 
0/8 
± 7/7 
0/7 
0/7 
0/6 
0/7 
0/7 
4/7 0/7 
± 1/7 
0/8 
± 2/8 
0/7 
1/7 
0/16 ± 4/8 
11/12 
± 1/12 
MHC-Il ± 5/13 
4/8 
± 4/8 
0/8 
7/8 
± 1/8 
0/8 
0/7 
0/7 
0/8 
8/8 
0/B 
Corpus luteum 
granulosa theca 
cells cells 
0/3 
0/3 
3/3 
0/3 
0/3 
0/3 
0/3 
0/3 
± 1/3 o/s 
1 
1/3 
± 2/3 
1/3 
± 2/3 
1/3 
0/3 
± 1/3 
0/3 
± 1/3 
0/3 
0/3 
0/3 
1/3 
1/3 
3/3 
2/3 
Fibroma 
0/3 
0/3 
Fibro-
Thecoma 
0/11 
± 1/11 
2/3 4/11 
± 4/11 
0/3 0/11 
0/3 
o/s ! 1/3 
I 
0/3 
0/3 
0/1 
1/1 
0/3 0/1 
0/3 
0/3 
0/3 
2/3 
± 1/3 
0/3 
0/Э 
0/3 
0/3 
0/1 
± 1/1 
0/3 
0/3 
0/3 
± 1/3 
0/3 0/3 
3/3 
0/3 
1/3 
± 1/3 
1/3 
0/11 
3/11 
± 4/11 
+ / - 5/9 
1/9 
0/9 
0/11 
0/9 
Malignant || 
Granulosa 
cell tumor 
0/3 
0/3 
3/3 
0/3 
Granulosa 
theca cell 
tumor 
0/2 
+ / - 1/2 
1/2 
+ / - 1/2 
0/2 
0/3 0/2 
3/3 1/2 
+ / - 1/3 
± 1/3 
0/3 
0/Э 
0/3 
0/3 
± S/9 2/3 
1/11 
+ / - 1 / 1 1 
1/11 
± 1/11 
0/11 
2/11 
± 1/11 
S/11 
+ / - 6 / 1 1 
+ / - 1/3 
0/3 
0/3 
0/3 
2/3 
3/3 
4/11 2/3 
+ / - 4 / 1 1 
1/1 
0/1 
0/1 
0/2 
Sertoli-
Leydig cell 
tumor 
0/2 
0/2 
0/2 
± 1/2 
0/2 
1/2 
nd 
nd 
nd 
0/2 
Leydig cell 
tumor 
0/1 
0/1 
1/1 
0/1 
0/1 
1/1 
nd 
nd 
nd 
0/1 
0/1 nd nd 
+ / - 1/1 
± 2/2 
0/2 
0/2 
± 1/2 
0/2 
2/2 
1/2 
nd 
± 2/2 
0/2 
0/2 
0/2 
0/2 
2/2 
nd 
0/1 
0/1 
0/1 
1/1 
0/1 
1/1 
± 1/2 ¡ 0/1 
I 
* The number of positive cases over the total number of cases tested in an immunoperoxidase assay. No symbol: 10-100 % positive 
tumor cells in a section; ( + / - ) : less than 10 % of positive tumor cells; (±): weakly positive cells in more than 10 % of the tumor cell 
population; D zona pallucida. 
Flg. 3. Immunoperoxidase staining patterns of ovarian granulosa-theca cell tumor (A), ovarian 
Sertoii-Leydig cell tumor (B, C), and (pre)anthral follicle, with positive zona pellucida ( D - ^ - ) , 
incubated with RCK 102 (A), CK 18-2 (В), BW 495/36 (С), and MOv 18 (D). 
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Table III. Intermediate filament - and tumor marker profile of ovarian germ cell derived tumors' 
I- 1 
Mab 
6B10 
OV-TL 
12/30 
RCK IOS 
M 2 0 
LE41 
C A M S 2 
RKSE 60 
1C7 
2D7 
LL002 
RCK 107 
Antigen 
Keratin 4 
Keratin 7 
Keratin 7 
Keratin 8 
Keratin 8 
Keratin 8 
Keratin 10 
Keratin 13 
Keratin 13 
Keratin 14 
Keratin 1 4 
Benign 
Dermoid 
cvst 
(terato) 
' 1 / 4 
+ / - * 1/4 
M 0/4 
' 0 / 4 
' 2 / 4 
" 0 / 4 
' 0 / 4 
» 2 / 4 
" 0 / 4 
Ό/4 
» 2/4 
" 0 / 4 
Ό / 4 
» 2 / 4 
" 0 / 4 
Ό / 4 
»2/4 
83
 0/4 
Ό / 4 
+ / - » 1/4 
Μ
 1/4 
»Ό/4 
Ό / 4 
»1/4 
+ / - » 1/4 
" 0 / 4 
Ό / 4 
' 1 / 4 
+ / - » 1/4 
" 0 / 4 
' 0 / 4 
+ / - » 2/4 
"' 1/4 
Μ 0 / 4 
Ό / 4 
»2/4 
" 1/4 
Ό / 4 
Malignant 
Oya-
germinoma 
0/2 
± 2/2 
2/2 
2/2 
± 2/2 
2/2 
0/2 
0/2 
0/2 
0/2 
0/2 
Endodermal 
sinus 
tumor 
+ / - 1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
+ / - 1/1 
1/1 
1/1 
0/1 
0/1 
Mab 
RGE53 
RCK 10β 
CK 18-2 
2C8 
LP2K 
RCK102 
OV-TL 
12/5 
RCK 103 
R V 2 0 2 
R D 3 0 1 
BW 
495/36 
HMFG-2 
Antigen 
Keratin 1 8 
Keratin 18 
Keratin 18 
Keratin 18 
Keratin 19 
Keratins 
5 + 8 
Keratins 
5 + 7 + 
14 + 19 
Keratins 
Vimentin 
Desmin 
Panepith. 
200 kDa 
HMFG 
Benign 
Dermoid 
cyst 
(terato) 
' 2 / 4 
" 0 / 4 
Ό / 4 
' 2 / 4 
" 0 / 4 
Ό / 4 
' 2 / 4 
" 0 / 4 
Ό / 4 
' 2 / 4 
" 0 / 4 
Ό / 4 
' 2 / 4 
" 0 / 4 
' 0 / 4 
' 2 / 4 
" 1/4 
Ό / 4 
' 2 / 4 
" 1 / 4 
Ό/4 
' 2 / 4 
" 1/4 
+ / - c l / 4 
+ / - * 1/4 
± » 1/4 
" 0 / 4 
' 1 / 4 
»1/4 
" 0 / 4 
Ό / 4 
»2/4 
" 0 / 4 
Ό / 4 
»2/4 
" 0 / 4 
Ό / 4 
Malignant 
Dys-
germmoma 
2/2 
2/2 
2/2 
+ / - 2/2 
0/2 
2/2 
± 1/2 
0/2 
2/2 
0/2 
2/2 
0/2 
Endodermal l| 
sinus 
tumor 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
0/1 
1/1 
1/1 
Table III. (continued 1) 
Mab 
B72.3 
BW 
431/31 
OV-TL 3 
OV-TL 10 
OV-TL 1 S 
OV-TL 16 
OV-TL 17 
OV-TL 19 
OV-TL 22 
Benign 
Antigen 
TAG-72 
CEA 
ОАЭ 
OA 10 
OA 15 
OA 16 
OA 17 
OA 19 
OA 22 
Dermoid 
cyst 
(terato) 
»1/4 
ю 0 / 4 
' 0 / 4 
* 2 / 4 
" 0 / 4 
' 0 / 4 
' 1 / 4 
ю 0 / 4 
' 1/4 
+ / - * 1/4 
m 0 / 4 
' 0 / 4 
»1/4 
" 0/4 
' 0 / 4 
»1/4 
± » 1/4 
»3 0/4 
' 0 / 4 
' 0 / 3 
"' 1/3 
»"0/3 
' 1 / 3 
± »1/3 
» 0 / 3 
' 0 / 3 
»0/3 
« 0 / 3 
' 0 / 3 
1 
Melignant 
Dya-
germmoma 
2/2 
0/2 
+ / - 2/2 
0/2 
0/2 
0/2 
+ / - 1/1 
0/1 
0/1 
Endodermel 
sinus 
tumor 
1/1 
+ / - 1/1 
+ / - 1/1 
0/1 
1/1 
0/1 
nd 
nd 
nd 
Mab 
OV-TL 23 
OV-TL 24 
OV-TL 27 
OV-TL 30 
OV-TL 31 
ОС 125 
MOv 18 
OV632 
HLA-I 
HLA-DR 
Antigen 
0 A 2 3 
0 A 2 4 
OA 27 
OA 30 
0 A 3 1 
Ca 125 
Glycoprot. 
38/40 kDa 
O A 6 3 2 
MHC-I 
МНС-ІІ 
Benign 
Dermoid 
cyst 
(terato) 
' 1 / 4 
+ / - »1/4 
ro
 1/4 
' 0 / 4 
»0/3 
ю 0 / 3 
± ' 1/3 
»0/3 
83
 0/3 
+ / - ' 1/3 
»0/4 
ю 0 / 4 
' 1 / 4 
»0/4 
ю 0 / 4 
Ό / 4 
»0/4 
к» 0/4 
' 0 / 4 
»1/4 
» О М 
' 0 / 4 
»0/4 
» 0 / 4 
' 0 / 4 
»2/4 
»' 1/4 
ю 0 / 4 
' 1 / 4 
Malignant 
Dys-
germinoma 
0/2 
0/1 
0/1 
1/2 
± 1/2 
0/2 
0/2 
0/2 
0/2 
2/2 
+ / - »1/4 ' 1/2 
± »1/4 ± 1/2 
ю 0 / 4 
' 1 / 4 
End odermal 
sinus 
tumor 
1/1 
nd 
nd 
1/1 
± 1/1 
1/1 
1/1 
0/1 
1/1 
0/1 
' The number of positive cases over the total number of cases tested in an immunoperoxidase assay. No symbol: 
10-100 % positive tumor cells in a section; ( + / - ) : less than 10 % of positive tumor cells; ( ± ) : weakly positive 
cells in more than 10 % of the tumor cell population. * cysts; B1 squamous epithelium; B2 keratinized squamous 
epithelium; в э = B1 + B 2 ; c possibly some epithelial elements. 
keratins 4 and 13 were found in one case. Vimentin was expressed weakly in 
cystic epithelium. Desmin found in these teratomal tissues was present in 
mucin epithelial cells, in one case and further limited to muscular cell types. 
The epithelial character of the cells was supported by a positive staining with 
BW 495/36, HMFG-2, TAG-72, and/or BW 431/31. The epithelial cells 
were not stained by OC 125 and OV632, but some staining was observed 
with MOv 18, OV-TL 3, OV-TL 15, OV-TL 16, and OV-TL 23. 
The squamous cells contained keratin 14 and likely keratin 5, since RCK 102 
(recognizing keratins 5 + 8) stained the epithelial cells, while keratin 8 was 
not detected. The cornified epithelium contained keratins 5, 14 and 10. 
Vimentin was not found in squamous epithelium. The markers BW 495/36, 
HMFG-2 and TAG-72 did not react with both cell types. None of the tumor 
markers, except for OV-TL 23 and OV-TL 17, were expressed. HLA-I was 
expressed in the group of ovarian teratomas except in the keratinized squa-
mous epithelium, while the HLA-DR was found weakly positive or positive 
in 5-10% of the cells in the epithelial cysts, negative in the squamous 
epithelium and positive in the suspected epithelial component). The two cases 
of dysgerminoma present, expressed the simple epithelial keratins 7, 8 and 
18, but not 19 and others (Fig. 4A). Vimentin was coexpressed with keratin. 
The epithelial character was further supported by a positive staining for BW 
495/36 (Fig. 4B) and TAG-72 (Fig. 4C), but not by HMFG-2. Of all tumor 
markers only OV-TL 30 reacted with the dysgerminoma cells. HLA-I and 
HLA-DR were focally expressed in these tumors. In the case of malignant 
endodermal sinus tumor keratins 7, 8, 18 and 19 (Fig. 4D), were found, in 
addition to keratin 13, while keratins 4 and 10 were expressed weakly. 
Vimentin was only focally expressed. The epithelial character was confirmed 
by a positive reaction with BW 495/36 (Fig. 4E) and a heterogeneously 
positive reaction for TAG-72 and HMFG-2. The tumor was heterogeneously 
stained with OC 125, MOv 18 (Fig. 4F), OV-TL 30, OV-TL 23, OV-TL 
15, but not with OV-TL 3 (Fig. 4G) and OV-TL 16. In the endodermal sinus 
tumor HLA-I antigen was expressed, while HLA-DR was negative. 
DISCUSSION 
This study describes the marker profile of normal ovarian cells and tumors 
derived from the different ovarian cell types. Three categories of ovarian 
tumors have been studied: (1) tumors derived from germinal epithelium, (2) 
gonadal stromal tumors and (3) tumors derived from germ cells. A marker 
1 1 6 
t * : * 
л \І- **.* ,' ι λ^** - <*?·#" i-i 
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F · # 
-'' m 
Fig. 4. Immunoperoxidase staining patterns of ovarian dysgerminoma (А, В, C), and ovarian 
endoderma] sinus tumor (D, E, F), incubated with RCK 106 (A), BW 495/36 (B), TAG-72 (C), 
LP2K (D), BW 495/36 (E), MOv 18 (F), and OV-TL 3 (G). 
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profile as defined by a selected panel of monoclonal antibodies can contribu-
te to our understanding of the cellular origin of the individual tumor types, 
their progression behaviour during transformation, and may also be of help 
in the differential diagnosis of ovarian tumor (sub)classes. 
Epithelial ovarian tumors are thought to arise from the ovarian surface 
epithelium or mesothelium2. The epithelial origin of four major types of 
ovarian tumors, i.e. serous, mucinous, endometrioid and clear cell tumors, 
was supported by the presence of the so called simple keratins nos. 8 and 
18, and mostly keratins nos. 7 and 19, confirming our previous data5. The 
higher positive score for keratin 19 in the present study as compared to our 
previous results5 and also noticed for some other markers, may to some 
extent, be related to a higher Mab concentration and/or sensitivity of detecti-
on procedures in combination with the use of acetone fixed frozen sections 
instead of unfixed sections. The fact that keratins nos. 5, 4, 13, 10 and 14, 
normally markers for squamous differentiation, were not found in ovarian 
mesothelial cells, only incidentally in cystomas and serous cystadenomas, but 
in a considerable number in serous carcinomas, mucinous adenomas and 
carcinomas, suggests that the expression of these keratins is related to serous 
or mucinous differentiation rather than to the remaining category of ovarian 
cancers. In these positive cases for keratins 4, 10, 13 or 14, no squamous 
differentiation was apparent. Theoretically it cannot be excluded however, 
that the keratin antibodies might cross-react with an epitope in a non-keratin 
protein, for example mucinous or serous constituents. In the literature of 
keratin expression in ovarian malignancies, sofar also no indication exists for 
the presence of keratins 4, 10, 13 and 14 in ovarian tumor cells28. The 
keratin 7 antibodies OV-TL 12/30 and RCK 105 were found to react with 
virtually all 109 of the epithelial ovarian neoplasms. Therefore, the keratin 7 
antibodies can be used with more confidence in the differential diagnosis of 
the primary ovarian epithelial cancer vs. metastases to the ovary, in particu-
lar G.I. tract cancers. 
Coexpression of vimentin and keratin was reported for normal mesothelial 
cells 17'29·30·31 granulosa cells and rete ovarii cords of the human ovary 32. 
High vimentin coexpression in mesothelial cells as well as in mesotheliomas29 
is in line with the finding that mesothelial derived ovarian cystomas and 
adenomas still express vimentin. The fact that vimentin coexpression is not 
limited to cells in culture or ascites, but also occurs in benign and malignant 
ovarian tumor cells of all subclasses, illustrates that vimentin can not be 
considered as an (exclusive) marker for mesenchymal derived (tumor) cells. 
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Although sporadic vimentin and keratin coexpression in ovarian carcinomas 
has been reported earlier,33·34·35·36 we now demonstrate that using antibody 
RV202 in acetone fixed sections a relatively high number of all subclasses of 
the ovarian epithelial tumors showed (focal) vimentin staining. Our results 
are in line with the observations of other investigators31, who conclude that 
coexpression of different types of intermediate filaments is a more common 
phenomenon in human tissues, either normal or malignant, than previously 
realized. Alternatively, high vimentin coexpression has also been suggested 
to be associated with the proliferative activity of cells37. Viale et al.,38 
showed that most serous tumors (80%), some endometrioid adenocarcino-
mas, and all clear cell carcinomas investigated exhibited a variable number 
of neoplastic cells co-synthesizing (the two distinct intermediate filament (IF) 
proteins), keratins and vimentin whereas only one of 29 mucinous tumors 
and none of the Brenner tumors displayed vimentin-immunoreactive cells. In 
this study, however, 23 out of 31 cases of mucinous neoplasias exhibited 
expression of both keratins and vimentin. 
BW495/36, and to a lesser extent HMFG-2, discriminate between negatively 
reacting mesothelial cells and positively reacting carcinoma cells, with a 
heterogenous expression in the group of cystomas. This finding again 
favours the idea that ovarian carcinoma develops and progresses from 
mesothelial cells. Using BW 495/36 the differential diagnosis between 
mesothelial cells and carcinomas in cytodiagnosis of ascites can be greatly 
facilitated. Similarly, the combined markers for keratins and BW495/36 were 
succesfully applied in the differential diagnosis of mesothelial cells versus 
endometrioid cells in case of endometriosis39,40. The marker TAG-72, 
assumed to differentiate between benign and malignant tumors41, appeared in 
our study to discriminate between negatively stained mesothelial cells, most 
cystomas and serous adenomas versus positively stained mucinous adenomas 
and most carcinomas. Although the marker did not discriminate between 
mucinous adenomas and carcinomas, it marks however the progression from 
serous adenomas to serous carcinomas, and might be considered therefore as 
a helpful marker in subtyping ovarian epithelial tumors. Therefore it is 
tempting to speculate that the two TAG-72 positive cystomas (out of 15) 
might progress into mucinous adenomas, rather than into serous adenomas. 
The ovarian tumor marker antibodies, OC 125, OV-TL 3, OV-TL 15, OV-
TL 16, OV-TL 17, OV-TL 19, OV-TL 22, OV-TL 23, OV-TL 24, OV-TL 
27, OV-TL 30, OV-TL 31 and MOv 18 showed an increasing reactivity in 
the progression from benign tumors to carcinomas. OV-TL 19 only weakly 
stained normal ovarian mesothelium and cystomas, but showed increased 
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positivity in adenomas and carcinomas. The above mentioned Mabs OV-TL 
15, OV-TL 30 and OV-TL 31 have been studied earlier by Boerman et al23. 
in immunoradiometric assays, and the corresponding ovarian carcinoma 
antigens were also found in much lower concentrations in cystic fluid in 
benign than in malignant ovarian tumors, while other antigen levels, such as 
Ca 125, were found to be much less discriminative. OV632 antibody was 
negative for mesothelial cells, cystomas and serous adenomas, in this way 
being a marker for progression within the serous subgroup only. In conclusi-
on it can be stated that none of the monoclonal antibodies against ovarian 
carcinoma-associated antibodies discriminated completely between benign 
ovarian epithelial tumors and carcinomas, nor between the subclasses of 
carcinomas when applied in this immunohistochemical study. However, in 
the group of benign ovarian epithelial tumors Mabs OV632, OV-TL 19 
and/or TAG-72 in general can discriminate between negative reacting 
ovarian cystomas, and serous adenomas from positive stained mucinous 
adenomas. When taking some restrictions into account, antibodies OC 125, 
OV-TL 3, OV-TL 19, MOv 18 and OV632, when combined show an 
increasing expression of the ovarian tumor associated antigens going from 
ovarian mesothelium to carcinomas. 
HLA-I remained expressed in normal and tumor cells. HLA-DR was hardly 
found in mesothelial cells but was expressed usually in more than half of the 
epithelial tumors. MHC class I and II antigens play an important role in the 
interaction between tumor cells and the immune system. As described earlier 
42,43,44.45,46 ¿
естей$е(^ expression of MHC class I antigens correlates with 
increased tumorigenesis. Our results are in line with those of Valea et al.''7, 
who described positive expression of HLA-I antigen by ovarian epithelial 
neoplasms, although in our study loss of HLA-I expression was seen in areas 
of tumor cells. In some human malignancies the presence of MHC class II 
correlates with the presence of inflammatory cells and with a better progno­
sis42·48·49, while other investigators reported the absence of any correlation 
between the expression of MHC class II antigens and the induction of an 
anti-tumor immune response in vitro42,50,51. Our results are in line with the 
positive HLA-DR antigen expression of 11 out of 21 samples of ovarian 
carcinoma cells (ranging between 30% and 95%) as described by DiBello et 
al50. 
Both mesenchymal cells as well as coelomic epithelium32 have been sug­
gested to give rise to ovarian gonadal tumors (sex cord-stromal tumors'). As 
reported earlier5,32 primary follicle cells show strong expression of keratins 8 
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and 18 in all samples and keratin 19 in half of the samples. Keratin 7 
expression was limited to traces in some samples. The expression of these 
keratins was reduced in Graafian follicles and corpus luteum. For human 
granulosa cells it was reported that the synthesis of keratins 8, 18, and to a 
lesser extent, keratins 7 and 19 could be suppressed by treating the cells with 
HCG52. The keratin expression pattern of primary follicle cells as well as 
maturing granulosa cells confirm the epithelial nature of these cells. Strikin-
gly, traces of keratin 7 were sometimes detected scattered throughout ovarian 
stroma and theca cells. Fibromas expressed some keratins (7 and 8) in some 
samples, while one fibro-thecoma tumor and both granulosa-theca cell 
tumors were found positive for keratins 7, 8, 18 and 19. The finding of 
keratins in these stromal tumors agree with our observations (unpublished) of 
occasional keratin expression in normal activated stromal cells, and does not 
point to an other histogenetic origin of these tumors31. Vimcntin was expres-
sed in all gonadal tumors and corresponding normal cells as shown previous-
ly32. The finding of desmin in 2 fibromas is consistent with the observation 
of Czernobilsky32. The (almost) negative staining reactions of both BW 
495/36 and HMFG-2 marker in both the follicle cells (mature granulosa) 
cells and mesothelial cells as well as the rather similar keratin profile of both 
cell types point to a close relation of the granulosa cells with mesothelial 
cells, supporting the granulosa cell histogenesis from epithelial cell types 
(coelomic epithelium or rete ovarii cords) as described by Czernobilsky32. 
Interestingly the negative score of TAG-72 in granulosa cells and mesothelial 
cells also underlines the relationship with mesothelial cells since TAG-72 has 
been reported to be negative in malignant mesotheliomas as well as in benign 
mesothelial proliferations53. 
No coexpression of BW495/36, HMFG-2 and TAG-72 with keratins, was 
found in ovarian stromal cells, theca cells and fibromas. However one fibro-
thecoma and both granulosa theca cell tumors were found positive for 
BW495/36, but negative for HMFG-2 and TAG-72. Explanation needs 
further confirmation in a larger number of samples. 
The finding that the one Leydig cell tumor was negative for BW495/36, 
HMFG-2 and TAG-72, but positive for keratin 7 does not disprove the 
mesenchymal origin of that tumor, since keratin 7 was also found in the 
above mentioned fibro-thecomas. Thus, expression of keratins as well as the 
positive reaction with BW495/36 in Sertoli-Leydig cell tumors, indicate an 
epithelial character of the Sertoli cell tumor compartment but not of the 
Leydig cells. 
The germ cell tumors are thought to arise from primitive germ cells. These 
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tumors may develop both in the gonads or at extra-gonadal sites along the 
line of migration of the primitive germ cells. The remarkable homology 
between the various germ cell tumor types in male and female is in agree-
ment with the theory about the histogenesis of these neoplasias as described 
by Tcilum54. Mature teratomas (dermoid cysts) usually contained ectodermal 
structures. The presence of the simple epithelial keratins 7, 8, 18 and 19 in 
dermoid cysts was supplemented with keratins 4, 13 and 14. The squamous 
cell types contained keratins 5, 10 and 14, but not keratins 8, 18, 4 and 13. 
This indicates that these squamous epithelial tumor cells are of the dermoid 
(cornifying stratified) type, since in normal human keratinizing squamous 
epithelia keratins 5, 14 and 10 are found. Vimentin was coexpressed with 
keratins in the simple dermoid cyst but not in squamous cell types. The 
markers BW495/36, HMFG-2 and TAG-72 confirmed the epithelial charac-
ter of the simple dermoid cysts, but were negative in the case of squamous 
cell differentiation in line with their specificity in normal adult human 
tissues. 
Also in case of dysgerminoma and endodermal sinus tumor the immunostai-
ning pattern supported the epithelial nature of the tumor cells. Although 
similarity of endodermal sinus tumor and dermoid cysts has been suggested 
(Ashley, 197855) and is supported by the identical keratin pattern and 
BW495/36, HMFG-2 and TAG-72 staining, both tumors can be distinguished 
on basis of the reactivity of the cysts with ovarian carcinoma markers. 
In conclusion: our data suggest that in the study of the proliferation, 
differentiation and early transformation from normal ovarian surface epitheli-
um (mesothelium) into cystomas, adenomas and carcinomas, a panel of 
different monoclonal antibodies as described below will be very useful. 
1) Mabs directed against keratins 4, 10, 13, 14 (increased expression in 
different ovarian tumor types). 
2) BW 495/36 and HMFG-2 (negative staining of ovarian mesothelium and 
increasing expression from cystomas to cystadenomas on). 
3) TAG-72 discriminative in positive reacting ovarian mucinous adenomas 
and almost all carcinomas. 
4) Antibodies OV-TL 3, OV-TL 16, OV-TL 19, OC 125, MOv 18 and 
OV632, when combined show an increasing expression of the ovarian tumor-
associated antigens going from ovarian mesothelium, cystomas, cystadeno-
mas to carcinomas. 
A combination of several of the above mentioned Mabs may also be useful 
in diagnostic pathology. 
Although the gonadal stromal tumors and germ cell tumors are not thought 
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to originate from epithelial cell types, most corresponding tumors coexpress 
one or more keratins with BW 495/36. Since gonadal tumors could be 
discriminated by their negative staining with HMFG-2 and TAG-72, while 
germ cell tumors expressed TAG-72, a proper combination of these markers 
might be very helpful m diagnostic pathology of ovarian malignancies. 
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CONCLUSIONS 
Given the difficulties in diagnosis, monitoring and treatment of ovarian 
cancer there is a continuous search for ovarian tissue markers, which are 
tested for their usefulness in surgical pathology, immunoscintigraphy and 
immunotherapy. 
The purpose of this thesis was to type the characteristics of known, as well 
as newly developed monoclonal antibody reagents in the histogenesis and 
diagnosis of ovarian cancer. In our studies main emphases was directed to 
the question, whether early changes in the transformation of normal ovarian 
cells into tumor cells can be detected with monoclonal antibodies. In Chapter 
I we briefly discuss epidemiological and etiological aspects of ovarian cancer 
and summarize the antibodies that have been used sofar in ovarian cancer 
diagnosis. Chapters 2 to 8 describe the characterization of newly developed 
monoclonal antibodies that were used in combination with established 
immunoreagents, to identify the phenotype of different stages of both benign 
and malignant ovarian neoplasia. These studies were carried out on partly 
new established ovarian carcinoma cell lines, on ascitic fluid cells, as well as 
on tissue sections of normal and neoplastic ovaries. The results of these 
studies can be summarized as follows. 
Epithelial ovarian tumors. 
In the distinction between the different types and stages of ovarian neoplasia 
(see Fig. 1), as well as discrimination of ovarian cancer from other malig-
nancies, antibodies to intermediate filaments and tumor antigens have shown 
to be helpful. The following items are relevant in this respect: 
- Using broad spectrum keratin antibodies such as OV-TL 12/5 (keratins 5, 
7, 14, 19) and RCK.102 (keratins 5, 8), carcinomas can be distinguished 
from most non-epithelial tumors. 
- Antibodies to keratin 7 recognize specific subtypes of adenocarcinomas and 
distinguish for example, ovarian carcinomas (keratin 7 positive) from 
carcinomas of the gastrointestinal tract (keratin 7 negative). 
- Since the keratin 7 monoclonal antibody OV-TL 12/30 retained its immu-
nohistochemical reactivity on paraffin embedded tissues, the antibody is 
considered as a very useful tool in routine histopathology and cyto-pathology 
Our study, however, illustrates that exceptions exist to the rule, that in gene-
ral tumor cells retain the original keratin profile of the normal cell type. In a 
limited number of tumor cases new keratin types were found to be expres-
sed. The non-mesothelial keratins 4, 10, 13, and 14 were expressed in 
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FIG. 1. DIAGRAM OF THE IMMUNE REACTIVITY PATTERNS OF MONOCLONAL ANTIBODIES IN VARIOUS STAGES 
OF PROGRESSION OF EPITHELIAL OVARIAN NEOPLASIA* 
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several samples of ovarian cystomas, adenomas and carcinomas. 
- Vimentin expression was seen in most ovarian tumors indicating that this 
intermediate filament protein does not discriminate between epithelial and 
mesenchymal derived tumors. 
- The panepithelial marker BW 495/36 discriminated between negatively 
stained mesothelial cells in ascitic fluid and positively stained ovarian 
carcinomas and/or colon carcinomas. This antibody is therefore considered 
as a good marker complementary to the antikeratin antibodies, since mesot-
helial cells and ovarian carcinoma cells could not be distinguished exclusive-
ly by their keratin profiles. The increasing expression of this antigen when 
going from cystomas to cysladenomas and carcinomas, suggests that this 
mono clonal antibody marks the onset of tumorigcnesis from mesothelial 
cells to ovarian cancer cells. 
- TAG-72 discriminated between positively reacting ovarian mucinous 
adenomas, mucinous carcinomas and the negatively reacting mesothelial 
cells, cystomas and serous adenomas. 
- Ovarian carcinoma-associated antigens were detected in most ovarian 
carcinomas with several different monoclonal antibodies such as OV-TL 3, 
OV-TL 10, OC 125 and MOv 18, (and others) while for example, colon 
carcinoma cells were often negative. Benign ovarian tumors, however, 
usually also reacted (to a lesser extent) with these antibodies. 
- The OV632 antibody discriminated between negatively staining mesothelial 
cells, cystomas, serous adenomas, and positively reacting serous carcinomas, 
mucinous adenomas and mucinous carcinomas. The antibody showed limited 
reactivity with samples of endometrioid carcinomas, clear cell carcinomas 
and adenocarcinomas. OV632 seems therefore to be a marker for progressi-
on within the serous subgroup, rather than a general pan-ovarian carcinoma-
marker. 
- Interestingly HLA-I remained expressed in almost all nucleated cells of the 
different ovarian tumor types. HLA-DR (expression usually limited to lymp-
hoid cells) became also expressed heterogeneously in most benign as well as 
malignant epithelial ovarian neoplasms. Therefore these markers do not 
contribute significantly as diagnostic markers in ovarian tumor pathology. 
Non-epithelial ovarian tumors 
Keratin expression was not limited to the group of epithelial tumors, but was 
also found in some gonadal as well as in germ cell tumors. 
- Germ cell tumors showed a variable expression of keratins, including nos. 
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7, 8, 18, 19, to a lesser extent keratins 4 and 13, and 14 for epithelial cysts. 
Keratin 14 was found in squamous cell differentiation, and keratin 10 in 
cornified squamous epithelium. 
- BW 495/36, HMFG-2 and TAG-72 were usually coexpressed with keratins 
in the germ cell tumors, except for negative HMFG-2 staining in dysger-
minomas. 
- In general the ovarian carcinoma associated antigens are not expressed in 
the group of germ cell tumors, except for some positive staining of endo­
derma! sinus tumor with OC 125, MO ν 18, OV-TL 15, OV-TL 23, and OV-
TL30. 
Normal granulosa cells showed keratin 7, 8, 18 and 19 expression, while 
maturing granulosa cells reduced their keratin production. 
- Although BW 495/36 and HMFG-2 antibody staining usually followed 
keratin expression, we found them not to be coexpressed with keratins in 
normal granulosa cells. 
- Concerning the gonadal-stromal tumors one or more of the simple epithelial 
keratins were found (weakly) in granulosa cell tumors, granulosa-theca cell 
tumors, Sertoli-Leydig cell tumors and a Leydig cell tumor. None of the 
other keratins were found. 
- BW 495/36 was expressed in several samples, while HMFG-2 and TAG-72 
were completely absent. 
- Reactivity with monoclonal antibodies against ovarian carcinoma-associated 
antigens were limited to some positivity of granulosa-(theca) cell tumors with 
OV-TL 3, OV-TL 16 and OV632, while MOv 18 reacted with two fibro-the-
comas and the Leydig cell tumor. 
- Gonadal tumors could therefore be distinguished from germ cell tumors by 
the absence in the former of TAG-72 and HMFG-2, while germ cell tumors 
usually expressed TAG-72 and to a lesser extent also HMFG-2. The BW 
495/36 marker did not discriminate between both groups. 
Ovarian cells in tissue culture 
The most relevant conclusions from our studies with cultured mesothelium 
and ovarian cells are that: 
- CA 125 is synthesized and shed into the culture medium by normal intrape­
ritoneal mesothelial cells. This may explain elevated levels of this antigen, 
normally found after surgery of non-cancer patients. 
- Several ovarian carcinoma cell lines in culture largely lost their ovarian 
carcinoma associated antigens recognized by Mabs OV-TL 3, OV-TL 10.OC 
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125 andMOv 18. 
- In a newly developed ovarian carcinoma cell line (OTN 14) it was shown 
that estradiol and CEA-production could occur in vitro, which is however 
considered exceptional and ectopic rather than being a regular characteristic 
of ovarian cells. 
Pitfalls in immunohistochemistry 
A limitation of the immunohistochemical approach is that the antigenic 
epitope recognized by certain monoclonal antibodies can change its configu-
ration under different conditions. This may result in an alteration of the 
detectability or accessibility of the (masked) antigenic epitope. This pheno-
menon is well illustrated by the fact that two different keratin 7 MAbs (OV-
TL 12/30 and RCK 105), three different keratin 18 MAbs (RGE53, RCK 
106, CK18-2) and broad-spectrum keratin MAbs RCK102 (5, 8) and OV-TL 
12/5 (5, 7, 14, 19) showed slightly different staining patterns. In addition, 
slightly altered glycoprotein epitopes might have different sensitivity for 
tissue fixation procedures. 
This study has shown that different steps in the development of ovarian tu-
mors can be largely described by phenotyping with monoclonal antibodies. 
Based on this immunohistochemical approach, the process of the ovarian 
tumorigenesis can be further unraveled. 
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CONCLUSIES 
Het gebruik van markers voor ovarium-(tumor)weefsels is de afgelopen jaren 
aanzienlijk toegenomen bij het vaststellen van de juiste diagnose en de meest 
efficiënte behandelingsprotocollen voor ovariumkanker. De markers worden 
daarbij getest op hun toepasbaarheid in de chirurgische pathologie, immu-
noscintigrafie en immunothérapie. 
Het doel van dit proefschrift is het typeren van karakteristieken van zowel 
langer bekende als recent ontwikkelde monoclonale antistoffen in de histoge-
nèse en diagnose van ovariumkanker. Daarnaast was de vraag of vroege 
veranderingen in de transformatie van normale ovariumcellen in tumorcellen 
konden worden aangetoond met behulp van deze reagentia. 
In Hoofdstuk 1 wordt in het kort ingegaan op de epidemiologische en 
etiologische aspecten van ovariumkanker en wordt een inventarisatie gemaakt 
van de antistoffen, die tot nu werden toegepast bij de bestudering van 
ovariumkanker. Hoofdstukken 2 t/m 8 beschrijven de karakterisering van 
nieuw ontwikkelde monoclonale antistoffen die gebruikt zijn in combinatie 
met reeds ontwikkelde immunoreagentia. Hiermee werd getracht het fenotype 
van de verschillende stadia van zowel goedaardige als kwaadaardige ovarium 
tumoren te beschrijven. Deze studies werden uitgevoerd met (deels nieuw 
geïsoleerde) ovarium-tumorcellijnen en cellen uit ascites, alsmede op coupes 
van normale ovariumweefsels en ovarium-tumorweefsels. 
Epitheliale ovariumtumoren 
Antistoffen gericht tegen intermediaire filamenten en tumor antigenen blijken 
van nut te zijn in de diagnostiek van zowel de verschillende typen en stadia 
van ovariumkanker (Fig. 1, blz. 130), als ook bij het onderscheid tussen 
ovariumkanker en andere kwaadaardige tumoren. 
De resultaten kunnen als volgt worden samengevat: 
- Met behulp van breedspectrum kératine antistoffen, zoals OV-TL 12/5 
(kératine 5, 7, 14, 19) en RCK 102 (kératine 5, 8), worden carcinomen on-
derscheiden van de meeste niet-epitheliale tumoren. 
- Antilichamen tegen kératine 7 herkennen specifieke subtypen van adenocar-
cinomen, waardoor b.v. onderscheid gemaakt kan worden tussen ovarium-
carcinomen en carcinomen van het maag-darm stelsel. 
- De monoclonale antistof OV-TL 12/30 wordt in de routine histopathologic 
en cytopathologie als zeer bruikbaar beschouwd omdat het zijn immunohis-
tochemische reactiviteit tegen kératine 7 in met paraffine ingebed weefsel be-
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houd. 
- Deze studie illustreert evenwel dat er uitzonderingen bestaan op de regel 
dat tumorcellen in het algemeen het kératine patroon behouden van de nor-
male cellen waaruit ze zijn ontstaan. In een beperkt aantal tumoren werden 
"nieuwe" typen kératines gevonden, en wel de niet-mesotheliale kératines 4, 
10, 13 en 14 in een aantal samples van ovariumcystomen, -adenomen en 
-carcinomen. 
- Vimentine expressie wordt aangetoond in de meeste ovariumtumoren. Dit 
betekent dat de anti-vimentine antisera niet discrimineren tussen epitheliale 
en mesenchymale tumoren. 
- De pan-epitheliale marker BW 495/36 blijkt te discrimineren tussen niet 
aankleurende mesotheelcellen in ascites vloeistof en positief aangekleurde 
ovariumcarcinoom- en/of colon-carcinoomcellen. Deze antistof kan daarom 
beschouwd worden als een goede aanvulling op de kératine antistoffen, 
omdat mesotheelcellen en ovarium-carcinoomcellen niet van elkaar onder-
scheiden kunnen worden aan de hand van hun kératine profiel. De toenemen-
de expressie van deze marker in de reeks ovariumcystomen -adenomen en 
-carcinomen suggereert dat dit antigen het begin markeert van de tumoroge-
nese vanuit de ovariële mesotheelcellen naar de ovarium-carcinoomcellen. 
- TAG-72 blijkt te discrimineren tussen positief reagerende mucineuze ovari-
umadenomen en -adenocarcinomen en de negatief reagerende mesotheelcel-
len, cystomen en sereuze adenomen. 
- Ovariumcarcinoom geassocieerde antigenen worden sterk tot expressie ge-
bracht in de meeste ovariumcarcinomen en aldus gedetecteerd d.m.v. een of 
meer verschillende monoclonale antistoffen uit de serie OV-TL 3, OVTL 10, 
OC 125 en MOv 18, terwijl bijvoorbeeld colon-carcinoomcellen niet reage-
ren met deze antistoffen. Goedaardige ovariumtumoren blijken echter even-
eens, zij het in wat mindere mate, te reageren met de meesten van deze anti-
stoffen. 
- Het monoclonal antilichaam OV632 discrimineert tussen negatief mesotheel 
en niet reagerende cystomen en sereuze adenomen aan de ene kant en posi-
tieve mucineuze adenomen, sereuze en mucineuze carcinomen aan de andere 
kant. Het antilichaam vertoont echter beperkte reactiviteit met endometrioid-
clearcel- en adenocarcinomen van het ovarium. De marker moet daarom 
eerder gezien worden als een progressie-marker binnen de sereuze subgroep, 
dan als een algemene pan-ovariumcarcinoom marker. 
- De expressie van het HLA-I antigeen gaat in de ovarium tumoren niet ver-
loren. Daarentegen blijkt het HLA-DR, waarvan de expressie normaliter be-
perkt is tot het lymphoide systeem, heterogeen tot expressie te komen in het 
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merendeel van zowel de goedaardige als de kwaadaardige ovariumtumoren. 
Beide markers leverden echter geen belangrijke bijdrage in de diagnostiek 
van ovariumtumoren. 
Niet-epitheliale ovarium tumoren 
De resultaten verkregen met de niet-epitheliale ovariumtumoren kunnen als 
volgt worden samengevat: 
- De aanwezigheid van keratins blijkt niet beperkt te blijven tot de groep van 
epitheliale tumoren, maar deze intermediaire filament eiwitten werden ook 
waargenomen in sommige gonadale tumoren en kiemceltumoren. In kiemcel-
tumoren wordt een wisselende expressie gevonden van kératines 7, 8, 18, en 
19, alsmede in beperkte mate ook van kératines 4, 13 en in cysten kératine 
14. Verder wordt kératine 14 aangetoond in plaveiselcel-differentiatie, terwijl 
kératine 10 in verhoornende plaveiselcellen wordt gevonden. 
- BW 495/36, HMFG-2 en TAG-72 worden meestal gezamenlijk met kérati-
nes aangetroffen in kiemceltumoren; HMFG-2 kwam echter niet voor in 
dysgerminomen. 
- Ovariumcarcinoom geassocieerde antigenen worden nauwelijks aangetoond 
in kiemceltumoren, met uitzondering van een endodermale sinus-tumor die 
blijkt te reageren met OC 125, MOv 18, OV-TL 15, OV-TL 23 en OV-TL 
30. 
- Ofschoon de jonge follikel-granulosa cellen expressie van kératines 7, 8, 18 
en 19 vertonen, neemt de produktie van kératines in rijpende granulosa 
cellen zeer sterk af. 
- Het monoclonale antilichaam BW 495/36 blijkt evenals HMFG-2 niet te 
reageren met normale granulosacellen en dus geen co-expressie met kératines 
te vertonen. 
- In de groep van de gonadale tumoren worden een of meerdere kératines uit 
de groep 7, 8, 18 en 19 (soms zwak) tot expressie gebracht in de granulosa-
cel-tumoren, granulosa-thecacel-tumoren, Sertoli-Leydigcel-tumoren en een 
Leydigcel-tumor. Geen van de andere kératines kon worden aangetoond. 
- Terwijl (geringe) reactiviteit met BW495/36 wordt aangetroffen in een 
aantal maligne gonadale tumoren werd nooit immunoreactiviteit met HMFG-
2 en TAG-72 gevonden. 
- De immuunreactiviteit van monoclonale antistoffen tegen ovariumcarci-
noom geassocieerde antigenen bleef beperkt tot OV-TL 3, OV-TL 16 en 
OV632 in enkele granulosa-(theca)cel-tumoren. 
Gonadale tumoren kunnen daarom onderscheiden worden van kiemceltumo-
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ren middels de afwezigheid van het TAG-72 en HMFG-2 antigen in de eerst-
genoemde groep, terwijl kiemceltumoren meestal wel reageren met TAG-72 
en in mindere mate ook met HMFG-2. BW495/36 discrimineert niet tussen 
beide groepen van tumoren. 
Ovarium cellen in kweek 
De belangrijkste conclusies uit de studies met gekweekte mesotheelcellen en 
ovariumcellen zijn dat: 
- CA 125 gesynthetiseerd en in het kweekmedium uitgescheiden kan worden 
door normale mesotheelcellen van de buikholte. Dit kan een verklaring zijn 
voor de verhoogde waarden van dit antigen, gevonden na operatie van 
patiënten zonder bekende maligniteit. 
- Verschillende ovariumcarcinoom-cellijnen verliezen grotendeels hun 
ovariumcarcinoom geassocieerde antigen expressie, bijvoorbeeld de antige-
nen detecteerbaar met Mabs OV-TL 3, OV-TL 10, OC 125, en MOv 18. 
- In een nieuw ontwikkelde ovariumcarcinoom cellijn (OTN 14) werd estra-
diol en CEA-productie aangetoond in vitro. Dit lijkt meer een uitzonderlijke 
dan een algemene eigenschap van ovariumtumorcellen in kweek. 
Beperkingen van de immunohistochemie 
Een beperking van de immunohistochemische benadering voor de herkenning 
van de differentiatie-merkers is dat de configuratie van de epitopen, die 
herkend worden door bepaalde monoclonale antistoffen vaak veranderen on-
der verschillende omstandigheden. Dit kan resulteren in een gewijzigde 
reactiviteit met de specifieke monoclonale antistof of bemoeilijkte de toegan-
kelijkheid van het (gemaskeerde) epitoop. Dit fenomeen wordt goed geïllus-
treerd door het feit dat 2 verschillende monoclonale antistoffen tegen kératine 
7 (OV-TL 12/30 en RCK 105) en drie verschillende monoclonale antistoffen 
tegen kératine 18 (RGE53, RCK106, CK18-2) verschillende reactie patronen 
vertonen. 
Samenvattend kan worden gesteld dat deze studie heeft aangetoond dat ver-
schillende stappen in de ontwikkeling van ovariumtumoren grotendeels 
gefenotypeerd kunnen worden m.b.v. monoclonale antistoffen. Gebaseerd op 
deze immunohistochemische karakterisatie van ovariumtumoren kan het 
proces van ovarium-tumor-ontwikkeling verder worden ontrafeld. 
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der Lee, Marius Coelen voor het nauwgezet afdrukken van foto s. Mary Scholten 
voor haar secretariële ondersteuning bij het schrijven van artikelen. Medewerkers 
van de Medische Fotografie en Bibliotheek, waarvan ik o.m. Peter Janssen wil 
noemen en vele anderen dank ik voor al hun bijdragen voor de tot standkoming 
van dit proefschrift. 
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CURRICULUM VITAE 
Catharina Christina Stolwijk-van Niekerk, geboren te Leiden, 24 November 1938. 
Verbonden aan het Academisch Ziekenhuis te Leiden afdeling Inwendige 
Geneeskunde (Hoofd Prof. Dr. W. R .O. Goslings) en werkzaam als algemeen 
klinisch analiste en later als hoofd analiste 1958-1967. 
Betrokken bij studies van biochemische, bacteriologische, endocrinologische, 
serologische aard en bij bevolkings onderzoeken: 
- Onderzoek naar bijnierschorsfunctie tijdens en na een acute ernstige infectie­
ziekte, (Dr. Raden J. Djajadiningrad). 
- De relatie van secretorstatus en bloedgroep tot infecties met streptococci groep 
A en hun niet-purulente complicaties, (Prof. Dr. H. A. Valkenburg, Dr. M. 
J. Haverkorn van Rijsewijk). 
- Keelontsteking in de huisartspraktijk, (Prof. Dr. H. A. Valkenburg, Dr. A. 
W. Bots). 
Verbonden aan de Katholieke Universiteit te Nijmegen (1967-heden). 
Laboratorium van de bloedtransfusie dienst 1967-1968, (Hoofd Prof. Dr. C. 
Haanen). 
Laboratorium van Biochemie 1969-1972, (Hoofd Prof. Dr. S. L. Bonting, 
Dr. G. D. Vogels). 
Afdeling Microbiologie van Wis en Natuurkunde 1972-1973, (Hoofd Prof. 
Dr. G. D. Vogels). 
Betrokken bij studie: 
- Regulation of Allantoin Metabolism in the genus Pseudomonas, (Dr. Ir. G. 
Rijnierse). 
Afdeling Cytologie en Histologie 1973-1988, (Hoofd Prof. Dr. С Jerusalem). 
Betrokken bij studies: 
- Release of antigens and immunogenicity versus the host response during infection 
with rodent malaria parasite, (Dr. L. G. Poels). 
- Ovarium tumor onderzoek (Dr. L. G. Poels), (werkzaam als hoofd laboratorium-
assistente). 
Afdeling Celbiologie en Histologie, (Hoofd Prof. Dr. A. M. Stadhouders, 1988-
1991, Prof. Dr. B. Wieringa, 1990-heden). 
- In 1990 Getuigschrift Hoger Beroepsonderwijs (ing.) behaald, Medische 
Laboratorium opleiding, afstudeer richting "Medische Microbiologie". 
- Promotie onderzoek: "Immunophenotyping on normal, benign and malignant 
cells of the ovary", 1987-1991. 
- Protein tyrosine fosfatasen onderzoeksproject 1992-heden. 
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STELLINGEN 
Behorend bij het proefschrift getiteld: 
"Immunophenotyping of normal, benign and malignant cells of the ovary. " 
1. De monoclonale antistof OV632 is eerder te beschouwen als een progressie-
merker binnen de sereuze epitheliale subgroep van ovariumtumoren, dan 
als een pan-ovarium carcinoom merker (dit proefschrift). 
2. De configuratie van een antigeen-epitoop kan zodanig veranderen t.g.v. 
bepaalde fysiologische of pathologische condities dat immunohistochemische 
herkenning belemmerd wordt. Door toepassing van meerdere monoclonale 
antistoffen gericht tegen hetzelfde antigeen kan dit maskeringsfenomeen 
onderkend en omzeild worden. Schaafsma et al., Am J Pathol 1990,136: 
329-343 
3. De codering van de verschillende monoclonale tumorantistoffen dient volgens 
een eensluidend internationaal systeem te gebeuren. 
4. In maligne lichaamsvochten kan OV-TL 12/30 een indicatie geven voor 
de primaire localisatie van de tumor in routinematig Papanicolaou (PAP)-
gekleurde preparaten. (Persoonlijke mededeling J. Baars). 
5. Erythrocyten kunnen gedurende hun leven 15 % van hun hemoglobine gehalte 
verliezen. Bosch et al., Blood 1992, 79: 254-260 
6. Het beleidsplan van de Faculteit der Medische Wetenschappen van de 
Katholieke Universiteit Nijmegen beoogt voor de periode 1992-1996 een 
reductie in de sfeer van ondersteunend beheerspersoneel. Wanneer dit z.g. 
"niet-wetenschappelijke personeel" door de bewerking van een dissertatie 
promoveert tot "wetenschappelijk personeel" levert het intrinsiek een bijdrage 
aan de uitvoering van deze voorgenomen reductie. 
7. Een vergelijkende studie naar de sociale systemen van de verschillende 
Westerse landen leidt tot de conclusie dat aan de Verenigde Staten de status 
van ontwikkelingsland moet worden toegekend. 
8. Het schrijven van een proefschrift door elk der beide partners binnen een 
huwelijk is wel degelijk goed uitvoerbaar, (zie stellingen behorend bij 
proefschrift The Nuclear Matrix: Composition and structural organization, 
1988. Ron Verheijen). 
Nijmegen, 24 September 1992 Catharina С Stolwijk - van Niekerk 
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